↑ 疾患リストへ　← 戻る

 6. パーキンソン病　［臨床試験数：1,307，薬物数：1,322（DrugBank：270），標的遺伝子数：161，標的パスウェイ数：166］ 

Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04147949July 20204 November 2019AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced DyskinesiaRandomized, Double-Blind, Placebo-Controlled, Crossover, Proof-of-Concept Phase 2 Study to Test Efficacy and Safety of AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced DyskinesiaParkinson Disease;Dyskinesia, Medication-Induced;L-Dopa Causing Adverse Effects in Therapeutic UseDrug: AV-101;Drug: PlaceboVistaGen Therapeutics, Inc.Not recruiting30 Years80 YearsAll20Phase 2
2NCT03309514June 20207 October 2019Transplantation of Neural Stem Cell-Derived Neurons for Parkinson's DiseaseClinical Investigation of Transplantation of Neural Stem Cell-derived Neurons for the Treatment of Parkinson's DiseaseParkinson's DiseaseBiological: Intracerebral microinjectionsNeuroGenerationNot recruiting35 Years85 YearsAll12Phase 1/Phase 2
3NCT02967250April 1, 202011 November 2019Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment7T Magnetic Resonance Spectroscopy Monitoring Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA TreatmentParkinson DiseaseDrug: ursodeoxycholic acidUniversity of MinnesotaNot recruiting18 YearsN/AAll20Phase 1United States
4NCT04152655January 1, 202011 November 2019A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson DiseaseA Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease (SEASEiPPD)REM Sleep Behavior Disorder;Parkinson DiseaseDrug: Idebenone;Drug: Placebo oral tabletSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityNot recruiting18 YearsN/AAll180Phase 2/Phase 3China
5NCT03436953December 201915 April 2019A Phase 2 Study of CX-8998 in Adults With Tremor Associated With Parkinson's DiseaseA Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Tremor Associated With Parkinson's DiseaseParkinson's Disease;TremorDrug: CX-8998;Drug: PlaceboCavion, Inc.Not recruiting40 Years80 YearsAll60Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6NCT04154072December 201911 November 2019A Clinical Study of NLY01 in Patient's With Early Parkinson's DiseaseMulticenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment With NLY01 in Early-stage Parkinson's DiseaseParkinson DiseaseDrug: NLY01;Drug: VehicleNeuraly, Inc.Not recruiting30 Years80 YearsAll240Phase 2
7ChiCTR19000272102019-11-0111 November 2019Effects of different anesthesia methods on postoperative delirium in patients with Parkinson's disease and biological markers of postoperative delirium in patients with Parkinson's diseaseEffects of different anesthesia methods on postoperative delirium in patients with Parkinson's disease and biological markers of postoperative delirium in patients with Parkinson's diseaseDelirium1:Total Intravenous Anesthesia;2:Balance Anesthesia;Tsinghua University Yuquan HospitalRecruitingFemale1:60;2:60;Phase 0China
8NCT03652870November 1, 201917 September 2018Antidepressants Trial in Parkinson's DiseaseA Randomised Placebo-Controlled Trial of Escitalopram and Nortriptyline With Standard Psychological Care for Depression in Parkinson's DiseaseDepression;Parkinson DiseaseDrug: Nortriptyline;Drug: Escitalopram;Drug: PlaceboUniversity College, LondonLondon North West Healthcare NHS Trust;King's College London;University Hospital Plymouth NHS Trust;NHS LothianNot recruiting18 Years85 YearsAll408Phase 3
9NCT04148391November 1, 201911 November 2019Evaluate NYX-458 in Subjects With MCI-PDA Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment Associated With Parkinson's DiseaseParkinson's Disease;Mild Cognitive ImpairmentDrug: Placebo Oral Capsule;Drug: NYX-458AptinyxCogState Ltd.;Worldwide Clinical TrialsNot recruiting50 Years80 YearsAll135Phase 2
10NCT04097080November 20197 October 2019Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's DiseaseComparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's DiseaseParkinson DiseaseDrug: NBTX-001;Drug: Standard of CareNobilis Therapeutics Inc.Recruiting18 YearsN/AAll60Phase 1Russian Federation
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
11NCT04117178November 201914 October 2019Monitoring Anti-Dementia Drugs by Serum LevelsMonitoring Anti-Dementia Drugs by Serum Levels: Importance of Serum Levels, Drug-monitoring, Side-effects, Clinical Efficacy and Compliance (Translation of Official Danish Title)Dementia;Dementia With Lewy Bodies;Dementia in Parkinsons Disease;Dementia Alzheimers;Alzheimer DiseaseDrug: Donepezil;Drug: Memantine;Diagnostic Test: Measurement of serum level of anti-dementia drugZealand University HospitalEpilepsihospitalet FiladelfiaNot recruiting18 YearsN/AAll110Phase 4
12NCT04127695October 31, 201928 October 2019A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's DiseaseA Randomized, Double-Blind, Placebo Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of ABBV-0805 in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: ABBV-0805;Drug: Placebo ABBV-0805AbbVieNot recruitingN/A85 YearsAll32Phase 1United States
13ChiCTR19000269562019-10-2128 October 2019Minimum alveolar concentration-awake of sevoflurane in patients with Parkinson's diseaseMinimum alveolar concentration-awake of sevoflurane in patients with Parkinson's diseaseParkinson’s diseaseParkinson’s disease group:Sevoflurane induction;Non-Parkinson’s disease group:Sevoflurane induction;The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of ChinaNot Recruiting4064BothParkinson’s disease group:30;Non-Parkinson’s disease group:30;N/AChina
14NCT04157933October 16, 201911 November 2019Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's DiseaseA Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Profile of AZ-009 in Subjects With Established Parkinson's DiseaseParkinson's DiseaseDrug: 009-A1;Drug: 009-A2;Drug: 009-A3;Drug: 009-A0;Drug: 009-B1 (active --> placebo) crossover;Drug: 009-B2 (placebo --> active) crossoverAlexza Pharmaceuticals, Inc.Recruiting30 Years85 YearsAll32Phase 1Netherlands
15NCT04146454October 14, 20194 November 2019Smartphone-based Wearable TelerehabilitationA New Smartphone-based Wearable Telerehabilitation System for People With Parkinson's DiseaseParkinson DiseaseOther: Smartphone-based balance exercisesUniversity of HoustonEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Recruiting50 Years75 YearsAll44N/AUnited States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
16JPRN-jRCTs03119011511/10/20195 November 2019PK & PD of coadministration of XOR inhibitor and inosinePharmacokinetics and pharmacodynamics study of coadministration of either allopurinol or febuxostat and inosineParkinson's disease
neurodegenerative disease		Coadministration of allopurinol and inosine, or coadministration of febuxostat and inosineNaoyuki KamataniRecruiting>= 20age old<= 40age oldMale28Phase 1none
17NCT03987750October 20191 July 2019Safinamide for Levodopa-induced Dyskinesia (PD-LID)A Phase 3, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of 2 Doses of Safinamide Compared to Placebo in the Treatment of LID in PD Patients With Motor FluctuationsDyskinesia, Drug-Induced;Parkinson DiseaseDrug: Safinamide Methanesulfonate 150mg;Drug: Safinamide Methanesulfonate 100mg;Drug: Safinamide Methanesulfonate matching placeboZambon SpANot recruiting30 YearsN/AAll300Phase 3
18NCT04127578October 20194 November 2019Phase 1/2a Clinical Trial of PR001A in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)A Phase 1/2a Randomized, Double-Blind, Sham Procedure-Controlled, Ascending Dose Study to Evaluate the Safety of PR001A in Patients With Parkinson's Disease With at Least One GBA1 MutationParkinson DiseaseBiological: PR001A;Other: Sham procedurePrevail TherapeuticsRecruiting40 Years75 YearsAll16Phase 1/Phase 2United States
19NCT03905811September 23, 201930 September 2019Terazosin for Parkinson's DiseaseA Pilot Study of Terazosin for Parkinson's DiseaseParkinson DiseaseDrug: Terazosin 5 MG;Drug: Placebo oral capsuleJordan SchultzUniversity of IowaNot recruiting40 Years90 YearsAll20Phase 1/Phase 2
20ChiCTR19000258942019-09-1116 September 2019Parallel randomized controlled trial for Shengyang Yiwei Granule in the treatment of early Parkinson's diseaseParallel randomized controlled trial for Shengyang Yiwei Granule in the treatment of early Parkinson's diseaseparkinson diseaseexperimental group:Parkinson's disease routine medication, plus Shengyang Yiwei granules, water blunt, one dose, morning and evening;control group:Parkinson's disease routine medication, add Buzhong Yiqi granules, water blunt, one dose, morning and evening;Kaida WangRecruitingBothexperimental group:45;control group:23;Phase 0China
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
21NCT03568968September 1, 201918 December 2018A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's DiseaseA Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease: the NOPARK StudyParkinson DiseaseDietary Supplement: Nicotinamide Riboside;Drug: PlaceboHaukeland University HospitalNot recruiting18 YearsN/AAll200N/A
22NCT03968133September 1, 201911 June 2019Treating Anxiety in Parkinson's Disease With a Multi-Strain ProbioticTreating Anxiety in Parkinson's Disease With a Multi-Strain Probiotic - a Randomized, Placebo-controlled TrialParkinson Disease;AnxietyDietary Supplement: Probiotic;Dietary Supplement: PlaceboUniversity of British ColumbiaThe W. Garfield Weston FoundationNot recruiting40 Years80 YearsAll72Phase 2/Phase 3Canada
23NCT04064983September 1, 20197 October 2019Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Parkinson's DiseaseIndividual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Parkinson's DiseaseParkinson DiseaseDrug: HB-adMSCHope BiosciencesNot recruiting18 YearsN/AAllN/AUnited States
24NCT03665493September 201915 July 2019Dopamine Effect on Inhibitory ControlDopamine Effect on Inhibitory ControlIdiopathic Parkinson's DiseaseDrug: PD patients H&Y=1.5-2 Medications ON;Drug: PD patients H&Y=1.5-2 Medications OFF;Behavioral: Healthy age-matched controls;Drug: PD patients H&Y=3 Medications OFF;Drug: PD patients H&Y=3 Medications ONGiovanni MirabellaNot recruiting40 Years70 YearsAll102N/A
25NCT03947216September 20193 June 2019Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.Study of Pimavanserin Efficacy for the Treatment of Impulse Control Disorders in Parkinson's DiseaseParkinson DiseaseDrug: Active drug: pimavanserin 17mg (2 strength tablets);Drug: Placebo: 2 tablets containing same excipients except active compound;Behavioral: Assessment of severity of ICD (impulse control disorders);Behavioral: Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors;Behavioral: Assessment of quality of life;Behavioral: Assessment of depression;Behavioral: Assessment of cognition;Behavioral: Assessment of severity of Parkinson Disease;Procedure: Blood analysis;Procedure: Cardiac monitoringUniversity Hospital, Strasbourg, FranceNS-PARK;EUCLID;F-CRINNot recruiting35 Years75 YearsAll130Phase 2France
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
26NCT03959540September 20193 June 2019Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's DiseaseA Multinational, Multicentre, Prospective Non-interventional Study to Assess Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's DiseaseParkinson DiseaseDrug: Opicapone;Drug: Levodopa (L-DOPA) + Standard careBial - Portela C S.A.Not recruiting75 YearsN/AAll100Phase 3
27NCT04075318August 29, 201916 September 2019Study of UB-312 in Healthy Participants and Parkinson's Disease PatientsA Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UBITh® PD Immunotherapeutic Vaccine (UB-312) in Healthy Participants and Participants With Parkinson's DiseaseParkinson Disease;ParkinsonismBiological: UB-312;Biological: PlaceboUnited Neuroscience Ltd.Centre for Human Drug Research, Netherlands;Worldwide Clinical TrialsRecruiting40 Years85 YearsAll62Phase 1Netherlands
28NCT04006210August 27, 20194 November 2019A Clinical Trial Investigating the Efficacy, Safety and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless).A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)Parkinson's DiseaseCombination Product: ND0612 Solution for SC infusion;Combination Product: Placebo for SC infusion;Drug: Carbidopa and Levodopa 25mg/100mg;Drug: Placebo for Carbidopa and Levodopa 25mg/100mgNeuroDerm Ltd.Recruiting30 Years80 YearsAll300Phase 3United States
29NCT04070495August 27, 201916 September 2019A Drug Interaction Study of KW-6356 and Clarithromycin or RifampicinA Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin (A Drug Interaction Study With a CYP3A4/5 Inhibitor or Inducer)Parkinson's DiseaseDrug: KW-6356;Drug: Clarithromycin;Drug: RifampicinKyowa Kirin Co., Ltd.Recruiting20 Years44 YearsMale20Phase 1Japan
30ChiCTR19000253722019-08-1827 August 2019Quantitative evaluation of drug response test in patients with Parkinson's disease and the influence of rehabilitation intervention on the evaluation of drug response and the exploration of related mechanismsQuantitative evaluation of drug response test in patients with Parkinson's disease and the influence of rehabilitation intervention on the evaluation of drug response and the exploration of related mechanismsParkinson's disease1:rehabilitation;1:take levodopa;30:Wear wearable devices;Tianjin Huanhu HospitalNot RecruitingBoth1:30;1:30;30:30;Phase 0China
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
31NCT04062526August 14, 201928 October 2019Evaluation of Neuroinflammation in Parkinson's Disease Using 18F-NOS PET/CTEvaluation of in Vivo Neuroinflammation in Parkinson's Disease Using 18F-NOS Positron Emission Tomography (PET/CT)Parkinson Disease;Healthy VolunteerDrug: [18F]NOSUniversity of PennsylvaniaRecruiting18 Years70 YearsAll30Early Phase 1United States
32NCT03976349August 12, 201911 November 2019A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's DiseaseA Phase 1 Single- and Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB094 Administered Intrathecally to Adults With Parkinson's DiseaseParkinson's DiseaseDrug: BIIB094;Drug: PlaceboBiogenIonis Pharmaceuticals, Inc.Recruiting35 Years80 YearsAll62Phase 1United States
33NCT04043338August 11, 201930 September 2019Single Ascending Dose Study Investigating the Safety, Tolerability, and PK of XC130-A10H in Healthy Adult SubjectsA Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study Investigating the Safety, Tolerability, and Pharmacokinetics of XC130-A10H in Healthy Adult SubjectsParkinson's DiseaseDrug: XC130-A10H;Drug: PlaceboXoc PharmaceuticalsCelerionRecruiting18 Years75 YearsAll40Phase 1United States
34ChiCTR19000237252019-08-0111 June 2019Study for the Role of Butylphthalide in Delaying the progression of Parkinson's disease (PD), Vascular Parkinson's disease (VP) and Parkinsonism-plus syndrome (PPS)Study for the Role of Butylphthalide in Delaying the progression of Parkinson's disease (PD), Vascular Parkinson's disease (VP) and Parkinsonism-plus syndrome (PPS)Parkinson's disease (PD), Vascular Parkinson's disease (VP) and Parkinsonism-plus syndrome (PPS)PD-Placebo:Placebo;PD-Butylphthalide:Butylphthalide;VP-Placebo:Placebo;VP-Butylphthalide:Butylphthalide;MSA-Placebo:Placebo;MSA-Butylphthalide :Butylphthalide ;PSP-Placebo:Placebo;PSP-Butylphthalide:Butylphthalide;Zhujiang Hospital of Southern Medical UniversityNot Recruiting1880MalePD-Placebo:50;PD-Butylphthalide:50;VP-Placebo:50;VP-Butylphthalide:50;MSA-Placebo:50;MSA-Butylphthalide :50;PSP-Placebo:50;PSP-Butylphthalide:50;Phase 0China
35NCT03808961August 1, 201927 May 2019Niacin for Parkinsons DiseaseNAPS: Niacin for Parkinsons DiseaseParkinson's DiseaseDietary Supplement: Niacin;Dietary Supplement: Niacinamide;Other: PlaceboVA Office of Research and DevelopmentNot recruiting35 YearsN/AAll100N/AUnited States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
36NCT03881371August 1, 20192 September 2019A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of LevodopaA Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of LevodopaParkinson DiseaseDrug: Safinamide;Other: PlaceboZambon SpARecruiting18 YearsN/AAll306Phase 3China
37NCT04056689July 23, 201914 October 2019Study to Evaluate DNL151 in Subjects With Parkinson's DiseaseA Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Subjects With Parkinson's DiseaseParkinson DiseaseDrug: DNL151 low dose;Drug: DNL151 high dose;Drug: PlaceboDenali Therapeutics Inc.Recruiting30 Years75 YearsAll24Phase 1Netherlands;United Kingdom
38NCT03575195July 15, 201926 August 2019Microbiota Intervention to Change the Response of Parkinson's DiseaseMicrobiota Intervention to Change the Response of Parkinson's DiseaseParkinson DiseaseDrug: Rifaximin;Other: PlaceboUniversity of California, San FranciscoNova Southeastern University;Gateway Institute for Brain ResearchRecruiting30 YearsN/AAll86Phase 1/Phase 2United States
39ChiCTR19000217082019-07-0111 March 2019Study for the brain network mechanism of pramipexole in the treatment of tremor-type PD patients based on DRD3 Ser9Gly polymorphiStudy for the brain network mechanism of pramipexole in the treatment of tremor-type PD patients based on DRD3 Ser9Gly polymorphismParkinson's DiseaseHealthy control group:No;tremor-dominant phenotype PD patients group:pramipexole;Department of Neurology, Brain Hospital Affiliated to Nanjing Medical UniversityNot Recruiting5070BothHealthy control group:80;tremor-dominant phenotype PD patients group:80;Phase 0China
40NCT03815916July 1, 201926 August 201931P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's DiseaseA Phase 2, Pilot Open Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Parkinson's DiseaseParkinson's DiseaseDrug: Gold NanocrystalsClene NanomedicineUniversity of Texas Southwestern Medical CenterRecruiting30 Years80 YearsAll24Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
41NCT03956979July 201911 June 2019A Study in Parkinson's Disease in paTients With mOderate to seveRe dyskInesiAA Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson's Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Combinations of JM-010DyskinesiasDrug: JM-010 A group;Drug: JM-010 B group;Drug: PlacebosContera PharmaBukwang PharmaceuticalNot recruiting18 Years80 YearsAll81Phase 2
42NCT03977441July 201917 June 2019the Efficacy and Safety of Agomelatine in the Patients With Parkinson's DiseaseA Multicenter, Randomized, Double-blind, Placebo-controlled Study: Evaluation of the Efficacy and Safety of Agomelatine in the Treatment of Sleep Disorders and Depression in Patients With Parkinson's DiseaseParkinson Disease;Depression;Sleep Disorders;Circadian Rhythm DisordersDrug: Agomelatine or PIaceboSecond Affiliated Hospital of Soochow UniversityNot recruiting30 Years75 YearsAll240Phase 4
43NCT03970239June 14, 201915 July 2019Serotonin in Impulse Control Disorders in Parkinson's DiseaseRole of the Serotoninergic System in Impulse Control Disorders in Parkinson's DiseaseParkinson Disease;Impulse Control DisordersDrug: Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin);Drug: Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin)Hospices Civils de LyonRecruiting30 Years80 YearsAll45N/AFrance
44NCT03938922June 13, 201926 August 2019A Study to Evaluate ENT-01 for the Treatment of Parkinson's Disease DementiaA Multicenter, Open Label Study to Evaluate Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Dementia.Parkinson Disease;DementiaDrug: Active Investigational Treatment ENT-01Enterin Inc.Not recruiting30 Years90 YearsAll40Phase 1United States
45NCT03939559June 10, 201927 May 2019The Efficiency of Home Based Dual Task Training in Parkinson DiseaseThe Efficiency of Home Based Dual Task Training in Parkinson DiseaseParkinson DiseaseProcedure: Static, dynamic and functional balance exercises;Procedure: Static, dynamic and functional balance exercises with dual taskIstanbul University-CerrahpasaNot recruiting30 Years80 YearsAll60N/A
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
46JPRN-UMIN0000369522019/06/0416 July 2019A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients.A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. - A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients.Patients who are suspected Parkinson's disease or related disorders, including dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, frontotemporal lobe degeneration, vascular parkinsonism, drug-induced parkinsonism, normal pressure hydrocephalus, and others.18F-FDOPA, 11C-Raclopride PETNagoya City Rehabilitation AgencyRecruiting20years-oldNot applicableMale and Female150Not applicableJapan
47ChiCTR19000225342019-06-0123 April 2019Efficacy of entacapone and pramipexole for non-motor symptoms of Parkinson’s disease: a prospective randomized controlled trialEfficacy of entacapone and pramipexole for non-motor symptoms of Parkinson’s disease: a prospective randomized controlled trialnon-motor symptoms of Parkinson’s diseaseentacapone group:Patients in the entacapone group will be administered entacapone (Novartis; import drug registration certificate number: H20160680), 10 times per day, 200 mg each time, for 3 weeks. ;pramipexole group:Patients in the pramipexole group will be administered pramipexole (Boehringer-Ingelheim; import drug registration certificate number: 20140918) , 3 times per day, 1 mg each time, for 3 weeks.;Geriatric Hospital of HainanNot Recruiting4075Bothentacapone group:194;pramipexole group:194;N/AChina
48NCT03924414June 1, 201929 April 2019Trial of Parkinson's And Zoledronic AcidTOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic Acid for the Prevention of Fractures in Patients With Parkinson's DiseaseParkinson Disease;OsteoporosisDrug: Zoledronic Acid 5Mg/Bag 100Ml Inj;Other: PlaceboCalifornia Pacific Medical Center Research InstituteNational Institute on Aging (NIA);University of California, San Francisco;Duke University;University of Pittsburgh;Parkinson's FoundationNot recruiting65 YearsN/AAll3500Phase 4
49NCT04064294June 1, 20199 September 2019Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase InhibitorsPreventing Levodopa Induced Dyskinesia in Parkinson?s Disease With StatinsParkinson Disease;Dyskinesia, Drug-InducedDrug: Intravenous InfusionVA Office of Research and DevelopmentOregon Health and Science UniversityRecruiting50 YearsN/AAll120Phase 1United States
50NCT03971617May 29, 201917 June 2019Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's DiseaseA Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Tolerability of Molecular Hydrogen in Patients With Parkinson's DiseaseParkinson DiseaseDrug: Hydrogen;Drug: Placebo oral tabletStony Brook UniversityRecruiting40 Years80 YearsAll70Phase 2/Phase 3United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
51NCT03970798May 22, 201926 August 2019A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or RosuvastatinA Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or RosuvastatinParkinson's DiseaseDrug: Midazolam;Drug: Caffeine;Drug: Rosuvastatin;Drug: KW-6356Kyowa Kirin Co., Ltd.Not recruiting20 Years44 YearsMale50Phase 1Japan
52NCT03671785May 15, 201926 August 2019Study of the Fecal Microbiome in Patients With Parkinson's DiseaseA Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Twice Weekly Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally for 12 Weeks in Subjects With Parkinson's DiseaseParkinson DiseaseDrug: PRIM-DJ2727;Drug: Placebo oral capsuleThe University of Texas Health Science Center, HoustonKelsey Research FoundationRecruiting55 Years75 YearsAll12Phase 1United States
53NCT03693872May 15, 201911 June 2019Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French HospitalsEvaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French HospitalsParkinson DiseaseDrug: Apomorphine;Drug: Dopaminergic Agonist + ApomorphineRennes University HospitalRecruiting18 YearsN/AAll42N/AFrance
54NCT03958708May 13, 20193 June 2019Modulation of Gut Microbiota by Rifaximin in PD PatientsModulation of Gut Microbiota by Rifaximin in PD PatientsParkinson Disease;InflammationDrug: Rifaximin 550 MGTaipei Medical University Shuang Ho HospitalRecruiting45 Years70 YearsAll20Phase 1/Phase 2Taiwan
55NCT03840837May 2, 201913 May 2019Cholinergic Neurotransmission in Mobility and Cognition in Parkinson DiseaseCholinergic Neurotransmission - A Common Underlying Mechanism of Cognitive and Gait Impairment in Parkinson DiseaseParkinson DiseaseDrug: Rivastigmine transdermal patchUniversity of MarylandNational Institute on Aging (NIA)Recruiting18 YearsN/AAll100Phase 4United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
56ChiCTR19000227152019-05-015 May 2019Accurate treatment under the multidisciplinary cooperative diagnosis and treatment model of Parkinson's diseaseAccurate treatment under the multidisciplinary cooperative diagnosis and treatment model of Parkinson's diseaseParkinson's DiseaseAnteversion group:DBS;Balance dysfunction group:DBS;Gait abnormality group:DBS;Tianjin Huanhu HospitalRecruitingBothAnteversion group:40;Balance dysfunction group:40;Gait abnormality group:40;N/AChina
57NCT03552068May 1, 201928 October 2019Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease:Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease: A Pilot Double Blind Randomized TrialParkinson's Disease;Mpulse Control DisordersDrug: placebo;Drug: ClonidineHospices Civils de LyonRecruiting30 Years80 YearsAll38Phase 2France
58NCT03903549May 201915 April 2019Initial Investigation of [18F]P17-059 in Parkinson's Disease Patients and Healthy VolunteersA Positron Emission Tomography (PET) Study to Investigate [18F]D6-FP-DTBZ ([18F]P17-059) for Potential Use as a Radioligand for Vesicular Monoamine Transporter (VMAT2)Parkinson DiseaseDrug: [18F]P17-059Five Eleven Pharma, Inc.Not recruiting45 Years90 YearsAll26Phase 1United States
59NCT03781167April 29, 201928 October 2019A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)A 52-Week, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's DiseaseParkinson's Disease (PD)Drug: ABBV-951AbbVieRecruiting30 YearsN/AAll130Phase 3United States;Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom
60NCT03899324April 26, 201926 August 2019Evaluation of the Efficacy and Safety of Bumetanide in Parkinson's DiseaseA Randomized Double-blind Placebo-controlled Multicenter Proof-of-concept Trial to Assess the Efficacy and Safety of Bumetanide in Parkinson's DiseaseParkinson DiseaseDrug: Bumetanide white, oblong, scored tablet;Drug: Placebo white, oblong, scored tabletB&A TherapeuticsRecruiting40 Years80 YearsAll40Phase 2France
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
61JPRN-JapicCTI-19476322/4/201916 July 2019Safety and PK study of LY03003An open-label study in Japanese patients with Parkinson's disease to evaluate the safety, pharmacokinetics and preliminary efficacy of LY03003 following intramuscular injections and its comparative bioavailability to Rotigotine transdermal patch.Parkinson's DiseaseIntervention name : Rotigotine
INN of the intervention : Rotigotine
Dosage And administration of the intervention : LY03003 IM injections 14, 28 and 56 mg/week.
Control intervention name : Rotigotine
INN of the control intervention : Rotigotine
Dosage And administration of the control intervention : Rotigotine transdermal patch applications 4.5, 9 and 18 mg/day.		Shandong Luye Pharmaceutical Co., Ltd./CMIC Co., Ltd.Recruiting20BOTH32Phase 1Japan
62NCT03661125April 11, 201926 August 2019SRC Inhibition as a Potential Target for Parkinson's Disease PsychosisA Randomised, Balanced, Double-blind Two-way Crossover Design Study to Evaluate the Effects of SRC Kinase Inhibitor, Saracatinib, on Brain Activity Associated With Visual Processing in Patients With Parkinson's Disease Psychosis.Parkinson Disease PsychosisDrug: Saracatinib;Drug: Placebo Oral TabletKing's College LondonAstraZeneca;King's College Hospital NHS TrustRecruiting40 YearsN/AAll30Early Phase 1United Kingdom
63NCT03775096April 4, 201924 June 2019Adrenergic Blockers for Cardiac Changes in Early Parkinson's DiseaseThe Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's DiseaseREM Sleep Behavior Disorder;Pre-motor Parkinson Disease;Symptomatic Parkinson DiseaseDrug: CarvedilolMichele Tagliati, MDRecruiting30 Years75 YearsAll15Phase 2United States
64NCT03877510April 3, 201928 October 2019Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in PD Patients With Motor FluctuationsAn Open-label Extension Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease Patients With Motor FluctuationsParkinson DiseaseDrug: IPX203 140 mg;Drug: IPX203 210 mg;Drug: IPX203 280 mg;Drug: IPX203 350 mgImpax Laboratories, LLCRecruiting40 YearsN/AAll300Phase 3United States;Czechia;Germany;Italy;Spain
65JPRN-jRCTs05118021429/03/201910 September 2019The usefulness of flutemetamol for diagnostic imaging of neurogenerative diseaseThe usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative disease - The usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative diseaseAlzheimer's disease,Dementia with Lewy Bodies,Parkinson's syndrome,Frontotemporal lober degeneration
Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's syndrome, Frontotemporal lober degeneration, Parkinson's disease, Mild cognitive impairment, Non-Alzheimer's disease, Progressive aphasia, Neurodegenerative disease, Cerebral corticobasal degeneration, Progressive supranuclear palsy		Amyloid PET: Given the flutemetamol (3mL) intravenously
FDG-PET:Given the FDG scanR (3mL) intravenously		Yoshiaki ItohRecruitingAges 20 and overN/ABoth100N/Anone
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
66NCT03922711March 26, 201914 October 2019A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's DiseaseA 14-week, Double-blind, Randomized, Three-arm, Parallel Group Study to Assess the Efficacy and Safety of Two Doses of Pridopidine Versus Placebo for the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson's Disease (gLIDe)Parkinson DiseaseDrug: Pridopidine;Drug: PlaceboPrileniaRecruiting30 Years85 YearsAll135Phase 2United States
67NCT03716570March 12, 201930 September 2019A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's DiseaseA Multicenter, Blinded, Placebo-Controlled, Randomized, Single and Multiple-Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Subjects With Parkinson's DiseaseParkinson's DiseaseDrug: BIIB054;Drug: PlaceboBiogenRecruiting40 Years80 YearsAll24Phase 1Japan
68ChiCTR19000217602019-03-0930 April 2019Effect-site concentration of remifentanil for I-gel insertion in male patients with Parkinson’s disease undergoing deep brain stimulator implantation during target-controlled infusion of propofolEffect-site concentration of remifentanil for I-gel insertion in male patients with Parkinson’s disease undergoing deep brain stimulator implantation during target-controlled infusion of propofolParkinson’s diseaseParkinson’s disease:propofol and remifentanil;Non-Parkinson’s disease:propofol and remifentanil;The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of ChinaRecruiting4064MaleParkinson’s disease:25;Non-Parkinson’s disease:25;N/AChina
69NCT03816020March 9, 201920 May 2019NAD-supplementation in Drug naïve Parkinson's DiseaseNAD-PARK: A Double-blinded Randomized Pilot Trial of NAD-supplementation in Drug naïve Parkinson's DiseaseParkinson Disease;Neurodegenerative DiseasesDietary Supplement: Nicotinamide Riboside;Other: PlaceboHaukeland University HospitalRecruiting18 YearsN/AAll30N/ANorway
70NCT03887884March 5, 201926 August 2019Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)Randomized, Multi-center, Open-label, Crossover Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder) and an Oral Dose of Carbidopa/Levodopa CD/LD Under Fed Conditions in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: CVT-301;Drug: SinemetAcorda TherapeuticsNot recruiting30 Years85 YearsAll23Phase 1United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
71NCT03865121March 4, 201911 November 2019Pilot Trial of Transnasal Nicotine in Parkinson DiseaseUncontrolled Pilot Trial of Transnasal Nicotine in Parkinson DiseaseParkinson DiseaseDrug: Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY)El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco SuarezHoward UniversityNot recruiting60 YearsN/AAll6Phase 2Mexico
72JPRN-jRCTs03118024801/03/201922 July 2019N/AIntervention study for the effect of Istradefylline on adjustment of Levodopa in Parkinson's Disease - Istra adjust PDParkinson's diseaseArm with treatment of Istradefylline and levodopa
Treatment with Istradefylline will be started at a dose of
20 mg administered once daily at Week 0. The dose of
Istradefylline will be increased to 40 mg once daily if
the patient has no tolerability issues and still has motor
symptoms at Week 1. Dose reduction is possible if the
patient has tolerability issues.
Patients will visit every 4 weeks from the following day
of Week0, and 50mg levodopa will be added of if CGI-S score
>=4 every time. Dose reduction is possible if the patient
has tolerability issues.
Arm without treatment of Istradefylline
50mg levodopa will be added at Week 0. Patients will visit
every 4 weeks from the following day of Week0, and 50mg
levodopa will be added of if CGI-S score >=4 every time.
Dose reduction is possible if the patient has tolerability
issues.		Taku HatanoKyowa Hakko Kirin Co., LtdRecruiting>=30 age old<=84 age oldBoth100N/Anone
73NCT03858270March 1, 201911 March 2019Inhibition of a-synuclein Cell-cell Transmission by NMDAR Blocker, MemantineInhibition of a-synuclein Cell-cell Transmission by NMDAR Blocker, MemantineParkinson DiseaseDrug: Memantine;Other: PlaceboWayne State UniversityNot recruiting45 Years85 YearsAll50Phase 3
74NCT03820037March 201911 February 2019Relative Bioavailability and Bioequivalence of OpicaponeA Phase I, Open-Label, Randomised, Three-Period, Three-Sequence, Partial Replicate Crossover Study to Investigate the Relative Bioavailability and Bioequivalence of Opicapone Obtained From Two Different Sources, Under Fasting Conditions After Single-dose Administration in Healthy SubjectsParkinson DiseaseDrug: Ongentys;Drug: BIA 9-1067 (test)Bial - Portela C S.A.Not recruiting18 Years55 YearsAll45Phase 1United Kingdom
75NCT03841604February 28, 201918 March 2019Effect of Safinamide on Parkinson's Disease Related Chronic PainA Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Safinamide 100mg Once Daily, as add-on Therapy, in Idiopathic Parkinson's Disease (PD) Patients With Motor Fluctuations and PD Related Chronic PainIdiopathic Parkinson DiseaseDrug: Safinamide Methanesulfonate;Drug: Safinamide methanesulfonate matching placeboZambon SpARecruiting30 YearsN/AAll177Phase 4Austria;France;Germany;Italy;Spain
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
76NCT03830528February 26, 201925 March 2019A Study of Single and Multiple Doses of KW-6356 in Healthy SubjectsA Phase I Study of KW-6356 in Japanese and Caucasian Healthy AdultsParkinson's DiseaseDrug: KW-6356 Low Dose;Drug: KW-6356 Middle Dose;Drug: KW-6356 High Dose;Drug: KW-6356 X Dose;Drug: KW-6356 Y Dose;Drug: PlaceboKyowa Hakko Kirin Co., LtdRecruiting20 Years44 YearsMale48Phase 1Japan
77NCT03655236February 18, 201928 October 2019PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson's DiseaseEarly Parkinson DiseaseDrug: K0706;Other: placeboSun Pharma Advanced Research Company LimitedRecruiting50 YearsN/AAll504Phase 2United States;Hungary
78NCT03968744February 18, 201911 June 2019Effect of Safinamide on Sleep Quality in Patients With Parkinson's DiseaseA Prospective, Open Label, Single Arm, Clinical Study to Evaluate the Effect of Safinamide on Sleep Quality and Polysomnographic Parameters in Patients With Parkinson's Disease: the Safe Sleep StudyIdiopathic Parkinson's Disease (at Later Stage)Drug: SafinamideAlain KaelinClinical Trial Unit Ente Ospedaliero CantonaleRecruiting18 YearsN/AAll23Phase 4Switzerland
79NCT03413384February 15, 20194 March 2019To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease DementiaA Randomized, Double Blinded, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease DementiaParkinson's Disease DementiaDrug: Ceftriaxone;Other: PlaceboBrainX CorporationRecruiting50 Years80 YearsAll106Phase 2Taiwan
80NCT03815071February 1, 201911 February 2019A Study on the Treatment of Parkinson's Disease With Autologous Neural Stem CellsClinical Study of the Safety and Efficacy of Autologous Neural Stem Cells in the Treatment of Parkinson's DiseaseParkinson DiseaseDrug: Ips-nsc cellsAllife Medical Science and Technology Co., Ltd.The First People's Hospital of Yunnan Province/First People's Hospital of Yunan Provinve New Kunhua Hospital;Henan Provincial Hospital;Beijing HospitalNot recruiting18 Years60 YearsAll10Early Phase 1
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
81NCT03845387February 20194 March 2019A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.A Phase II Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.Parkinson DiseaseDrug: KDT-3594;Drug: PramipexoleKissei Pharmaceutical Co., Ltd.Recruiting20 Years79 YearsAll100Phase 2Japan
82NCT03790670January 30, 201926 August 2019Biomarker Assessments of Leukine During Treatment of Parkinson's DiseaseSafety, Tolerability and Biomarker Assessments of Leukine (Sargramostim) During Extended Timed Treatment for Parkinson's Disease: A Phase I Pilot StudyParkinson DiseaseDrug: sargramostimUniversity of NebraskaNot recruiting35 Years85 YearsAll5Phase 1United States
83EUCTR2017-002426-20-AT22/01/201930 April 2019Effect of Safinamide on Parkinson’s Disease Related Chronic PainA randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of safinamide 100 mg once daily, as add-on therapy, in idiopathic Parkinson’s Disease (IPD) patients with motor fluctuations and PD related chronic pain - Pain studyIdiopathic Parkinson's Disease, Hoehn and Yahr stage between 2-3 inclusive during the “ON” phase, experiencing motor fluctuations while on stable doses of L-Dopa (with or without benserazide/carbidopa, with or without addition of a catechol O-methyltransferase (COMT) inhibitor) and may be on stable doses of other PD medications (a dopamine agonist, an anticholinergic and/or amantadine), yet are experiencing more than 2 hours of OFF time per day and chronic PD related pain.
MedDRA version: 20.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Xadago
Product Name: Xadago
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Safinamide methansulfonate
CAS Number: 202825-46-5
Other descriptive name: SAFINAMIDE METHANESULFONATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Trade Name: Xadago
Product Name: Xadago
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Safinamide methansulfonate
CAS Number: 202825-46-5
Other descriptive name: SAFINAMIDE METHANESULFONATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use		Zambon SpAAuthorised Female: yes
Male: yes		177Phase 4Spain;Austria
84NCT03826134January 17, 201923 April 2019A Positron Emission Tomography (PET) Study to Examine the Brain Binding Properties of a Novel Radioactive Compound [11C]-PXT012253 in Healthy SubjectsInterventional, Phase I, Open-label, First in Human, Single-center Positron Emission Tomography (PET) Study Investigating Test-retest Properties of [11C]-PXT012253 as a Radiotracer in Healthy SubjectsParkinson DiseaseDrug: [11C]PXT012253H. Lundbeck A/SNot recruiting20 Years50 YearsAll7Early Phase 1Sweden
85JPRN-UMIN0000356022019/01/112 April 2019Hydrogen gas inhalation randomized double blinded trial for Parkinson's diseaseParkinson's diseasehydrogen gas16 weeks inhalation
two times of the inhalation for 60 minutes per day
8 weeks obsebation after the inhalation
placebo gas
16 weeks inhalation
two times of the inhalation for 60 minutes per day
8 weeks obsebation after the inhalation		Juntendo University Koshigaya HospitalRecruiting40years-old80years-oldMale and Female20Not selectedJapan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
86NCT03638479January 8, 201911 June 2019Utilizing Smart Devices to Identify New Phenotypical Characteristics in Movement DisordersUtilizing Smart Devices to Identify New Phenotypical Characteristics in Movement DisordersParkinson Disease;Essential Tremor;Movement Disorders;Parkinson's Syndrome;Atypical ParkinsonismOther: Data CaptureWestfälische Wilhelms-Universität MünsterRecruiting18 YearsN/AAll500Phase 2Germany
87NCT03659682January 2, 201917 September 2018GLP1R in Parkinson's DiseaseEffect of GLPIR Stimulation on Neuroprotection and Inflammation in Parkinson's DiseaseParkinson DiseaseDrug: SemaglutideOslo University HospitalNot recruiting40 Years75 YearsAll120Phase 2
88NCT03727295January 1, 201912 November 2018Idebenone Treatment of Early Parkinson's DiseasesymptomsA Multicenter, Randomized, Double-blind, Placebo-controlled Study of Idebenone in the Treatment of Early-stage Parkinson's Disease With Motor and Non-motor SymptomsOxidative Stress is an Important Cause of Parkinson's DiseaseDrug: Idebenone/placeboSecond Affiliated Hospital of Soochow UniversityQilu Pharmaceutical Co., Ltd.Not recruiting30 Years80 YearsAll180Phase 4
89ChiCTR18000199422018-12-3110 December 2018A Multicenter Randomized Controlled Trial for Effect of Zishen Pingchan Granules Combined with Pramipexole in the treatment of Depression in Parkinson’s DiseaseA Multicenter Randomized Controlled Trial for Effect of Zishen Pingchan Granules Combined with Pramipexole in the treatment of Depression in Parkinson’s DiseaseParkinson’s DiseaseExperimental group:Zishen Pingchan Granules combined with Pramipexole;Control group:Zishen Pingchan Granules placebo combined with Pramipexole;The Affiliated Brain Hospital of Nanjing Medical University( Nanjing Brain Hospital)Not Recruiting3085BothExperimental group:150;Control group:150;New Treatment Measure Clinical StudyChina
90NCT03391882December 19, 201811 November 2019A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)An Open-Label, Randomized, Crossover Trial Utilizing a Single-Blinded Rater to Evaluate APL-130277 Compared to Subcutaneous Apomorphine in Levodopa Responsive Subjects With Parkinson's Disease Complicated by Motor FluctuationsMotor OFF Episodes Associated With Parkinson's DiseaseDrug: APL-130277;Drug: subcutaneous apomorphineSunovionRecruiting18 YearsN/AAll106Phase 3Austria;France;Germany;Italy;Spain;United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
91NCT03781791December 10, 201829 July 2019Orally Administered ENT-01 for Parkinson's Disease-Related Constipation (KARMET)A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)Constipation;Parkinson DiseaseDrug: Active Investigational Treatment ENT-01;Drug: Placebo TreatmentEnterin Inc.Not recruiting30 Years90 YearsAll72Phase 2United States
92NCT03710707December 4, 201817 June 2019Study to Evaluate DNL201 in Subjects With Parkinson's DiseaseA Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Subjects With Parkinson's DiseaseParkinson DiseaseDrug: DNL201 low dose;Drug: DNL201 high dose;Drug: PlaceboDenali Therapeutics Inc.Recruiting30 Years75 YearsAll30Phase 1United States
93NCT03944447December 1, 20187 October 2019Outcomes Mandate National Integration With Cannabis as MedicineOutcomes Mandate National Integration With Cannabis as MedicineChronic Pain;Chronic Pain Syndrome;Chronic Pain Due to Injury;Chronic Pain Due to Trauma;Fibromyalgia;Seizures;Hepatitis C;Cancer;Crohn Disease;HIV/AIDS;Multiple Sclerosis;Traumatic Brain Injury;Sickle Cell Disease;Post Traumatic Stress Disorder;Tourette Syndrome;Ulcerative Colitis;Glaucoma;Epilepsy;Inflammatory Bowel Diseases;Parkinson Disease;Amyotrophic Lateral Sclerosis;Chronic Traumatic Encephalopathy;Anxiety;Depression;Insomnia;Autism;Opioid-use Disorder;Bipolar DisorderDrug: Cannabis, MedicalOMNI Medical Services, LLCRecruiting7 YearsN/AAll100000Phase 2United States
94NCT03639064December 201827 August 2018Cannabis Oil for Pain in Parkinson's DiseaseA Phase II, Randomized, Open-label, Double-blind, Two-center Study to Evaluate the Tolerability, Safety and Dose-finding of Oil Cannabis Preparation for Pain in Parkinson's DiseaseParkinson DiseaseDrug: Cannabis OilUniversity Health Network, TorontoParkinson Society CanadaNot recruiting18 YearsN/AAll15Phase 2
95NCT03942172November 27, 201827 May 2019Treatment of Balance Disorders in Parkinson's Patients Using SpotOn Balance GlassesTreatment of Balance Disorders in Parkinson's Patients Using SpotOn Balance GlassesParkinson DiseaseDevice: SpotOn balance glassesSpotOn Therapeutics Ltd.Not recruiting30 YearsN/AAll50N/AIsrael
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
96NCT03822364November 26, 20189 September 2019Staccato Apomorphine Single and Multi Dose PKA Randomized Study of the Safety, Tolerability, and Pharmacokinetics of AZ-009 (Staccato Apomorphine) in Healthy Volunteers and the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZ-009 in Subjects With Parkinson's DiseaseParkinson DiseaseDrug: 009-5;Drug: 009-4;Drug: 009-3;Drug: 009-2;Drug: 009-0;Drug: active comparator;Drug: 009-1Alexza Pharmaceuticals, Inc.Not recruiting18 Years60 YearsAll56Phase 1Netherlands
97NCT03823638November 20, 201811 February 2019Safety, Tolerability and Effects of Mannitol in Parkinson's DiseaseA Phase II Single Center, Randomized, Double Blind and Placebo Controlled Study Assessing the Safety, Tolerability and Effects of Progressively Increased Dose of Oral Mannitol in Parkinson's DiseaseParkinson DiseaseDietary Supplement: Oral D-Mannitol of PlaceboHadassah Medical OrganizationRecruiting40 Years75 YearsAll60Phase 2Israel
98NCT03713957November 12, 201822 October 2019A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive ImpairmentA Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive ImpairmentParkinson DiseaseDrug: GRF6021;Other: PlaceboAlkahest, Inc.Michael J. Fox Foundation for Parkinson's ResearchRecruiting40 Years85 YearsAll90Phase 2United States;Australia
99NCT03733561November 9, 201811 March 2019A Study to Assess Pharmacokinetic Profiles of LY03003 and NeuproA Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy VolunteersParkinson DiseaseDrug: LY03003;Drug: Neupro 4Mg/24Hr Transdermal PatchLuye Pharma Group Ltd.Recruiting18 Years45 YearsAll40Phase 1United States
100NCT03667404November 6, 201811 November 2019Resistant Maltodextrin for Gut Microbiome in Parkinson's Disease: Safety and Tolerability StudyGut Microbial Remodeling With Resistant Maltodextrin for Motor and Non-motor Symptoms in Parkinson's Disease: Safety and Tolerability StudyParkinson Disease;Intestinal Bacteria Flora Disturbance;Dietary ModificationDietary Supplement: Resistant maltodextrin;Dietary Supplement: maltodextrinNorthwestern UniversityUniversity of Illinois at ChicagoRecruiting60 YearsN/AAll30Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
101NCT03670953November 6, 201811 November 2019A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Patients With Motor FluctuationsA Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 With Immediate-Release Carbidopa-Levodopa in Parkinson's Disease Patients With Motor FluctuationsParkinson's Disease (Disorder)Drug: IR CD-LD;Drug: IPX203 ER CD-LD;Other: IPX203 placebo;Other: IR CD-LD placeboImpax Laboratories, LLCRecruiting40 YearsN/AAll510Phase 3United States;Czechia;France;Germany;Italy;Spain
102NCT03069911November 1, 201826 August 2019Trial of OnabotulinumtoxinA for Depression in Parkinson DiseaseRandomized Controlled Trial of OnabotulinumtoxinA for Depression in Parkinson DiseaseParkinson Disease;DepressionBiological: OnabotulinumtoxinA;Biological: ControlJohns Hopkins UniversityNot recruiting18 Years95 YearsAll3Phase 1United States
103NCT03727139November 1, 201819 November 2018Rasagiline Tablets Special Drug Use-Results Survey Survey on Long-term SafetyAZILECT Tablets Special Drug Use-Results Survey Survey on Long-term SafetyParkinson's DiseaseDrug: RasagilineTakedaRecruitingN/AN/AAll1000N/AJapan
104EUCTR2017-003415-19-ES31/10/20187 January 2019A Clinical Study in Parkinson’s Disease Patients With Moderate to Severe Abnormal Movements to See If JM-010 is Effective and Safe/Tolerable.A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson’s Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Combinations Of JM-010Parkinson’s Disease Patients With Moderate to Severe Dyskinesia;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: JM-010
Product Code: JM-010
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Buspirone hydrochloride
CAS Number: 33386-08-2
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4-
INN or Proposed INN: Zolmitriptan
CAS Number: 139264-17-8
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.8-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Product Name: JM-010
Product Code: JM-010
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Buspirone hydrochloride
CAS Number: 33386-08-2
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 8-
INN or Proposed INN: Zolmitriptan
CAS Number: 139264-17-8
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.8-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use		Contera PharmaAuthorisedFemale: yes
Male: yes		81Phase 2France;Spain;Germany
105ChiCTR18000179492018-10-3027 August 2018Clinical study for the effect of the combination of Shudipingchan prescription and Monoamine oxidase inhibitor on improving early PD symptoms and delaying the progression of the diseaseClinical study for the effect of the combination of Shudipingchan prescription and Monoamine oxidase inhibitor on improving early PD symptoms and delaying the progression of the diseaseParkinson's diseaseGroup 1:Selegiline and Shudipingchan granule;Group 2:Selegiline and simulant TCM granule;Longhua Hospital Shanghai University of Traditional Chinese MedicineNot Recruiting3085BothGroup 1:72;Group 2:72;New Treatment Measure Clinical StudyChina
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
106ChiCTR18000180172018-10-303 September 2018Clinical study for the effect of the combination of Shudipingchan prescription and Monoamine oxidase inhibitor on improving early Parkinson‘s Disease symptoms and delaying the progression of the diseaseClinical study for the effect of the combination of Shudipingchan prescription and Monoamine oxidase inhibitor on improving early Parkinson‘s Disease symptoms and delaying the progression of the diseaseParkinson's diseaseTreatment group:Selegiline+Shudipingchan granule;Control group:Selegiline+TCM simulant;Longhua Hospital Shanghai University of Traditional Chinese MedicineNot Recruiting3085BothTreatment group:92;Control group:92;New Treatment Measure Clinical StudyChina
107EUCTR2017-002426-20-ES19/10/20187 January 2019Effect of Safinamide on Parkinson’s Disease Related Chronic PainA randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of safinamide 100 mg once daily, as add-on therapy, in idiopathic Parkinson’s Disease (IPD) patients with motor fluctuations and PD related chronic pain - Pain studyIdiopathic Parkinson's Disease, Hoehn and Yahr stage between 2-3 inclusive during the “ON” phase, experiencing motor fluctuations while on stable doses of L-Dopa (with or without benserazide/carbidopa, with or without addition of a catechol O-methyltransferase (COMT) inhibitor) and may be on stable doses of other PD medications (a dopamine agonist, an anticholinergic and/or amantadine), yet are experiencing more than 2 hours of OFF time per day and chronic PD related pain.
MedDRA version: 20.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Xadago
Product Name: Xadago
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Safinamide methansulfonate
CAS Number: 202825-46-5
Other descriptive name: SAFINAMIDE METHANESULFONATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Trade Name: Xadago
Product Name: Xadago
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Safinamide methansulfonate
CAS Number: 202825-46-5
Other descriptive name: SAFINAMIDE METHANESULFONATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use		Zambon SpAAuthorisedFemale: yes
Male: yes		177Phase 4Spain
108NCT03720418October 17, 201816 September 2019Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson's DiseaseA Phase I/II Safety and Dose Evaluation Study of OXB-102 in Patients With Bilateral Idiopathic Parkinson's DiseaseParkinson DiseaseDrug: OXB-102;Other: Imitation Surgical Procedure (ISP)Axovant Sciences Ltd.Oxford BioMedicaRecruiting48 Years70 YearsAll30Phase 1/Phase 2France;United Kingdom
109EUCTR2016-004610-95-DE01/10/20184 December 2018Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants with Parkinson’s DiseaseA Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson’s Disease - SPARKParkinson's Disease
MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Code: BIIB054
Pharmaceutical Form: Solution for injection/infusion
INN or Proposed INN: n/a
Current Sponsor code: BIIB054
Other descriptive name: BIIB054
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous use		Biogen Idec Research LimitedAuthorisedFemale: yes
Male: yes		311Phase 2France;United States;Canada;Spain;Austria;Israel;Germany;Italy;United Kingdom;Sweden
110NCT03703570September 29, 201828 January 2019A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing PreparationsA Phase 2b Study of KW-6356 in Subjects With Parkinson's Disease on Treatment With Levodopa-containing PreparationsParkinson's DiseaseDrug: KW-6356;Drug: PlaceboKyowa Hakko Kirin Co., LtdRecruiting20 Years80 YearsAll486Phase 2Japan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
111NCT03665454September 24, 201826 August 2019PF 06412562 in Subjects With Advanced Stage Parkinson's DiseaseA Phase Ib Safety, Tolerability, and Efficacy Study of Two Days of Oral Split Dose (25/20 mg) Administration of PF 06412562 in Subjects With Advanced Stage Parkinson's DiseaseParkinson DiseaseDrug: PF-06412562;Drug: Standard of Care PlaceboMilton S. Hershey Medical CenterPfizerNot recruitingN/AN/AAll8Phase 1United States
112NCT03582137September 17, 20184 February 2019A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's DiseaseA Randomized, Double Blind, Placebo-controlled Parallel Study of Tolerability and Efficacy of Cannabidiol (CBD) on Motor Symptoms in Parkinson's DiseaseParkinson DiseaseDrug: Cannabidiol;Other: PlaceboUniversity of Colorado, DenverColorado Department of Public Health and EnvironmentRecruiting40 Years85 YearsAll75Phase 2United States
113NCT03608371August 31, 201817 June 2019BTRX-246040 Study in Subjects With Parkinson's Disease With Motor FluctuationsPhase 2A, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BTRX-246040 in Parkinson's Disease Subjects With Motor FluctuationsParkinson Disease;Motor DisorderDrug: BTRX-246040;Drug: PlaceboBlackThorn Therapeutics, Inc.Not recruiting30 Years76 YearsAll24Phase 2United States
114NCT03229174August 23, 201830 September 2019Brain Perfusion & Oxygenation in Parkinson's Disease With NOHEvaluation of Brain Perfusion and Oxygenation in PD Patients With Neurogenic Orthostatic Hypotension: 4 Week Comparison of Droxidopa Versus PlaceboParkinson Disease;Neurogenic Orthostatic HypotensionDrug: Droxidopa;Drug: PlaceboWilliam Ondo, MDLundbeck LLCRecruiting18 Years85 YearsAll28Phase 4United States
115NCT03621046August 20, 201821 January 2019Use of Low-dose Zolpidem in Parkinson's DiseaseA Placebo Controlled Double Blind Randomised Controlled Proof of Concept Study of Zolpidem for the Treatment of Motor and Cognitive Deficits in Late-stage Parkinson'sParkinson DiseaseDrug: Zolpidem;Other: PlaceboAston UniversityUniversity Hospital Birmingham NHS Foundation TrustRecruiting40 Years80 YearsAll28Phase 2United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
116NCT03567447August 17, 20184 November 2019Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH)Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH)Parkinson Disease;Falls PatientDrug: Droxidopa;Other: PlaceboSt. Joseph's Hospital and Medical Center, PhoenixH. Lundbeck A/S;Arizona State UniversityRecruiting30 Years83 YearsAll10Phase 2United States
117NCT03675282August 14, 20187 October 2019Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and ControlsQuantitative Mapping of Substantia Nigra Iron in Parkinson's Disease and ControlsParkinson Disease;REM Sleep Behavior Disorder;HealthyDrug: (11C)PE2IWeill Medical College of Cornell UniversityNational Institute of Neurological Disorders and Stroke (NINDS)Recruiting20 Years100 YearsAll100Phase 1/Phase 2United States
118NCT03773796August 6, 20187 October 2019Nabilone for Non-motor Symptoms in Parkinson's DiseaseNabilone for Non-motor Symptoms in Parkinson's Disease: An Open-label Study to Evaluate Long-term Safety and EfficacyParkinson DiseaseDrug: Nabilone 0.25 mgMedical University InnsbruckRecruiting30 Years100 YearsAll48Phase 3Austria
119ChiCTR18000169492018-08-019 July 2018Efficacy assessment and standard treatment of rasagiline in Chinese patients with early Parkinson's diseaseEfficacy assessment and standard treatment of rasagiline in Chinese patients with early Parkinson's diseaseParkinson's diseaseRasagiline early start group:rasagiline-rasagiline;Rasagiline delay start group:placebo-rasagiline;Beijing HospitalNot Recruiting3080BothRasagiline early start group:130;Rasagiline delay start group:130;New Treatment Measure Clinical StudyChina
120ChiCTR18000170842018-08-0127 August 2019Investigation of new approaches and technologies in the management of Parkinson's diseaseThe efficacy of Butylphthalide on cognitive impairment of patients with idiopathic PD and DBS patients: A Randomized, double-blind, placebo-controlled, multicenter trialParkinson's diseaseButylphthalide group:Butylphthalide, 2 capsules/time, 3 times/day, for 48 weeks;Control group:Placebo, 2 capsules/time, 3 times/day, for 48 weeks;Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyRecruiting1880BothButylphthalide group:140;Control group:140;Phase 4China
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
121JPRN-UMIN0000332852018/08/0122 July 2019The preventive effect of medicine for osteoporosis on osteopenia in patients with Parkinson's disease: multicenter/ non-blind/ randomised/ exploratory clinical trialThe preventive effect of medicine for osteoporosis on osteopenia in patients with Parkinson's disease: multicenter/ non-blind/ randomised/ exploratory clinical trial - The preventive effect of medicine for osteoporosis on osteopenia in patients with Parkinson's diseaseParkinson's diseaseOral bisphosphonate agent group: taking orally Minodronic Acid Hydrate (50mg) 1 tablet per 4 weeks
Intravenous bisphosphonate agent group: injecting Zoledronic Acid (5mg) 1 ampule per 48 weeks		Department of Orthopaedic Surgery, Niigata University Medical and Dental HospitalDepartment of Neurology, Nishi-Niigata Chuo HospitalNot Recruiting50years-oldNot applicableMale and Female100Not selectedJapan
122EUCTR2017-005170-19-SE30/07/20187 January 2019A Long-Term Follow-up Safety Study for Patients with Parkinson’s Disease (PD) Implanted with the Drug Delivery System (DDS) and/or Who Received Treatment in the Main Study and/or Extension StudyA Long-Term Follow-up Safety Study for Patients with Idiopathic Parkinson’s Disease (PD) Implanted with the DDS and/or Who Received Treatment in the Main Study and/or Extension Study - Long-Term Follow-up Safety After DDS Implantation with/without CDNF InfusionsIdiopathic Parkinson's Disease
MedDRA version: 20.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Cerebral Dopamine Neurotrophic Factor
Product Code: CDNF
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: Not Applicable
Other descriptive name: recombinant human Cerebral Dopamine Neurotrophic Factor
Concentration unit: µg/µl microgram(s)/microlitre
Concentration type: equal
Concentration number: 1.0-		Renishaw plcAuthorisedFemale: yes
Male: yes		20Phase 1;Phase 2Sweden
123NCT03599726July 30, 201826 August 2019Improving Walking Automaticity in Parkinson's Disease: Levodopa or DonepezilImproving Walking Automaticity in Parkinson's Disease: Levodopa or DonepezilParkinson DiseaseDrug: Donepezil;Drug: PlaceboOregon Health and Science UniversityMedical Research Foundation, OregonRecruiting50 Years90 YearsAll20Early Phase 1United States
124NCT03611569July 25, 201830 September 2019Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's DiseaseInterventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Properties of Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's DiseaseHealthy;Parkinson DiseaseDrug: Lu AF82422;Drug: PlaceboH. Lundbeck A/SRecruiting18 Years80 YearsAll44Phase 1United States
125NCT03587168July 20, 20185 November 2018The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Parkinson's DiseaseThe Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Parkinson's DiseaseParkinson DiseaseOther: Four Square Step Test;Other: Functional Reach Test;Other: Trunk Impairment Scale;Other: Timed Up and Go Test;Other: Hoehn and Yahr Scale;Other: Unified Parkinson's Disease Rating Scale;Other: Berg Balance Scale;Other: the timed 360° turn testGazi UniversityNot recruiting40 YearsN/AAll86Phase 3Turkey
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
126JPRN-jRCTs05218015819/07/201822 July 2019The effect of rehabilitation robots for patients with Parkinson's disease.A study on the effectiveness of balance rehabilitation support robot (balance exercise assist robot) for Parkinson's patient.Parkinson's Disease;D010300Robot group: The participants performs twelve per a session, 2sessions per a week for 8 weeks.
Control group: The participants receives balance exercise by physical therapist twice a week for 8 weeks.		Kazuhisa DomenRecruiting40 age old80 age oldBoth50N/Anone
127NCT03594656July 15, 201811 June 2019Effects of Lingzhi on Disease Progression in Patients With Untreated Early Parkinson's DiseaseEffects of Lingzhi on Disease Progression in Patients With Untreated Early Parkinson's Disease: A Multicenter, Randomized, Double-blind, Placebo-controlled TrialParkinson DiseaseDrug: Ganoderma;Drug: PlacebosXuanwu Hospital, BeijingRecruiting30 Years80 YearsAll288Phase 3China
128NCT03624920July 12, 20187 October 2019Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime SleepinessSafety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime SleepinessParkinson DiseaseDrug: THN102 Dosage A;Drug: THN102 Dosage B;Drug: THN102 Dosage CTheranexusNot recruiting18 Years80 YearsAll71Phase 2United States;Czechia;France;Germany;Hungary
129NCT03774459July 9, 201826 August 2019ANAVEX2-73 Study in Parkinson's Disease DementiaA Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients With Parkinson's Disease With DementiaParkinsons Disease With DementiaDrug: High dose ANAVEX2-73;Drug: Mid dose ANAVEX2-73;Drug: Placebo oral capsuleAnavex Life Sciences Corp.Anavex Germany GmbHRecruiting50 Years85 YearsAll120Phase 2Australia;Spain
130NCT03146130July 5, 201820 August 2018Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control DisordersStudy of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders (TCI) Induced by Dopaminergic Treatments in Parkinson's DiseaseImpulse Control Disorder;ParkinsonBiological: Variation of behaviors of Parkinson's diseaseCentre Hospitalier Universitaire, AmiensRecruiting18 YearsN/AAll70Phase 3France
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
131NCT03775538July 5, 201825 March 2019Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical StudyA Randomised, Double-Blind, Multi-centre, Active Treatment, Extension and Safety Study for Patients With Idiopathic Parkinson's Disease (PD) Who Previously Completed the CDNF/DDS Main Study HP-CD-CL-2002Parkinson Disease;Movement Disorders;Neuro-Degenerative Disease;Nervous System Diseases;Brain DiseasesDrug: Cerebral Dopamine Neurotrophic Factor;Device: Renishaw Drug Delivery SystemHerantis Pharma Plc.Renishaw plc.Recruiting35 Years75 YearsAll18Phase 1/Phase 2Finland;Sweden
132EUCTR2017-004335-36-ES04/07/201824 September 2018A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Parkinson’s Disease with Dementia Patients.A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Parkinson’s Disease with Dementia Patients. - A Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73Cognition in Parkinson’s Disease with dementia;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: ANAVEX2-73
Pharmaceutical Form: Capsule
INN or Proposed INN: ANAVEX2-73
Current Sponsor code: ANAVEX2-73
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Product Name: ANAVEX2-73
Pharmaceutical Form: Capsule
INN or Proposed INN: ANAVEX2-73
Current Sponsor code: ANAVEX2-73
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-		Anavex Life Sciences Corp.AuthorisedFemale: yes
Male: yes		120Phase 2Spain
133NCT03521635July 3, 20184 November 2019The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-DopaA Two- Stage Multicenter, Open-label, Randomized, Active Controlled Parallel Group Study Comparing the Efficacy and Safety of Pramipexole SR Versus Pramipexole IR Administered Orally Over an 18-week Treatment on Nocturnal Symptoms in L-Dopa+ Treated Patients With Advanced Parkinson's Disease (PD)Parkinson DiseaseDrug: Pramipexole SR;Drug: Pramipexole IRBoehringer IngelheimNot recruiting30 YearsN/AAll98Phase 4China
134JPRN-UMIN0000334092018/07/022 April 2019Prevention of local skin reaction by heparinoid due to rotigotine transdermal patch: a pilot randomized clinical trial.Parkinson's diseasePretreatment by heparinoid
In the pretreatment group, heparinoid is applied daily to the sites (shoulder, upper arm, abdomen, thigh, buttocks on both sides) to be applied rotigotine transdermal patch from the beginning of 1 week before. The dose is one finger tip unit (about 0.5 g) for two palms. The period is 8 weeks.
Non-pretreatment by heparinoid.
The non-pretreatment group use rotigotine without using heparinoid. The period is 8 weeks.		Wakayama Medical UniversityRecruiting20years-old85years-oldMale and Female20Phase 1Japan
135NCT03566589July 2, 201820 August 2018Effects of PS128 on Parkinsonian SymptomsEffects of Lactobacillus Plantarum PS128 on the Parkinsonian Symptoms in Parkinson's Disease: a Pilot StudyParkinson DiseaseDietary Supplement: Lactobacillus plantarum PS128Professor Lu Neurological ClinicNot recruiting40 Years80 YearsAll30N/ATaiwan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
136JPRN-UMIN0000334542018/07/012 April 2019A study on the effectiveness of balance rehabilitation support robot (balance exercise assist robot) for Parkinson's patient.Parkinson's Diseaserobot assisted balance training (RABT)
The group is taken 40-minute / session, twice a week during 8-weeks. Total intervention sessions are 16.
traditional balance training (TBT)
The group is taken 40-minute / session, twice a week during 8-weeks. Total intervention sessions are 16.		Hyogo College of MedicineRecruiting40years-old80years-oldMale and Female50Not selectedJapan
137NCT03576638July 201816 July 2018Study to Assess Pharmacokinetics of Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Parkinson's Disease PatientsAn Open Label Phase 2 Study to Assess the Pharmacokinetics of the Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Patients With Parkinson's DiseaseParkinson DiseaseDrug: Accordion Pill Carbidopa/Levodopa;Drug: Sinemet CR 25Mg-100Mg Extended-Release TabletIntec Pharma Ltd.Not recruiting30 YearsN/AAll12Phase 2
138NCT03562494June 28, 201822 October 2019VY-AADC02 for Parkinson's Disease With Motor FluctuationsA Randomized, Placebo Surgery Controlled, Double-blinded, Multi-center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of VY-AADC02 in Advanced Parkinson's Disease With Motor FluctuationsParkinson DiseaseBiological: VY-AADC02;Other: PlaceboNeurocrine BiosciencesVoyager TherapeuticsRecruiting40 Years75 YearsAll42Phase 2United States
139NCT03407378June 26, 201816 September 2019A Study to Investigate a New Treatment in Patients With Parkinson's DiseaseA Proof of Concept Study to Investigate the Effect of IPT803 Adjunct Treatment in Patients With Parkinson's DiseaseParkinson DiseaseDrug: IPT803;Genetic: Optional pharmacogenetic assessment;Other: Questionnaires;Other: Optional Blood-Oxygen-level Dependent functionalMRI;Other: Motor Assessments before taking regular PD treatment;Other: Motor Assessments on regular PD treatmentTools4PatientRecruiting35 YearsN/AAll120Phase 1/Phase 2United States;Belgium;France
140EUCTR2017-001420-21-DE18/06/201828 February 2019Clinical Efficacy, Safety and Tolerability of P2B001 in Early Parkinson's DiseaseA Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects With Early Parkinson’s Disease and to a Calibration Arm of Pramipexole ER.Early Parkinson's Disease
MedDRA version: 20.0 Level: HLT Classification code 10034005 Term: Parkinson's disease and parkinsonism System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Code: P2B001
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE
CAS Number: 191217-81-9
Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.6-
INN or Proposed INN: Rasagiline mesylate
CAS Number: 161735-79-1
Other descriptive name: RASAGILINE MESILATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.75-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Product Name: Pramipexole dihydrochloride
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE
CAS Number: 191217-81-9
Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.6-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Product Name: Rasagiline
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Rasagiline mesylate
CAS Number: 161735-79-1
Other descriptive name: RASAGILINE MESILATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.75-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Trade Name: Pramipexole dihydrochloride extended-release tablets		Pharma Two B LtdAuthorised Female: yes
Male: yes		525Phase 3France;United States;Canada;Spain;Germany
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
141EUCTR2017-001420-21-ES13/06/201818 June 2018Clinical Efficacy, Safety and Tolerability of P2B001 in Early Parkinson's DiseaseA Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects With Early Parkinson’s Disease and to a Calibration Arm of Pramipexole ER.Early Parkinson's Disease
MedDRA version: 20.0 Level: HLT Classification code 10034005 Term: Parkinson's disease and parkinsonism System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Code: P2B001
Pharmaceutical Form: Capsule
INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE
CAS Number: 191217-81-9
Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.6-
INN or Proposed INN: Rasagiline mesylate
CAS Number: 161735-79-1
Other descriptive name: RASAGILINE MESILATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.75-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Product Name: Pramipexole dihydrochloride
Pharmaceutical Form: Capsule
INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE
CAS Number: 191217-81-9
Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.6-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Product Name: Rasagiline
Pharmaceutical Form: Capsule
INN or Proposed INN: Rasagiline mesylate
CAS Number: 161735-79-1
Other descriptive name: RASAGILINE MESILATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.75-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Trade Name: Pramipexole dihydrochloride extended-release tablets
Product Name: Pramipexole dihydrochloride extended-release tablets
Pharmaceutical Form: Tablet
INN or Proposed INN: PRAMIPEXOLE DIHYDROCHLORIDE
CAS Number: 191217-81-9
Other descriptive name: PRAMIPEXOLE DIHYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: range
Concentration number: 0.375-4.5
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use		Pharma Two B LtdAuthorisedFemale: yes
Male: yes		525Phase 3France;United States;Canada;Spain;Germany
142NCT03439943June 13, 201820 August 2018Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's DiseaseMulticenter, Randomised, Placebo-controlled, Double Blinded, Parallel Arm Proof-of-concept Trial of Lixisenatide in Patients With Early Parkinson's DiseaseParkinson DiseaseDrug: Lixisenatide;Drug: placeboUniversity Hospital, ToulouseCure Parkinson;Réseau NS-Park;EUCLID;SanofiRecruiting40 Years75 YearsAll158Phase 2France
143EUCTR2017-004006-18-NL07/06/201818 June 2018The effect of inhaled levodopa on the recovery from off periods in patients with Parkinson's diseaseTherapeutic effects of an inhaled levodopa dry powder formulation on the recovery from off periods in patients with Parkinson's disease - Effectiveness of inhaled levodopa in Parkinson's diseaseParkinson's disease is a progressive neurodegenerative disorder characterized by a lack of dopamine production due to the loss of dopamine producing cells in the substantia nigra. This lack of dopamine causes disruption of motor circuits in the brain resulting in motor function impairments like tremor, rigidity and bradykinesia.
MedDRA version: 20.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Levodopa powder for inhalation
Product Code: Levodopa Cyclops
Pharmaceutical Form: Inhalation powder
INN or Proposed INN: levodopa
CAS Number: 59-92-7
Current Sponsor code: levodopa
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: range
Concentration number: 60-90
Trade Name: Madopar 125 mg, orodispersible tablet
Pharmaceutical Form: Orodispersible tablet		Pharmaceutical Technology and Biopharmacy, University of GroningenAuthorisedFemale: yes
Male: yes		8Phase 2Netherlands
144NCT03456687June 5, 201823 April 2019Effects of Exenatide on Motor Function and the BrainEffects of Exenatide on Motor Function and the BrainParkinson's DiseaseDrug: ExenatideUniversity of FloridaNational Institute of Neurological Disorders and Stroke (NINDS)Recruiting40 Years77 YearsAll15Phase 1United States
145EUCTR2018-000346-19-SE04/06/201811 June 2018An extended clinical study to test the safety of Cerebral Dopamine Neurotrophic Factor (CDNF) by brain infusion via Drug Delivery System (DDS) in patients with Parkinson's disease.A Randomised, Double-Blind, Multi-centre, Active Treatment, Extension and Safety Study for Patients with Idiopathic Parkinson’s Disease (PD) Who Previously Completed the CDNF/DDS Main Study HP-CD-CL-2002. - Extension StudyIdiopathic Parkinson's Disease
MedDRA version: 20.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Cerebral Dopamine Neurotrophic Factor
Product Code: CDNF
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: Not Applicable
Other descriptive name: recombinant human Cerebral Dopamine Neurotrophic Factor
Concentration unit: µg/µl microgram(s)/microlitre
Concentration type: equal
Concentration number: 1.0-		Herantis Pharma PlcAuthorisedFemale: yes
Male: yes		18Phase 1;Phase 2Sweden
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
146NCT03684122June 1, 20187 October 2019Use of Mesenchymal Stem Cells (MSCs) Differentiated Into Neural Stem Cells (NSCs) in People With Parkinson's (PD).A Safety and Efficacy Study of the Effects of Mesenchymal Stem Cells (MSCs) Differentiated Into Neural Stem Cells (NSCs) on the Motor and Non-motor Symptoms in People With Parkinson's Disease (PD).Parkinson DiseaseBiological: Injection of Umbilical cord derived MSCsUniversity of JordanRecruiting20 Years75 YearsAll10Phase 1/Phase 2Jordan
147EUCTR2017-002780-17-ES21/05/201812 November 2018Study in Male and Female Patients with Advanced Parkinson’s Disease to Assess the blood levels of Levodopa Administered as ND0612 via a Pump System plus Additional Oral Administered Levodopa/Carbidopa versus Levodopa Administered as Duodopa.A Pivotal, Open-Label, Randomized, Crossover, Four Sequences Study in Male and Female Patients with Advanced Parkinson’s Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion via a Pump System plus Additional Oral Administered Levodopa/Carbidopa versus Levodopa Administered as Carbidopa-Levodopa Enteral SuspensionParkinson’s Disease
MedDRA version: 20.0 Level: HLT Classification code 10034005 Term: Parkinson's disease and parkinsonism System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: ND0612
Product Code: ND0612
Pharmaceutical Form: Solution for infusion in administration system
INN or Proposed INN: carbidopa
CAS Number: 38821-49-7
Current Sponsor code: -
Other descriptive name: CARBIDOPA
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 7.5-
INN or Proposed INN: levodopa
CAS Number: 59-92-7
Current Sponsor code: -
Other descriptive name: LEVODOPA
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 60-
Trade Name: SINEMET Plus
Product Name: SINEMET
Pharmaceutical Form: Tablet
INN or Proposed INN: levodopa
CAS Number: 59-92-7
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
INN or Proposed INN: carbidopa
CAS Number: 38821-49-7
Other descriptive name: CARBIDOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Trade Name: Duodopa LD/CD 20/5 mg/mL
Product Name: Duodopa LD/CD 20/5 mg/mL
Pharmaceutical Form: Intestinal gel
INN or Proposed INN: levodopa
CAS Number: 59-92-7
Other descriptive name: LEVODOPA
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 20-
INN or Proposed INN: carbidopa
CAS Number: 38821-49-7
Other descriptive name: CARBIDOPA
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 5-		NeuroDerm Ltd.Not RecruitingFemale: yes
Male: yes		50Phase 3France;United States;Spain;Austria;Netherlands;Italy
148EUCTR2016-004610-95-ES18/05/201818 June 2018Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants with Parkinson’s DiseaseA Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson’s Disease - SPARKParkinson's Disease
MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Code: BIIB054
Pharmaceutical Form: Solution for injection/infusion
INN or Proposed INN: n/a
Current Sponsor code: BIIB054
Other descriptive name: BIIB054
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous use		Biogen Idec Research LimitedAuthorisedFemale: yes
Male: yes		311Phase 2France;United States;Canada;Spain;Austria;Israel;Germany;Italy;United Kingdom;Sweden
149NCT03589066May 15, 201819 November 2018Pharmacokinetic Study of LY03003 in Patients With Parkinson's DiseaseAn Open-label, Randomized, Parallel-group Trial to Evaluate the Pharmacokinetics of Two Formulations of LY03003 After a Single Intramuscular Injection Administered to Patients With Parkinson's DiseaseParkinson DiseaseDrug: LY03003Luye Pharma Group Ltd.Not recruiting18 YearsN/AAll24Phase 1United States
150EUCTR2017-004475-31-CZ09/05/201830 April 2019Safety and efficacy study of two THN102 doses in subjects with excessive daytime sleepiness associated with Parkinson’s disease.Randomised, double-blind, placebo-controlled, complete 3-way cross-over phase IIa trial to investigate safety and efficacy of two THN102 doses in subjects with excessive daytime sleepiness associated with Parkinson’s diseaseExcessive daytime sleepiness associated with Parkinson’s disease
MedDRA version: 20.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0 Level: PT Classification code 10041349 Term: Somnolence System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Flecainide acetate
Product Code: THN02
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Flecainidum
CAS Number: 54143-56-5
Other descriptive name: FLECAINIDE ACETATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1 -
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Flecainide acetate
Product Code: THN02
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Flecainidum
CAS Number: 54143-56-5
Other descriptive name: FLECAINIDE ACETATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 9 -
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Trade Name: Modiodal
Product Name: over-encapsulated Modafinil
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: MODAFINIL
CAS Number: 68693-11-8
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use		Theranexus S.A.Authorised Female: yes
Male: yes		60Phase 2France;United States;Hungary;Czech Republic;Germany
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
151NCT03637023May 8, 201822 July 2019Virtual Reality for Parkinson's DiseaseClinical and Rest-fMRI Effects of Virtual Reality Practice on Motor and Cognitive Symptoms in Parkinson's Disease, a Randomized Control TrialParkinson Disease;Virtual Reality Therapy;Functional Magnetic Resonance ImagingBehavioral: Virtual Reality;Behavioral: Exercise Therapy;Drug: Pharmacological TreatmentFarzin Hajebrahimi, PT, MScRecruiting50 Years85 YearsAll45N/ATurkey
152NCT03587649May 7, 201830 September 2019Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density LossEvaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss in the Brain of Patients With Probable Alzheimer's Disease, Probable Parkinson's Disease (PD) Subjects as Compared to Healthy Volunteers (HV).Alzheimer Disease;Parkinson Disease;Healthy VolunteersDrug: [18F]MNI-1126InvicroRecruiting18 Years55 YearsAll15Phase 1United States
153NCT03843944May 1, 201822 October 2019Overnight Switch From Rasagiline To SafinamideOvernight Switch From Rasagiline To Safinamide In Fluctuating Patients With Parkinson's Disease: A Tolerability And Safety StudyParkinson DiseaseDrug: SafinamideIRCCS San RaffaeleNot recruiting30 Years80 YearsAll20Phase 4Italy
154NCT03230526April 20, 201825 June 2018Identification of a Biomarker Predictive of Evolution of Parkinson DiseaseBrain Microglial Activation in the Early Stage of the Parkinson's Disease: a Predictive Biomarker of the Evolution?Parkinson DiseaseDrug: [18F]DPA-714 PET scanNantes University HospitalRecruiting40 Years67 YearsAll64Phase 2France
155NCT03374917April 18, 201825 March 2019A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient EnvironmentAn Open-Label Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 for up to 4 Weeks in an Outpatient EnvironmentParkinson's Disease (PD)Drug: ABBV-951AbbVieNot recruiting30 Years85 YearsAll20Phase 1United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
156EUCTR2017-004475-31-HU17/04/201830 April 2018Safety and efficacy study of two THN102 doses in subjects with excessive daytime sleepiness associated with Parkinson’s disease.Randomised, double-blind, placebo-controlled, complete 3-way cross-over phase IIa trial to investigate safety and efficacy of two THN102 doses in subjects with excessive daytime sleepiness associated with Parkinson’s diseaseExcessive daytime sleepiness associated with Parkinson’s disease
MedDRA version: 20.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0 Level: PT Classification code 10041349 Term: Somnolence System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Flecainide acetate
Product Code: THN02
Pharmaceutical Form: Capsule
INN or Proposed INN: Flecainidum
CAS Number: 54143-56-5
Other descriptive name: FLECAINIDE ACETATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1 -
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Product Name: Flecainide acetate
Product Code: THN02
Pharmaceutical Form: Capsule
INN or Proposed INN: Flecainidum
CAS Number: 54143-56-5
Other descriptive name: FLECAINIDE ACETATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 9 -
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Trade Name: Modiodal
Product Name: over-encapsulated Modafinil
Pharmaceutical Form: Capsule
INN or Proposed INN: MODAFINIL
CAS Number: 68693-11-8
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use		Theranexus S.A.AuthorisedFemale: yes
Male: yes		60Phase 2France;United States;Czech Republic;Hungary;Germany
157EUCTR2017-004253-16-AT13/04/201810 September 2018Investigation of the effect of Nabilon in patients suffering from Parkinson´s Disease with non-Motor symptoms (e.g.sleeping dirsorders, cognitive dysfunction, hallucinations, autonomic dysfunction,...)Nabilone for non-motor symptoms in Parkinson’s disease: An open-label study to evaluate long-term safety and efficacySubject with non-Motor symptoms of Parkinson´s disease
MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Nabilone
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: NABILONE
CAS Number: 51022-71-0
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.25-		Medizinische Universität Innsbruck, Universitätsklinik für NeurologieAuthorisedFemale: yes
Male: yes		48Phase 3Austria
158EUCTR2017-002707-10-DK10/04/201823 July 2018Measurements of drug concentration in the blood for anti-dementia drugs, in order to improve efficacy and reduce side-effectsSerum-monitoring of anti-dementia drugs, and the relevance to side-effects, clinical efficacy and complianceDementia in Alzheimers Disease, Parkinsons Disease and Dementia with Lewy Bodies
MedDRA version: 20.0 Level: PT Classification code 10012271 Term: Dementia Alzheimer's type System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0 Level: LLT Classification code 10012284 Term: Dementia due to Parkinson's disease System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0 Level: PT Classification code 10067889 Term: Dementia with Lewy bodies System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0 Level: PT Classification code 10075174 Term: Mixed dementia System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Memantin Orion
Pharmaceutical Form: Tablet
INN or Proposed INN: MEMANTINE
CAS Number: 19982-08-2
Current Sponsor code: PR1
Concentration unit: mg milligram(s)
Concentration type: range
Concentration number: 10-20
Product Name: Donepezil Sandoz
Product Code: 25330
Pharmaceutical Form: Tablet
INN or Proposed INN: DONEPEZIL
CAS Number: 120014-06-4
Current Sponsor code: PR2
Concentration unit: mg milligram(s)
Concentration type: range
Concentration number: 5-10		Regional Dementia Research Centre, Dept of NeurologyAuthorisedFemale: yes
Male: yes		110Phase 4Denmark
159EUCTR2016-003456-70-DE04/04/201817 September 2018A clinical trial to compare APL-130277 sublingual film to Subcutaneous Apomorphine in Parkinson’s Disease patientsAn Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson’s Disease Complicated by Motor FluctuationsLevodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF episodes)
MedDRA version: 20.0 Level: LLT Classification code 10034006 Term: Parkinson's disease aggravated System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Sublingual film
Route of administration of the placebo: Sublingual use
Trade Name: APO-go
Product Name: s.c. apomorphine
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 10-
Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 15-
Pharmaceutical form of the placebo: Sublingual film
Route of administration of the placebo: Sublingual use
Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Sublingual film
Route of administration of the placebo: Sublingual use
Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal		Sunovion Pharmaceuticals Inc.AuthorisedFemale: yes
Male: yes		106Phase 3United Kingdom;Italy;Germany;Austria;Spain;France
160ChiCTR18000153312018-04-0126 March 2018Dopaminergic Mechanisms of Temporal Working Memory in Parkinson's DiseaseDopaminergic Mechanisms of Temporal Working Memory in Parkinson's DiseaseParkinson's diseasede novo PD patients:levodopa 4 weeks;de novo PD patients:pramipexole 4 weeks;de novo PD patients:selegiline 4 weeks;Institute of Psychology, Chinese Academy of SciencesRecruiting5080Bothde novo PD patients:50;de novo PD patients:50;de novo PD patients:50;OtherChina
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
161NCT03827746April 1, 201816 September 2019The Effect of Kinesiophobia on Physical Activity, Balance and Falling in Parkinson's Disease PatientsThe Effect of Kinesiophobia on Physical Activity, Balance and Falling in Parkinson's Disease PatientsParkinson Disease;Kinesiophobia;Physical Activity;Balance;FallingOther: Tampa Kinesiophobia Scale, Berg-Balance Test, International Physical Activity Questionnaire-Short Form, Falls Efficacy ScaleIstanbul Kültür UniversityMarmara University;Istanbul University-Cerrahpasa;Koç UniversityNot recruiting40 Years85 YearsAll60Phase 2Turkey
162NCT03446807April 201811 June 2018Safety and Efficacy of Droxidopa for Fatigue in Patients With ParkinsonismSafety and Efficacy of Droxidopa for Fatigue in Patients With ParkinsonismParkinson Disease;Multiple System Atrophy;Progressive Supranuclear PalsyDrug: Droxidopa;Drug: Placebo Oral TabletLoma Linda UniversityH. Lundbeck A/SNot recruiting50 YearsN/AAll32Phase 2United States
163EUCTR2017-004297-34-GB31/03/201823 July 2018Use of low-dose zolpidem in Parkinson's.A placebo controlled double blind randomised controlled proof of concept study of zolpidem for the treatment of motor and cognitive deficits in late-stage Parkinson’s - Zolpidem for treatment of motor and cognitive deficits in Parkinson'sParkinson's Disease
MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Stilnoct
Product Name: Stilnoct
Product Code: 207-3120
Pharmaceutical Form: Coated tablet
INN or Proposed INN: Zolpidem Tartrate
CAS Number: 99294-93-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-5
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use		Aston UniversityAuthorisedFemale: yes
Male: yes		28Phase 2United Kingdom
164NCT03648671March 28, 20183 September 2018Pain in Parkinson's Disease With Motor Fluctuations.Spontaneous and Evoked Pain in Parkinson's Disease With Motor Fluctuations: an Observational, Prospective, Clinical and Neurophysiological Study in Patients Under L-dopa Add on Therapies.Parkinson DiseaseDrug: safinamide metansolfonato (12 weeks);Drug: rasagilina mesilato (12 weeks)Universita di VeronaAzienda Ospedaliera Universitaria Integrata VeronaRecruiting18 Years80 YearsAll48Phase 4Italy
165EUCTR2018-000405-23-FI27/03/201830 April 2018Postitron emission tomography imaging of neuroinflammation in Parkinson´s diseaseIn vivo PET imaging of neuroinflammation in Parkinson’s disease using the purinergic P2X7 receptor ligand [11C]SMW139 (PRI-PD) - PRI-PDParkinson´s disease
MedDRA version: 20.0 Level: LLT Classification code 10034007 Term: Parkinson's disease NOS System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: (2-chloro-5-[11C]methoxy-N-(((3s,5s,7s)-3,5,7-trifluoroadamantan-1-yl)methyl) benzamide)
Product Code: [11C]SMW139
Pharmaceutical Form: Injection		Juha Rinne / PET CentreAuthorisedFemale: yes
Male: yes		14Phase 2Finland
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
166EUCTR2016-004610-95-AT23/03/201819 November 2018Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants with Parkinson’s DiseaseA Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson’s Disease - SPARKParkinson's Disease
MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Code: BIIB054
Pharmaceutical Form: Solution for injection/infusion
INN or Proposed INN: n/a
Current Sponsor code: BIIB054
Other descriptive name: BIIB054
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous use		Biogen Idec Research LimitedAuthorisedFemale: yes
Male: yes		311Phase 2France;United States;Canada;Spain;Austria;Israel;Germany;Italy;United Kingdom;Sweden
167NCT03301272March 22, 20189 September 2019Effectiveness of Botox on Reducing Rest Tremor in Parkinson's DiseaseEffectiveness of Onabotulinumtoxin A on Reduction of Rest Tremor in Parkinson's Disease: a Pilot StudyParkinson DiseaseDrug: Onabotulinumtoxin A Injection;Other: PlaceboUniversity of North Carolina, Chapel HillNot recruiting45 Years80 YearsAll16Phase 2United States
168NCT03457493March 22, 201827 May 2019TSPO-PET for Neuroinflammation in Parkinson's DiseaseUAB Neuroinflammation in Parkinson's Disease - TSPO-PET SubstudyParkinson DiseaseDrug: DPA-714-PET/MRIUniversity of Alabama at BirminghamRecruiting30 YearsN/AAll20Phase 1/Phase 2United States
169NCT03462641March 9, 201815 July 2019Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil ArmModulation of GABA-A Receptors and Axial Motor Impairments in Parkinson Disease-Flumazenil ArmParkinson DiseaseDrug: Flumazenil;Drug: PlaceboUniversity of MichiganNational Institute of Neurological Disorders and Stroke (NINDS)Recruiting50 Years99 YearsAll30Phase 1/Phase 2United States
170NCT03482882March 9, 201826 August 2019Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and DepressionAn Open-label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults With Parkinson's Disease and DepressionTreatment of Depression in Adults With Parkinson's Disease (PD)Drug: PimavanserinACADIA Pharmaceuticals Inc.Not recruiting50 YearsN/AAll47Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
171NCT03149809March 1, 201815 July 2019Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson DiseaseBehavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson DiseaseOveractive Bladder;Parkinson DiseaseDrug: solifenacin;Behavioral: Pelvic floor muscle exercise-based behavioral therapyVA Office of Research and DevelopmentRecruitingN/AN/AAll90Phase 3United States
172NCT03368170February 27, 201826 August 2019Efficacy and Tolerability of IRL790 in Parkinson's Disease DyskinesiaA Randomized, Placebo-controlled, Phase IIa Study Evaluating the Efficacy and Tolerability of IRL790 in Parkinson's Disease DyskinesiaParkinson DiseaseDrug: IRL790Integrative Research Laboratories ABThe Clinical Trial CompanyNot recruiting18 Years79 YearsAll75Phase 2Sweden;United Kingdom
173NCT03419806February 16, 201811 June 2018Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal Duodopa in Patients With Parkinson's DiseaseLevodopa Pharmacokinetics in Patients With Parkinson's Disease and Symptom Fluctuation: A Phase I, Open-label, Randomized, Multicentre, Crossover Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal DuodopaParkinson DiseaseDrug: Infudopa i.v.;Drug: Infudopa s.c.;Drug: LCIG (Duodopa)Vastra Gotaland RegionThe Swedish Research Council;Dizlin Medical Design AB;Göteborg UniversityRecruiting30 YearsN/AAll28Phase 1Sweden
174NCT03882398February 15, 20181 April 2019Effects of a High-intensity Progressive-cycle Program on Quality of Life and Motor Symptomatology in Parkinson's DiseaseEffects of a High-intensity Progressive-cycle Program on Quality of Life and Motor Symptomatology in Parkinson's Disease Population: a Pilot Randomized Controlled TrialParkinson Disease;Exercise;Physical Activity;Quality of LifeOther: Balance;Other: EnduranceUniversity of VigoNot recruiting60 Years80 YearsAll14N/ASpain
175NCT03496870February 8, 20181 April 2019A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.A Phase 1, Open-Label Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Repeated Doses of Opicapone, and Effect on Levodopa Pharmacokinetics in Subjects With Parkinson's DiseaseParkinson DiseaseDrug: Opicapone;Drug: Carbidopa LevodopaNeurocrine BiosciencesNot recruiting18 Years85 YearsAll16Phase 1United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
176NCT03189563February 6, 201814 January 2019Safety and Efficacy of DA-9805 for Parkinson's DiseaseA Phase IIa, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of DA-9805 in Subjects With Parkinson's DiseaseParkinson's DiseaseDrug: DA-9805 45mg;Drug: DA-9805 90mg;Other: PlaceboDong-A ST Co., Ltd.Not recruiting30 Years79 YearsAll60Phase 2United States
177JPRN-UMIN0000309302018/01/292 April 2019Study on efficacy and safety of the simultaneous treatment with febuxostat and inosine of patients with Parkinson's disease.Parkinson's diseaseAdministration of febuxostat 20 mg and inosine 500 mg twice a day for 58 daysStaGen Co. Ltd.Recruiting20years-old80years-oldMale and Female30Not selectedJapan
178NCT03329508January 29, 201811 November 2019A Phase 3 Study With P2B001 in Subjects With Early Parkinson'sA Phase 3, Twelve-week Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to Its Individual Components in Subjects With Early Parkinson's Disease and to a Calibration Arm of Pramipexole ER.Parkinson DiseaseDrug: P2B001;Drug: Rasagiline;Drug: Pramipexole;Drug: Pramipexole ERPharma Two B Ltd.Recruiting35 Years80 YearsAll525Phase 3United States;Canada;Germany;Spain
179NCT03440112January 29, 201815 July 2019Modulation of GABA-A Receptors in Parkinson Disease-Clarithromycin ArmModulation of GABA-A Receptors and Axial Motor Impairments in ParkinsonParkinson DiseaseDrug: Clarithromycin;Drug: PlaceboNicolaas Bohnen, MD, PhDNational Institute of Neurological Disorders and Stroke (NINDS)Recruiting50 YearsN/AAll30Phase 1/Phase 2United States
180ChiCTR18000145422018-01-2229 January 2018Up-down sequential testing of propofol - induced half-effective dose ( ed50 ) in patients with Parkinson's disease and non - Parkinson's diseaseUp-down sequential testing of propofol - induced half-effective dose ( ed50 ) in patients with Parkinson's disease and non - Parkinson's diseaseParkinson's DiseasePD group:propofol;NPD group:propofol;Xuanwu Hospital of CCMURecruiting1865BothPD group:40;NPD group:40;OtherChina
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
181NCT03531086January 19, 201825 March 2019Idiopathic Parkinson's Progression and Dopamine Transporter SPECTExploring Dopamine Transporter Single-photon Emission Computer Tomography Quantification as a Measure of Disease Progression in Idiopathic Parkinson's DiseaseParkinson DiseaseDrug: Ioflupane I 123Julie GurwellRecruiting40 Years75 YearsAll12Phase 1United States
182NCT03331848January 15, 201811 June 2018Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety, and Tolerability of 8-week Oral Treatment With PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)Parkinson DiseaseDrug: Placebo oral capsule;Drug: PXT002331 - 20mgPrexton TherapeuticsNot recruiting35 Years85 YearsAll0Phase 2
183NCT03318523January 10, 201816 September 2019Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's DiseaseA Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's DiseaseParkinson's DiseaseDrug: BIIB054;Drug: PlaceboBiogenNot recruiting40 Years80 YearsAll311Phase 2United States;Austria;Canada;France;Germany;Israel;Italy;Spain;United Kingdom
184NCT03550183January 10, 201811 June 2018Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Parkinson's DiseaseSafety and Efficacy Investigation of Patients With Parkinson's Disease by Transplantation of Umbilical Cord Derived Mesenchymal Stem CellsParkinson's DiseaseBiological: mesenchymal stem cellsHebei Newtherapy BIo-Pharma technology Co., Ltd.Recruiting40 Years80 YearsAll20Phase 1China
185EUCTR2016-003456-70-AT04/01/20181 October 2018A clinical trial to compare APL-130277 sublingual film to Subcutaneous Apomorphine in Parkinson’s Disease patientsAn Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson’s Disease Complicated by Motor FluctuationsLevodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF episodes)
MedDRA version: 20.0 Level: LLT Classification code 10034006 Term: Parkinson's disease aggravated System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Sublingual film
Route of administration of the placebo: Sublingual use
Trade Name: APO-go
Product Name: s.c. apomorphine
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 10-
Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 15-
Pharmaceutical form of the placebo: Sublingual film
Route of administration of the placebo: Sublingual use
Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Sublingual film
Route of administration of the placebo: Sublingual use
Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal		Sunovion Pharmaceuticals Inc.AuthorisedFemale: yes
Male: yes		106Phase 3France;Spain;Austria;Germany;Italy;United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
186NCT03321019December 12, 201727 May 2019Airway Protective Mechanisms in PD (R01)Mechanisms of Airway Protection Dysfunction in Parkinson's DiseaseParkinson DiseaseDrug: Capsaicin;Device: Resistive respiratory loads;Other: Event-related evoked potential using electroencephalography (EEG).;Procedure: Fluoroscopic swallow evaluationUniversity of FloridaEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Recruiting45 Years85 YearsAll245Phase 1United States
187JPRN-UMIN0000300842017/12/012 April 2019Practical evaluation of PET studies with [18F]-GE180, [18F]-FDOPA and [18F]-FLT for a future clinical trial of iPSC-based cell therapy in Parkinson's diseaseneuroinflammatory disorder, Parkinson's disease, Brain tumor[18F]GE180 is injected intravenously as 3-4 MBq/Kg. PET is dynamically scanned for 90 minutes.

Carbidopa 150mg is administrated orally 1hr before scan.[18F]FDOPA is injected intravenously as 3-4 MBq/Kg. Dynamic PET is scanned for 90 minutes.

[18F]FLT is injected intravenously as 3-4 MBq/Kg. Statical PET is scanned after 60 minutes		Kyoto UniversityNot Recruiting50years-oldNot applicableMale and Female12Phase 1,2Japan
188NCT03377322December 1, 20174 November 2019Trial of Probiotics for Constipation in Parkinson's DiseaseA Randomized Double-Blinded Placebo-Controlled Trial of Probiotics for Constipation in Parkinson's DiseaseParkinson DiseaseDrug: Probiotic Capsule;Drug: Placebo CapsuleUniversity of MalayaNot recruiting40 Years85 YearsAll72N/AMalaysia
189NCT03944785November 30, 201722 October 2019Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)A Prospective, Observational Study to Evaluate Changes in Non-Motor Symptoms and Other Clinical Outcome Assessments of Parkinson's Disease Patients Treated With XADAGO (Safinamide)TabletsIdiopathic Parkinson DiseaseDrug: XADAGO (safinamide)US WorldMeds LLCRecruiting30 Years80 YearsAll540N/AUnited States
190NCT03194217November 10, 201722 July 2019BEN-2001 in Parkinson Disease Patients With Excessive Daytime SleepinessDose Finding Phase IIb Study of Bavisant to Evaluate Its Safety and effiCacy in treAtment of exceSsive Daytime sleePiness (EDS) in PARkinson's Disease (PD).Excessive Daytime Sleepiness;Parkinson DiseaseDrug: BEN-2001;Drug: PlaceboBenevolentAI BioNot recruiting50 Years80 YearsAll248Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
191NCT03305809November 9, 201711 November 2019A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)Lewy Body DementiaDrug: LY3154207;Drug: PlaceboEli Lilly and CompanyRecruiting40 Years85 YearsAll340Phase 2United States;Canada;Puerto Rico;China
192NCT02611167November 1, 201719 November 2018Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's DiseasePilot Phase I Study of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's DiseaseParkinson's DiseaseBiological: Allogeneic bone marrow-derived MSCsThe University of Texas Health Science Center, HoustonNot recruiting45 Years70 YearsAll20Phase 1/Phase 2United States
193NCT03205956October 19, 20178 April 2019Measuring Parkinson's Disease ProgressionDopamine Buffering Capacity Measured by phMRI as a Novel Biomarker of Disease Progression in PDParkinson's DiseaseDrug: LevodopaKevin J. Black, MDThe Michael J. Fox Foundation for Parkinson's ResearchRecruiting40 Years79 YearsAll40Phase 1United States
194NCT03272165October 17, 201711 November 2019Single Ascending Dose Study of MEDI1341 in Healthy VolunteersA Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MEDI1341 in Healthy Male and Female Volunteers.Parkinson's DiseaseDrug: MEDI1341;Drug: PlaceboAstraZenecaCovance;MMS Holdings, Inc;CatalentRecruiting18 Years80 YearsAll48Phase 1United States;United Kingdom
195NCT03205488October 16, 20179 October 2018Nilotinib in Parkinson's DiseaseA Randomized, Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two Cohort Study to Define the Safety, Tolerability, Clinical and Exploratory Biological Activity of the Chronic Administration of Nilotinib in Participants With Parkinson's DiseaseParkinson DiseaseDrug: Cohort 1:Nilotinib Oral Capsules (150mg or 300mg);Drug: Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1);Drug: PlaceboNorthwestern UniversityUniversity of Rochester;University of Iowa;Michael J. Fox Foundation for Parkinson's ResearchRecruiting40 Years79 YearsAll135Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
196NCT03250117October 10, 20176 May 2019Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral RopiniroleAn Open-Label, Relative Bioavailability Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ropinirole Implants in Patients With Parkinson's Disease Switched From Oral Immediate-Release Ropinirole While on L-DopaParkinson DiseaseDrug: Ropinirole oral product;Drug: Ropinirole ImplantTitan PharmaceuticalsRecruiting30 Years80 YearsAll20Phase 1/Phase 2United States
197EUCTR2017-001673-17-FI03/10/201719 November 2018A study to evaluate the safety and tolerability of IRL752 treatment in patients with Parkinson's disease dementia.A randomized, double-blind, placebo-controlled, multi-centre phase IIa study evaluating the safety and tolerability of IRL752 in patients with Parkinson's Disease DementiaDementia in Parkinson's disease
MedDRA version: 20.0 Level: LLT Classification code 10012284 Term: Dementia due to Parkinson's disease System Organ Class: 100000014717 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: IRL752
Pharmaceutical Form: Capsule
INN or Proposed INN: IRL752
CAS Number: 1227638-29-0
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use		Integrative Research Laboratories ABNot RecruitingFemale: yes
Male: yes		40Phase 2Finland;Sweden
198NCT03769896October 3, 20177 October 2019Nabilone for Non-motor Symptoms in Parkinson's DiseaseNabilone for Non-motor Symptoms in Parkinson's Disease: A Randomized Placebo-controlled, Double-blind, Parallel-group, Enriched Enrolment Randomized Withdrawal StudyParkinson DiseaseDrug: Nabilone 0.25 mg;Drug: PlaceboMedical University InnsbruckNot recruiting30 Years100 YearsAll48Phase 2Austria
199NCT03257046September 28, 201720 August 2018Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's DiseaseA Randomized, Placebo-Controlled, Double-Blind Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ITI-214 in Patients With Idiopathic Parkinson's DiseaseParkinson DiseaseDrug: ITI-214;Other: PlaceboIntra-Cellular Therapies, Inc.Recruiting50 YearsN/AAll40Phase 1/Phase 2United States
200EUCTR2015-004175-73-FI27/09/201712 March 2018A clinical study to test the safety of CDNF by brain infusion in patients with Parkinson's disease.A Phase I-II, Randomised, Double-Blind, Placebo Controlled, Safety and Tolerability Study of Intermittent Bilateral Intraputamenal Cerebral Dopamine Neurotrophic Factor (CDNF) Infusions Administered via an Investigational Drug Delivery System to Patients with Idiopathic Parkinson’s Disease (PD) of Moderate Severity.Idiopathic Parkinson's Disease
MedDRA version: 20.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: CDNF
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: Not Applicable
Other descriptive name: recombinant human Cerebral Dopamine Neurotrophic Factor
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 1.0-
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intracerebral use		Herantis Pharma PlcAuthorisedFemale: yes
Male: yes		18Phase 1;Phase 2Finland
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
201NCT03295786September 26, 201715 July 2019Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's DiseasePhase 1-2, Randomised, Double-Blind, Placebo Controlled, Safety and Tolerability Study of Intraputamenal Cerebral Dopamine Neurotrophic Factor (CDNF) Infusions Via an Investigational Drug Delivery System to Patients With Parkinson's DiseaseParkinson Disease;Movement Disorders;Neurodegenerative Diseases;Nervous System Diseases;Brain DiseasesDrug: Cerebral Dopamine Neurotrophic Factor;Device: Renishaw Drug Delivery SystemHerantis Pharma Plc.Renishaw plc.Recruiting35 Years75 YearsAll18Phase 1/Phase 2Finland;Sweden
202NCT03104725September 25, 20178 April 2019Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?Parkinson DiseaseDrug: N-Acetylcysteine;Procedure: Lumbar Puncture;Radiation: FluoroscopyNational Institute of Neurological Disorders and Stroke (NINDS)Recruiting18 Years99 YearsAll41Phase 1United States
203EUCTR2017-000192-86-AT15/09/201720 August 2018Investigation of the effect of Nabilon in patients suffering from Parkinson´s Disease with non-motor symptoms (e.g.sleeping disorders,cognitive dysfunction, hallucinations, autonomic dysfunction including urinary incontinence, constipation,...)Nabilone for non-motor symptoms in Parkinson´s disease: A Randomized Placebo-controlled, double-blind, parallel-group, enriched enrollment randomized withdrawal StudySubjects with non-motor symptoms of Parkinson´s disease
MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Nabilone
Pharmaceutical Form: Capsule
INN or Proposed INN: NABILONE
CAS Number: 51022-71-0
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.25-		Medizinische Universität Innsbruck, Universitätsklinik für NeurologieAuthorisedFemale: yes
Male: yes		48Phase 2Austria
204NCT03306329September 13, 201712 February 2018DNS-7801 vs. Placebo in Parkinson's DiseaseA Phase 2a, Double-Blind, Placebo-Controlled Two-Part Study To Investigate the Safety and Efficacy of Increasing Doses Of DNS-7801 In Parkinson's Disease (PD) Subjects With Motor FluctuationsParkinson's DiseaseDrug: DNS-7801 (low-dose);Drug: DNS-7801 (high dose);Drug: PlaceboDart NeuroScience, LLCNot recruiting30 YearsN/AAll5Phase 2United States
205NCT03272230September 6, 20171 April 2019Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based SystemAssessment of Apathy in a Real-life Situation, With a Video and Sensors-based System in Healthy Subject and Patient With Cerebral DiseaseApathy;Frontotemporal Dementia;Parkinson Disease;Depressive SymptomsBehavioral: ECOCAPTURE;Behavioral: Cognitive and Behavioral experimental tasks;Diagnostic Test: Neuropsychological assessment;Behavioral: ICM_APATHY_TASKS;Other: MRI;Biological: Neurohormonal mechanisms;Diagnostic Test: Supplementary Neuropsychological Assessment - Parkinson's DiseaseInstitut National de la Santé Et de la Recherche Médicale, FranceRecruiting40 Years85 YearsAll135N/AFrance
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
206JPRN-jRCTs04118001804/09/201710 September 2019Pupillary autonomic dysfunction and visual hallucination in Parkinson's diseaseAssociation between pupillary autonomic dysfunction and visual hallucination in Parkinson's disease - Pupillary autonomic dysfunction and visual hallucination in Parkinson's diseaseParkinson's disease and related diseasesTwo drops of 0.05% pilocarpine hydrochloride, which is a parasympathomimetic agent, on the right eye, 2 drops of 0.04% dipivefrin hydrochloride, which is a sympathomimetic agent, to the left eyeMasahisa katsunoRecruiting40ageNot applicableBoth40Phase 2None
207ChiCTR-INR-170120132017-09-0124 July 2017Clinical study of botulinum toxin type A in the treatment of depressive symptoms in patients with Parkinson's diseaseClinical study of botulinum toxin type A in the treatment of depressive symptoms in patients with Parkinson's diseaseParkinson‘s disease, DepressionBTX-A:BOTOX Allergan;Placebo:0.9% Sodium Chloride Injection;Shanghai Tongji Hospital, Tongji UniversityNot Recruiting1880BothBTX-A:40;Placebo:40;New Treatment Measure Clinical StudyChina
208NCT03232996September 1, 201716 December 2017Evaluation of a Computer Game Based Rehabilitation System for Assessment and Treatment of Balance and Gait Impairments in Individuals With Parkinson's Disease.Evaluation of a Computer Game Based Rehabilitation System for Assessment and Treatment of Balance and Gait Impairments in Individuals With Parkinson's Disease.Parkinson Disease;ParkinsonOther: Computer game based balance and walking rehabilitation for individuals with Parkinson's DiseaseUniversity of ManitobaNot recruiting55 Years70 YearsAll30N/ACanada
209NCT03292016August 22, 201713 May 2019A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by OFF EpisodesA Comparative Bioavailability Study to Evaluate the Single Dose Pharmacokinetic Properties of APL-130277 With Two Different Formulations of Subcutaneous Apomorphine in a Randomized, 3-Period Crossover Design in Subjects With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)Parkinson DiseaseDrug: APL-130277;Drug: APO-go;Drug: ApokynSunovionNot recruiting18 YearsN/AAll8Phase 2United States
210NCT03204929August 14, 201715 July 2019Dose Escalation Study of Cu(II)ATSM in Parkinson's DiseaseA Phase 1 Dose Escalation Study of Cu(II)ATSM Administered Orally to Patients With Early Idiopathic Parkinson's DiseaseParkinson DiseaseDrug: Cu(II)ATSMCollaborative Medicinal Development Pty LimitedNot recruiting30 YearsN/AAll38Phase 1Australia
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
211EUCTR2017-000877-35-CZ09/08/20179 October 2017A phase IIb, randomized, double blind, parallel group, placebo control, multicentre, 6-week dose-finding study to assess the efficacy and safety of Bavisant for the treatment of excessive daytime sleepiness in subjects with Parkinson's disease.Dose finding phase IIb study of Bavisant to evaluate its safety and efficacy in treatment of excessive daytime sleepiness (EDS) in parkinson’s Disease (PD). - Treatment of excessive daytime sleepiness with Bavisant in Parkinson’s Disease Patients (CASPAR)Excessive daytime sleepiness with Parkinson's Disease
MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Bavisant
Product Code: JNJ-31001074
Pharmaceutical Form: Tablet
INN or Proposed INN: Bavisant dihydrochloride monohydrate
Other descriptive name: BAVISANT HYDROCHLORIDE MONOHYDRATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.5-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: Bavisant
Product Code: JNJ-31001074
Pharmaceutical Form: Tablet
INN or Proposed INN: Bavisant dihydrochloride monohydrate
Other descriptive name: BAVISANT HYDROCHLORIDE MONOHYDRATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: Bavisant
Product Code: JNJ-31001074
Pharmaceutical Form: Tablet
INN or Proposed INN: Bavisant dihydrochloride monohydrate
Other descriptive name: BAVISANT HYDROCHLORIDE MONOHYDRATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 3-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use		BenevolentAI BioAuthorisedFemale: yes
Male: yes		240Phase 2United States;Czech Republic;Poland;Spain;Germany;Italy;United Kingdom
212NCT03187301August 3, 201726 November 2018A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations OFF EpisodesA Phase 2, Randomized, Double-Blind, Placebo Controlled, 3-Period Crossover, Positive Control, QT-Evaluation Study of APL-130277 in Subjects With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)Parkinson's Disease;Off Episodes of Parkinson DiseaseDrug: APL-130277;Drug: Placebo;Drug: MoxifloxacinSunovionNot recruiting18 YearsN/AAll42Phase 2United States;Italy
213ChiCTR-IPR-170118752017-08-0110 July 2017Effects of Baduanjin Combined Balance Training on Gait and Posture Control of Patients with Mild and Moderate Parkinson's DiseaseEffects of Baduanjin Combined Balance Training on Gait and Posture Control of Patients with Mild and Moderate Parkinson's DiseaseParkinson's DiseaseControl group:Conventional drug therapy;Baduanjin group:Baduanjin aerobic exercise;Balance function training group:Balance function training group;Affiliated Lianyungang Hospital of Xuzhou Medical UniversityNot Recruiting4080BothControl group:30;Baduanjin group:30;Balance function training group:30;Pilot studyChina
214NCT03412513July 17, 201712 February 2018Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's DiseaseMirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease: a Double-blind, Randomized Placebo-controlled TrialOveractive Bladder;Parkinson DiseaseDrug: Mirabegron;Drug: PlaceboSeoul National University HospitalRecruiting40 Years80 YearsAll144Phase 4Korea, Republic of
215NCT03026231July 15, 201720 August 2018Characterization of Fecal Microbiome Changes After Administration of PRIM-DJ2727 in Parkinson's Disease PatientsA Prospective, Randomized Placebo Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Weekly Administration of Lyophilized PRIM-DJ2727 Given Orally in Subjects With Parkinson's DiseaseParkinson's DiseaseBiological: PRIM-DJ2727;Drug: Placebo (for PRIM-DJ2727)The University of Texas Health Science Center, HoustonKelsey Research FoundationNot recruiting45 Years70 YearsAll0Phase 1/Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
216NCT03185481July 6, 201723 April 2019Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor FluctuationsA PHASE 2, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON'S DISEASEParkinson's Disease With Motor FluctuationsDrug: 1 mg QD to 15 mg QD PF-06649751;Drug: 3 mg QD to 15 mg QD PF-06649751;Drug: 7 mg QD to 15 mg QD PF-06649751;Drug: 15 mg QD PF-06649751;Drug: 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study);Drug: 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study);Drug: 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study);Drug: 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QDPfizerNot recruiting40 Years87 YearsAll5Phase 2United States
217NCT03162874July 4, 201718 March 2019Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's PatientsA Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment With PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects With Parkinson's Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia (AMBLED)Parkinson DiseaseDrug: Placebo oral capsule;Drug: PXT002331 - dose 1;Drug: PXT002331 - dose 2Prexton TherapeuticsRecruiting35 Years85 YearsAll165Phase 2Austria;France;Germany;Italy;Spain;United Kingdom
218NCT03288155July 1, 201716 September 2019Can a Flavonoid-rich Pure Cocoa Reduce Fatigue in People With Parkinson's (PD)A Study to Determine Whether the Daily Consumption of Flavonoid-rich Pure Cocoa Can Reduce Fatigue in People With Parkinson's (PD)Parkinson Disease;FatigueDietary Supplement: CocoaOxford Brookes UniversityEuropean Parkinson Therapy CentreNot recruiting18 YearsN/AAll30N/AItaly
219NCT04146519July 1, 20174 November 2019Parkinson's Disease Therapy Using Cell TechnologyDevelopent and Implement a Method of Parkinson's Disease Therapy Using Cell TechnologyTransplantation:Mesenchymal Stem Cell TransplantationBiological: Autologous mesenchymal stem cellsBelarusian Medical Academy of Post-Graduate EducationNot recruiting18 YearsN/AAll12Phase 2Belarus
220EUCTR2016-003961-25-DE30/06/20174 December 2018A study to evaluate the safety and tolerability of tozadenant in Parkinson disease patients who are taking levodopa and experiencing wearing offA Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson’s Disease Experiencing End of Dose “Wearing-Off”Parkinson's Disease
MedDRA version: 19.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: tozadenant
Product Code: TOZ
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: tozadenant
CAS Number: 870070-55-6
Current Sponsor code: TOZ
Other descriptive name: TOZADENANT
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 60-		Biotie TherapiesNot RecruitingFemale: yes
Male: yes		450Phase 3United States;Czech Republic;Hungary;European Union;Canada;Spain;Australia;Germany;Italy;United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
221NCT03042416June 29, 201728 October 201918F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety18F-DOPA PET Imaging: an Evaluation of Biodistribution and SafetyCongenital Hyperinsulinism;Neuroblastoma;Neuroendocrine Tumors;Parkinson Disease;Brain GliomaDrug: 18F-DOPAUniversity of AlbertaAlberta Health ServicesRecruitingN/AN/AAll400Phase 3Canada
222NCT03100149June 27, 20176 May 2019A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's DiseaseA Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015 (PRX002) in Participants With Early Parkinson's Disease With a 52-Week Blinded ExtensionParkinson's DiseaseDrug: RO7046015;Drug: PlaceboHoffmann-La RocheProthena Biosciences LimitedNot recruiting40 Years80 YearsAll316Phase 2United States;Austria;France;Germany;Spain
223NCT03195231June 25, 201716 December 2017Wuling Powder for the Treatment and Underlying Mechanism of Depressive Symptoms in Patients With Parkinson's DiseaseWuling Powder for the Treatment and Underlying Mechanism of Depressive Symptoms in Patients With Parkinson's Disease: a Randomised, Double-blind, Placebo-controlled Trial.Antidepressive AgentsDrug: Wuling Powder;Drug: PlaceboBeijing HospitalTongji Hospital;Shanghai Tong Ren Hospital;The First Hospital of Hebei Medical UniversityNot recruiting40 YearsN/AAll120Phase 4
224NCT03083132June 13, 201726 August 2019Modafinil for Freezing of Gait (FOG) in Parkinson's Disease (PD)Modafinil as a Novel Therapy for the Treatment of Freezing of Gait in Parkinson's DiseaseParkinson DiseaseDrug: modafinil 50mg;Drug: Placebo oral capsuleUniversity of ArkansasNot recruiting50 Years90 YearsAll20Early Phase 1United States
225NCT03973502June 12, 201717 June 2019Application of 18F-FDOPA PET and Magnetic Resonance Spectroscopy (MRS) With HCV and PDApplication of 18F-FDOPA PET and Magnetic Resonance Spectroscopy (MRS) in Research of the Association Between HCV Infection and Parkinson's Disease.Hepatitis C;Hepatitis B;Parkinson DiseaseDrug: 18F-DOPA PETNational Taiwan University HospitalRecruiting20 YearsN/AAll230N/ATaiwan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
226EUCTR2017-000135-14-AT26/05/20177 January 2019A study to look at how safe, well tolerated, and what effect on the body, study drug PXT002331 has in patients with Parkinson's Disease who are already taking the drug LevodopaA Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment with PXT002331 (foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects with Parkinson’s Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia (AMBLED) - AMBLED StudyParkinson’s Disease
MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: foliglurax
Product Code: PXT002331
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: foliglurax
CAS Number: 1883329-52-9
Current Sponsor code: PXT002331
Other descriptive name: CVD00118-E
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: foliglurax
Product Code: PXT002331
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: foliglurax
CAS Number: 1883329-52-9
Current Sponsor code: PXT002331
Other descriptive name: CVD00118-E
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 30-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use		Prexton Therapeutics B.V.AuthorisedFemale: yes
Male: yes		165Phase 2Spain;Austria;Germany
227NCT03111485May 24, 201718 March 2019Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's DiseaseEffect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's DiseaseParkinson's Disease;Obstructive Sleep ApneaDrug: Sinemet CR;Drug: Placebo oral capsuleMcGill University Health CenterWeston Brain InstituteRecruiting18 YearsN/AAll42Phase 4Canada
228NCT03033498May 17, 201725 March 2019A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's DiseaseA Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of 24 Hour and 72 Hour Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's DiseaseParkinson's Disease (PD)Drug: ABBV-951AbbVieRecruiting45 Years85 YearsAll30Phase 1United States
229NCT03174938May 15, 201711 June 2018The Swedish BioFINDER 2 StudyThe Swedish BioFINDER 2 StudyDementia;Alzheimer Disease;Parkinson Disease;Lewy Body Disease;Parkinson-Dementia Syndrome;Frontotemporal Degeneration;Semantic Dementia;Progressive Nonfluent Aphasia;Progressive Supranuclear Palsy;Corticobasal Degeneration;Multiple System Atrophy;Mild Cognitive ImpairmentDiagnostic Test: Flutemetamol F18 Injection;Diagnostic Test: [18F]-RO6958948;Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau;Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and PtauSkane University HospitalLund UniversityRecruiting20 Years100 YearsAll1505N/ASweden
230NCT03242499May 15, 201716 December 2017Lovastatin as a Neuroprotective Treatment for Early Stage Parkinson's DiseaseLovastatin as a Neuroprotective Treatment for Early Stage Parkinson's Disease: a Single-center, Double-blind, Placebo-controlled Randomized TrialParkinson DiseaseDrug: Lovastatin;Drug: PlaceboNational Taiwan University HospitalRecruiting30 Years90 YearsAll80Phase 2Taiwan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
231NCT03047629May 11, 201720 August 2018Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related ConstipationA Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related ConstipationParkinson's Disease;ConstipationDrug: ENT-01;Other: PlaceboEnterin Inc.Not recruiting30 Years86 YearsAll50Phase 1/Phase 2United States
232NCT03065192May 11, 20178 April 2019Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's DiseaseAn Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Using a Posterior Trajectory Into the Putamen of Participants With Parkinson's Disease With Fluctuating Responses to LevodopaIdiopathic Parkinson's Disease;Parkinson's Disease;Basal Ganglia Disease;Brain Diseases;Central Nervous System Diseases;Movement Disorders;Nervous System Diseases;Neurodegenerative Diseases;Parkinsonian DisordersDrug: VY-AADC01Neurocrine BiosciencesVoyager TherapeuticsNot recruiting40 Years75 YearsAll16Phase 1United States
233NCT02982512May 1, 201711 June 2018Dexmedetomidine on Basal Ganglia Neuronal Activity in Parkinson's DiseaseEffects of Different Concentrations of Dexmedetomidine on Basal Ganglia Neuronal Activity (Local Field Potentials) in Parkinson's DiseaseDexmedetomidine;Deep Brain Stimulation;Parkinson DiseaseDrug: DexmedetomidineClinica Universidad de Navarra, Universidad de NavarraRecruiting18 YearsN/AAll12Phase 4Spain
234NCT02702076May 201716 December 2017Apomorphine in Parkinson's Disease Patients With Visual HallucinationsRandomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Continuous Subcutaneous Infusion in Parkinson's Disease Patients With Refractory Visual HallucinationsParkinson's Disease;Hallucinations, VisualDrug: Apomorphine;Drug: PlaceboUniversity Medical Center GroningenRecruiting30 YearsN/AAll35Phase 2Netherlands
235NCT03119636May 201716 December 2017Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's DiseaseA Phase I/II, Open-Label Study to Assess the Safety and Efficacy of Striatum Transplantation of Human Embryonic Stem Cells-derived Neural Precursor Cells in Patients With Parkinson's DiseaseParkinson's DiseaseBiological: NPC transplantation;Drug: LevodopaChinese Academy of SciencesThe First Affiliated Hospital of Zhengzhou UniversityRecruiting50 Years80 YearsAll50Phase 1/Phase 2China
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
236ChiCTR-IPR-170111552017-04-2018 April 2017Dihydroergotoxine mesylate for the treatment of sialorrhea in Parkinson's diseaseDihydroergotoxine mesylate for the treatment of sialorrhea in Parkinson's diseaseParkinson’s diseasetreatment group:dihydroergotoxine mesylate 2.5 mg, twice daily, two weeks;intervention group:identical placebo 2.5 mg, twice daily, two weeks;Nanjing First Hospital Affiliated to Nanjing Medical UniversityRecruiting1880Bothtreatment group:10;intervention group:10;Post-marketChina
237NCT03140956April 19, 201716 December 2017Pharmacokinetic of Levodopa Study in Healthy MalesPharmacokinetics of Levodopa After Repeated Doses of Different Pellet Formulations; An Open, Randomized Study With Crossover Design in Healthy Male SubjectsParkinson DiseaseDrug: Levodopa, carbidopa, ODM-104Orion Corporation, Orion PharmaNot recruiting18 Years65 YearsMale20Phase 1Finland
238NCT03115827April 18, 201711 March 2019Norepinephrine-targeted Therapy for Action Control in Parkinson DiseaseNorepinephrine-targeted Therapy for Action Control in Parkinson DiseaseParkinson DiseaseDrug: Droxidopa;Drug: CarbidopaVanderbilt University Medical CenterH. Lundbeck A/S;American Academy of NeurologyNot recruiting18 YearsN/AAll15Phase 4United States
239NCT03128450April 15, 201716 December 2017A Study To Evaluate the Safety and Efficacy of Human Neural Stem Cells for Parkinson's Disease PatientA Single Arm, Open-Label,Pilot Study to Evaluate the Safety and Efficacy of Human Neural Stem Cells Injection (ANGE-S003) Through Nasal Way Delivery to Patients With Parkinson's DiseaseParkinson DiseaseBiological: human neural stem cellSecond Affiliated Hospital of Soochow UniversityRecruiting35 Years70 YearsAll12Phase 2/Phase 3China
240EUCTR2016-004629-18-NL13/04/20178 May 2017The influence of stress on Parkinson's tremorThe noradrenergic basis of Parkinson’s tremor: a systems-level fMRI approach - Noradrenergic basis of Parkinson tremorTremor in Parkinson's disease
;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Propranolol
Product Name: Propranolol HCl CF 40 mg tablet
Product Code: RVG 55618
Pharmaceutical Form: Tablet		Radboud University NijmegenAuthorisedFemale: yes
Male: yes		Phase 3Netherlands
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
241NCT03011476April 11, 201711 June 2018Effect of Acetylcholinesterase Inhibitors on the Gait of the Patients With Parkinson DiseaseEffect of Acetylcholinesterase Inhibitors on the Gait of the Patients With Parkinson Disease Characterized by Postural Instability and Gait DisturbanceParkinson DiseaseDrug: Donepezil;Drug: PlacebosKyung Hee University HospitalRecruiting40 Years75 YearsAll20Phase 4Korea, Republic of
242NCT02953665April 3, 201713 May 2019Safety and Efficacy of Liraglutide in Parkinson's DiseaseA Phase II, Randomized, Double-blinded, Placebo-controlled Trial of Liraglutide in Parkinson's DiseaseParkinson DiseaseDrug: Liraglutide;Drug: PlaceboCedars-Sinai Medical CenterThe Cure Parkinson's Trust;Novo Nordisk A/SRecruiting25 Years85 YearsAll57Phase 2United States
243JPRN-UMIN0000261282017/04/012 April 2019Association between pupillary autonomic dysfunction and visual hallucination in Parkinson's diseaseParkinson's diseaseadministe pilocarpine and dipivefrine
administe pilocarpine and dipivefrine		Nagoya UniversityRecruiting40years-old90years-oldMale and Female60Not selectedJapan
244NCT02970019March 30, 201711 November 2019Safety and Tolerability Study of K0706 in Subjects With Parkinson's DiseaseA Double-blind, Placebo-controlled Study to Determine Safety, Tolerability, Pharmacokinetic of K0706.Parkinson DiseaseDrug: K0706;Drug: PlaceboSun Pharma Advanced Research Company LimitedNot recruiting18 Years65 YearsAll58Phase 1United States
245EUCTR2016-003456-70-GB22/03/20173 September 2018A clinical trial to compare APL-130277 sublingual film to Subcutaneous Apomorphine in Parkinson’s Disease patientsAn Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson's Disease Complicated by Motor FluctuationsLevodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF episodes)
MedDRA version: 20.0 Level: LLT Classification code 10034006 Term: Parkinson's disease aggravated System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Sublingual film
Route of administration of the placebo: Sublingual use
Trade Name: APO-go
Product Name: s.c. apomorphine
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 2-
Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 15-
Pharmaceutical form of the placebo: Sublingual film
Route of administration of the placebo: Sublingual use
Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Sublingual film
Route of administration of the placebo: Sublingual use
Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal		Sunovion Pharmaceuticals Inc.AuthorisedFemale: yes
Male: yes		106Phase 3United Kingdom;Italy;Germany;Austria;Spain;France
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
246JPRN-UMIN0000264922017/03/157 October 2019Intervention study of Istradefylline for the Treatment of Abnormal Posture in Patients with Parkinson's DiseaseIntervention study of Istradefylline for the Treatment of Abnormal Posture in Patients with Parkinson's Disease - Intervention Study of Istradefylline for the Treatment of Abnormal Posture in Patients with Parkinson's Disease.Parkinson's diseaseIn this research, the duration of evaluation will be 24 weeks.
Treatment with istradefylline will be started at a dose of 20 mg administered once daily. The dose of istradefylline will be increased to 40 mg once daily if the patient has no tolerability issues and still has motor symptoms at Week 4. After the Week 4, the dose will be allowed to be reduced to 20 mg once daily, if the patient exhibits any tolerability issues such as the occurrence of adverse drug reactions caused by istradefylline.		Osaka Red Cross HospitalClinical Research Center, Wakayama Medical UniversityNot Recruiting30years-oldNot applicableMale and Female30Not selectedJapan
247NCT02864004March 3, 201714 October 2019Apomorphine Pump in Early Stage of Parkinson's Disease (EARLY-PUMP)Apomorphine Pump in Early Stage of Parkinson's DiseaseParkinson's DiseaseDrug: Apomorphine;Other: Best Medical TreatmentRennes University HospitalRecruiting18 Years65 YearsAll192Phase 3France
248NCT03068481February 20, 201715 April 2019Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's DiseaseA Phase I Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's DiseaseParkinson DiseaseDrug: KDT-3594;Drug: PlaceboKissei Pharmaceutical Co., Ltd.Not recruiting20 Years74 YearsAll36Phase 1Japan
249NCT02799381February 9, 201714 October 2019A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease DYSCOVER (DYSkinesia COmparative Interventional Trial on Duodopa VERsus Oral Medication)Parkinson's Disease (PD)Drug: ABT-SLV187;Drug: optimized antiparkinsonian treatmentAbbVieNot recruiting30 YearsN/AAll63Phase 3United States;Finland;Greece;Hungary;Italy;Slovakia;Spain
250JPRN-UMIN0000256452017/02/012 April 2019Cross sectional analysis of Intestinal flora of Parkinson's disease:Parkinson's diseaseLevodopa/carbidopa intestinal gelJuntendo University School of MedicineNot RecruitingNot applicableNot applicableMale and Female20Not applicableJapan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
251NCT03119194January 27, 201716 December 2017Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067An Open-Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067 in Healthy Male SubjectsParkinson DiseaseDrug: [14C]-BIA 9-1067Bial - Portela C S.A.Not recruiting30 Years65 YearsMale7Phase 1United Kingdom
252JPRN-UMIN0000257032017/01/162 April 2019Effect of thiamine for the treatment of motor and non-motor symptom in hereditary neurological or neurodegenerative disordersParkinson's disease spinocerebellar ataxiafursultiamine 100mgDepartment of Neurology and Clinical Pharmacology, Ehime University Graduate School of MedicineNot Recruiting20years-oldNot applicableMale and Female50Not applicableJapan
253NCT03330470January 1, 201724 September 2018Molecular Mediators of Physical Exercise and Carnosine Induced Effects in Patients With Preclinical and Early Stage Neurodegenerative DiseaseMolecular Mediators of Physical Exercise and Carnosine Induced Effects in Patients With Preclinical and Early Stage Neurodegenerative DiseaseSubjective Cognitive Impairment;Mild Cognitive Impairment;Parkinson Disease;Healthy VolunteersBehavioral: exercise;Dietary Supplement: carnosine supplementation;Behavioral: stretching;Dietary Supplement: supplementation with placeboSlovak Academy of SciencesComenius University;University Hospital Bratislava;National Cheng Kung UniversityRecruiting55 Years80 YearsAll100N/ASlovakia;Taiwan
254NCT02954978January 201725 March 2019Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's DiseaseA Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib Treatment on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's DiseaseParkinson Disease;Parkinsons Disease With DementiaDrug: Placebo Oral Capsule;Drug: Nilotinib 150mg oral capsule [Tasigna];Drug: Nilotinib 300mg oral capsule [Tasigna]Georgetown UniversityNot recruiting40 Years90 YearsAll75Phase 2United States
255NCT03034564January 201716 December 2017A Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's DiseaseA Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's DiseaseParkinson Disease;Fatigue;ParkinsonismDrug: Northera;Drug: Placebo Oral TabletThe Cooper Health SystemRecruiting18 YearsN/AAll70Phase 4United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
256NCT03037203January 201710 September 2018A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive SleepinessA 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive SleepinessExcessive Sleepiness;Parkinson DiseaseOther: Placebo;Drug: JZP-110Jazz PharmaceuticalsNot recruiting35 Years80 YearsAll60Phase 2United States
257NCT02969369December 31, 201626 August 2019A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease PsychosisA Multicenter Randomized Double-blind Followed by an Open-label Extension Study to Evaluate the Efficacy, Safety, and Tolerability of SEP-363856 in Subjects With Parkinson's Disease PsychosisParkinson Disease PsychosisDrug: Placebo capsule;Drug: SEP-363856SunovionRecruiting55 Years105 YearsAll36Phase 2United States
258ChiCTR-IOR-160101682016-12-2018 April 2017Propofol-remifetanyl vs dexmedetomidine continous infusion for deep brain stimulation implantationPropofol-remifetanyl vs dexmedetomidine continous infusion for deep brain stimulation implantationParkinson's Diseasepropofol-remifentanyl group:propofol-remifentany infusion for monitored anesthesia care during awake deep brain stimulation surgery;dexmedetomidine group:dexmedetomidine infusion for monitored anesthesia care during awake deep brain stimulation surgery;West China Hospital, Sichuan UniversityRecruiting18Bothpropofol-remifentanyl group:25;dexmedetomidine group:25;OtherChina
259NCT02906020December 15, 201622 October 2019A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene MutationMulticenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant.Parkinson's DiseaseDrug: GZ/SAR402671;Drug: PlaceboGenzyme, a Sanofi CompanyRecruiting18 Years80 YearsAll243Phase 2United States;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom
260JPRN-UMIN0000248592016/12/142 April 2019The effectiveness of motor and psychiatric symptoms for Parkinson's disease patients by switching from Dopamine agonist to Zonisamide or combining Dopamine agonist and Zonisamide.Parkinson's diseaseSwitching from Dopamine agonist to Zonisamide.

Intervention period of 12 weeks.		Medical Corporation Abe Neurology ClinicNot Recruiting30years-oldNot applicableMale and Female50Not applicableJapan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
261NCT02789020December 20168 April 2019Image Parkinson's Disease Progression StudyImage Parkinson's Disease Progression StudyParkinson's DiseaseDrug: Rasagiline;Other: Placebo;Device: Magnetic Resonance Imaging;Device: functional Magnetic Resonance Imaging;Other: Physical Function Performance TestUniversity of FloridaNational Institute of Neurological Disorders and Stroke (NINDS)Recruiting40 Years77 YearsAll116Phase 2United States
262NCT02879136December 20169 July 2018TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's DiseaseTAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease: A Single Center, Randomized Pilot StudyParkinson's Disease, IdiopathicDrug: Methylphenidate;Other: Physical Therapy;Drug: AtomoxetineShnehal PatelRecruiting18 Years90 YearsAll42Early Phase 1United States
263NCT02934919December 201624 October 2016Evaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label StudyEvaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label StudyImpulse Control Disorders;Parkinson DiseaseDrug: NalmefeneUniversity Hospital, Clermont-FerrandNot recruiting18 Years80 YearsBoth30Phase 2France
264NCT02941822December 20165 March 2018Ambroxol in Disease Modification in Parkinson DiseaseA Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients With Parkinson Disease: Ambroxol in Disease Modification in Parkinson DiseaseParkinson DiseaseDrug: AmbroxolUniversity College, LondonCure Parkinson's Trust;PRO.MED.CS Praha a.s - Czech RepublicNot recruiting40 Years80 YearsAll20Phase 2United Kingdom
265NCT03000569December 201622 October 2018A Study to Evaluate SAGE-217 in Subjects With Parkinson's DiseaseA Phase 2, Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in Subjects With Parkinson's DiseaseParkinson DiseaseDrug: SAGE-217Sage TherapeuticsNot recruiting40 Years75 YearsAll29Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
266JPRN-UMIN0000245362016/11/2822 July 2019Intervention Study for the effect of Istradefylline on onset of Dyskinesia in Patients with Parkinson's Disease.Intervention Study for the effect of Istradefylline on onset of Dyskinesia in Patients with Parkinson's Disease. - ODYSSEI Study(Onset of Dyskinesia and Safety/Efficacy of Istradefylline)Parkinson's diseaseTreatment with istradefylline combined with optimal medical therapy.

Treatment with istradefylline will be started at a dose of 20 mg administered once daily at Week 0. The dose of istradefylline will be increased to 40 mg once daily if the patient has no tolerability issues and still has motor symptoms at Week 4.

From the following day of Week 4, Optimal medical therapy including istradefylline will be applied to each patient.
Optimal medical therapy without istradefylline.

Treatment with increased dose of previously used antiparkinson drugs or addition of new antiparkinson drug other than istradefylline will be started at Week 0.

After Week 4, Optimal medical therapy without istradefylline will be applied to each patient.		Fukuoka UniversityNot Recruiting30years-old80years-oldMale and Female280Not applicableJapan
267EUCTR2016-001690-33-FI25/11/20165 December 2016Apomorfiini-infuusiohoito edenneen Parkinsonin taudin hoidossaApomorfiini-infuusiohoito edenneen Parkinsonin taudin hoidossaEdennyt parkinsonin tauti
MedDRA version: 19.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Dacepton 5 mg/ml infuusioneste, liuos
Product Name: Dacepton 5 mg/ml
Pharmaceutical Form: Infusion		Eero PekkonenAuthorisedFemale: yes
Male: yes		Phase 4Finland
268NCT03007888November 14, 201613 May 2019A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's DiseaseA Randomized, Multiple Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's DiseaseAdvanced Parkinson's DiseaseDrug: IR CD-LD;Drug: ER CD-LDIMPAX Laboratories, Inc.Not recruiting40 Years100 YearsAll28Phase 2United States
269EUCTR2016-001762-29-IT08/11/20168 January 2018A Phase 2, Randomized, Double-Blind, Placebo Controlled, 3-Period Crossover, Positive Control, QT-Evaluation Study of APL-130277 in Subjects with Parkinson’s Disease Complicated by Motor Fluctuations (“OFF” Episodes)A Phase 2, Randomized, Double-Blind, Placebo Controlled, 3-Period Crossover, Positive Control, QT-Evaluation Study of APL-130277 in Subjects with Parkinson’s Disease Complicated by Motor Fluctuations (“OFF” Episodes) - CTH-201Parkinson's Disease (PD)
MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: APL-130277
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine Hydrocloride Hemihydrate
CAS Number: 41372-20-7
Current Sponsor code: Apomorphine Hydrocloride
Other descriptive name: Apomorphine Hydrocloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Product Name: APL-130277
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine Hydrocloride Hemihydrate
CAS Number: 41372-20-7
Current Sponsor code: Apomorphine Hydrocloride
Other descriptive name: Apomorphine Hydrocloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 15-
Product Name: APL-130277
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine Hydrocloride Hemihydrate
CAS Number: 41372-20-7
Current Sponsor code: Apomorphine Hydrocloride
Other descriptive name: Apomorphine Hydrocloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
Product Name: APL-130277
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine Hydrocloride Hemihydrate
CAS Number: 41372-20-7
Current Sponsor code: Apomorphine Hydrocloride
Other descriptive name: Apomorphine Hydrocloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Product Name: APL-130277
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine Hydrocloride Hemihydrate
CAS Number: 41372-20-7
Current Sponsor code: Apomorphine Hydrocloride
Other descriptive name: Apomorphine Hydrocloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 30-
Trade Name: AVALOX - 400 MG COMPRESSE RIVESTITE CON FILM 5 COMPRESSE IN BLISTER PP/AL
Product Name: Avalox
Product Code: n.a.
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: MOXIFLOXACINA CLORIDRATO		SUNOVION PHARMACEUTICALSAuthorisedFemale: yes
Male: yes		40Phase 2Italy
270NCT03531060November 8, 201611 June 2018A Clinical Study of IRL790 in Patients With Parkinson's Disease Experiencing Levodopa Induced DyskinesiaA Randomised, Double-blind, Placebo-controlled, Phase Ib Study Evaluating the Safety and Tolerability of IRL790 in Patients With Parkinson's Disease (PD) Experiencing Levodopa (L-Dopa) Induced Dyskinesia (LID).Parkinson DiseaseDrug: IRL790;Drug: PlaceboIntegrative Research Laboratories ABNot recruiting50 Years85 YearsAll15Phase 1/Phase 2
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
271ChiCTR-IPR-160093952016-11-0118 April 2017Clinical trial on efficacy and safety of add-on treatment of Butylphthalide in patients with Parkinson's disease in early and moderate stageClinical trial on efficacy and safety of add-on treatment of Butylphthalide in patients with Parkinson's disease in early and moderate stageParkinson’s diseaseButylphthalide group and Control group:Butylphthalide 200mg/time(2 capsules) , three time/day, for 24 weeks;Control:No treatment;The Second Affiliated Hospital of Soochow UniversityNot Recruiting35BothButylphthalide group and Control group:36;Control:36;Post-marketChina
272JPRN-UMIN0000256382016/11/012 April 2019Adenosine A2A receptors in Parkinson's diseaseParkinson's disease11C-preladenant-PET scanningTokyo Metropolitan Institute of GerontologyNot Recruiting40years-old89years-oldMale and Female40Not selectedJapan
273NCT02857244November 20168 January 2018A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson PatientsA Multidisciplinary Approach to Manage Gait Difficulty in Parkinson PatientsParkinson's DiseaseDrug: Duloxetine;Drug: Donepezil;Drug: ModafinilUniversity of ChicagoNot recruiting18 Years100 YearsAll0Phase 2United States
274NCT02968433November 201615 April 2019The Stanford Parkinson's Disease Plasma StudyThe Stanford Parkinson's Disease Plasma (SPDP) Study: Intravenously-Administered Plasma From Young Donors for Treatment of Moderate Parkinson's DiseaseParkinson Disease(PD)Drug: Infusions of young plasmaStanford UniversityNot recruiting50 Years80 YearsAll15Phase 1United States
275EUCTR2015-001786-10-DE24/10/20165 February 2018A clinical study of the effects of EPI-589 on safety and indicators of oxidative stress in patients with Parkinson's disease.A Phase 2A Safety and Biomarker Study of EPI-589 in Mitochondrial Subtype and Idiopathic Parkinson’s Disease Subjects - Safety and Biomarker Study with EPI-589 in Parkinson's DiseaseParkinson’s disease
MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: EPI-589
Product Code: EPI-589
Pharmaceutical Form: Coated tablet
INN or Proposed INN: Kinoquinone (proposed)
CAS Number: 1147883-03-1
Current Sponsor code: EPI-589
Other descriptive name: (R)-troloxamide quinone
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 250-		BioElectron Technology Corporation (formerly Edison Pharmaceuticals Inc.)AuthorisedFemale: yes
Male: yes		40Phase 2United States;Germany;United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
276EUCTR2016-002680-34-ES20/10/20167 January 2019Effects of different concentrations of dexmedetomidine on basal ganglia neuronal activity (local field potentials) in Parkinson's disease.Effects of different concentrations of dexmedetomidine on basal ganglia neuronal activity (local field potentials) in Parkinson's disease.Parkinson's disease
MedDRA version: 19.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]		Trade Name: Dexdor
Product Name: Dexdor
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: DEXMEDETOMIDINE
CAS Number: 113775-47-6
Other descriptive name: DEXMEDETOMIDINA
Concentration unit: µg/kg microgram(s)/kilogram
Concentration type: range
Concentration number: 0.15-1		Clínica Universidad de Navarra/Universidad de NavarraNot RecruitingFemale: yes
Male: yes		12Phase 4Spain
277NCT02871427October 20, 20168 April 2019Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior DisorderAn Open-label Study of Nelotanserin in Patients With Lewy Body Dementia Who Have Frequent Visual Hallucinations or REM Sleep Behavior DisorderLewy Body Dementia;Dementia With Lewy Bodies;Parkinson's Disease Dementia;Visual Hallucinations;REM Sleep Behavior DisorderDrug: NelotanserinAxovant Sciences Ltd.Not recruiting50 YearsN/AAll80Phase 2United States
278EUCTR2016-002454-20-FR17/10/20163 April 2017Apomorphine Pump in Early Stage of Parkinson’s DiseaseApomorphine Pump in Early Stage of Parkinson’s Disease - EARLY-PUMPParkinson’s disease
MedDRA version: 19.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: APOKINON
Product Name: APOKINON
Pharmaceutical Form: Solution for infusion		CHU de RennesAuthorisedFemale: yes
Male: yes		Phase 3France
279NCT02847650October 17, 201628 January 2019Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the DiseaseA 15-week, Phase 2, Double Blind, Randomized, Placebo-controlled, Flexible Dose Study To Investigate The Efficacy, Safety And Tolerability Of Pf-06649751 In Subjects With Early Stage Parkinson's DiseaseParkinson DiseaseDrug: Placebo;Drug: PF-06649751PfizerNot recruiting45 Years80 YearsAll57Phase 2United States;France;Germany;Israel
280EUCTR2015-002571-24-GB14/10/201628 February 2019A Pilot Study to Evaluate the Safety, Tolerability (any side effects of the drug) and Pharmacodynamic (biochemical and physiological effects of drugs). The effects of Ambroxol in Patients with Parkinson Disease: Ambroxol in Disease Modification in Parkinson Disease.A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients with Parkinson Disease: Ambroxol in Disease Modification in Parkinson Disease - AiM-PDParkinson disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: AMBROSAN 60mg Tablets
Product Name: Ambroxol
Pharmaceutical Form: Tablet
INN or Proposed INN: Ambroxol hydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 60-		Joint Research OfficeNot Recruiting Female: yes
Male: yes		20Phase 2United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
281EUCTR2016-002391-27-GB07/10/201628 February 2019Opicapone in clinical practice (OPTIPARK)This action will amend the information submitted in this data field for all relevant applications. Please refer to the guidance under the Amendment tab and consider whether further notification to review bodies is required. - Opicapone in clinical practice (OPTIPARK)_V1Parkinson's disease (PD) patients with wearing-off motor fluctuations
MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Ongentys
Product Name: Ongentys
Pharmaceutical Form: Capsule, hard		BIAL - Portela & Ca, S.A.Not Recruiting Female: yes
Male: yes		550Phase 4Germany;United Kingdom
282NCT02935842October 1, 20165 November 2018Evaluation of Intensive Language TherapyEffectiveness of High-frequency Specific Speech Therapy on Verbal Fluency Decline and/ or Verbal Apraxia in Patients With Parkinson's Disease With and Without Deep Brain Stimulation (DBS) - a Randomized Controlled Single-blinded TrialParkinson's DiseaseOther: Specific SL-therapy;Other: Rhythmic Balance-Movement Training (rBMT)University Hospital, Basel, SwitzerlandNot recruiting45 Years80 YearsAll64N/ASwitzerland
283NCT02538315October 201616 December 2017Using [18F]FDOPA PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease PatientsUsing 3,4-dihydroxy-6-[18F]-Fluoro-l-phenylalanine ( [18F]FDOPA) PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease PatientsParkinson`s DiseaseDrug: [18F]FDOPA PET/CTUniversity of SaskatchewanUniversity of ManitobaRecruiting18 YearsN/AAll30N/ACanada
284NCT02803749October 201627 May 2019Buspirone in Parkinson's DiseaseThe Tolerability of Buspirone for the Treatment of Anxiety in Parkinson's DiseaseParkinson Disease;AnxietyDrug: Buspirone;Drug: PlaceboUniversity of RochesterMichael J. Fox Foundation for Parkinson's ResearchNot recruiting18 YearsN/AAll21Phase 2United States
285NCT02910102October 20168 January 2018Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With DementiaA Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease DementiaAlzheimer's Disease;Dementia With Lewy Bodies;Parkinson's Disease DementiaDrug: RVT-101 35 mg;Drug: PlaceboAxovant Sciences Ltd.Not recruiting50 Years89 YearsAll38Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
286NCT02940912October 201616 December 2017Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's DiseaseDouble Bind Randomized Placebo-controlled Cross-over Study to Evaluate Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's DiseaseParkinson DiseaseDrug: Apomorphine;Drug: PlaceboClinique Beau SoleilRecruiting35 Years90 YearsAll45Phase 4France
287NCT03022799October 201616 December 2017KM-819 for Patients With Parkinson's DiseaseA First in Human, Randomized, Double-blind, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following Single and Multiple Oral Doses of KM-819 in Healthy Young Adult and Elderly Subjects With Exploration of Food EffectParkinson DiseaseDrug: KM-819;Drug: PlaceboKainos Medicine Inc.Recruiting19 YearsN/AAll88Phase 1Korea, Republic of
288NCT03462680September 28, 201629 July 2019GPR109A and Parkinson's Disease: Role of Niacin in Outcome MeasuresGPR109A and Parkinson's Disease: Role of Niacin in Outcome MeasuresParkinson's DiseaseDietary Supplement: niacin;Other: placeboVA Office of Research and DevelopmentRecruiting35 YearsN/AAll80N/AUnited States
289EUCTR2015-005078-39-DE21/09/201622 January 2018-A multicenter, parallel-group, rater-blinded, randomized clinical study investigating the efficacy, safety, tolerability and pharmacokinetics of 2 dosing regimens of ND0612H, a solution of levodopa/carbidopa delivered via a pump system as a continuous subcutaneous infusion in subjects with advanced Parkinson's diseaseSubjects with advanced Parkinson's disease
MedDRA version: 18.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: levodopa/carbidopa solution
Product Code: ND0612
Pharmaceutical Form: Solution for injection/infusion
INN or Proposed INN: Levodopa
CAS Number: 59-92-7
Current Sponsor code: -
Other descriptive name: LEVODOPA
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 60-
INN or Proposed INN: Carbidopa
CAS Number: 38821-49-7
Current Sponsor code: -
Other descriptive name: CARBIDOPA
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 7.5-		NeuroDerm Ltd.Not RecruitingFemale: yes
Male: yes		47Phase 2United States;Austria;Israel;Germany;Italy
290JPRN-UMIN0000243122016/09/202 April 2019Studies of efficacy and safety of the combined use of febuxostat and inosine for patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis, and changes of blood and urine purine compounds.Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosisTreatment with febuxostat 20 mg and inosine 0.5 g, twice a day for 2 weeksTsukuba International Clinical Pharmacology ClinicNot Recruiting20years-old80years-oldMale and Female12Not selectedJapan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
291NCT02688465September 5, 201611 June 2018Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).Parkinson's DiseaseDrug: ApomorphineFondation Ophtalmologique Adolphe de RothschildNot recruiting18 YearsN/AAll15Phase 4France
292NCT02815800September 2, 201611 June 2018Efficacy of Ethnodyne Visio in Parkinson's DiseaseParkinson's DiseaseDietary Supplement: ETHNODYNE VISIOUniversity Hospital, Strasbourg, FranceETHNODYNENot recruiting40 Years75 YearsAll24N/AFrance
293NCT02385500September 20167 October 2019Fesoterodine on Urgency Episodes in Parkinson's Disease PopulationRandomized Cross-Over Study of Fesoterodine on Urgency Episodes in Parkinson's Disease PopulationUrinary Bladder, Overactive;Parkinson DiseaseDrug: Fesoterodine;Drug: PlaceboSir Mortimer B. Davis - Jewish General HospitalNot recruiting50 Years85 YearsAll5Phase 4Canada
294NCT02601586September 20162 September 2019Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's DiseaseEvaluation of the Analgesic Effects of Prolonged-release Oxycodone and of Levodopa, Versus Placebo, on Central Neuropathic Pain in Parkinson's Disease: OXYDOPA TrialParkinson DiseaseDrug: PR Oxycodone;Drug: Levodopa;Drug: Oxycodone Placebo;Drug: Levodopa placeboUniversity Hospital, ToulouseRecruiting40 Years75 YearsAll84Phase 2/Phase 3France
295NCT02897063September 201625 February 2019Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic FailureThe Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Aim 2 of RDCRN (Rare Diseases Clinical Research Network) Project 2Autonomic Failure;Pure Autonomic Failure;Multiple System Atrophy;Parkinson Disease;Orthostatic HypotensionDrug: Droxidopa;Drug: Midodrine;Drug: PlaceboVanderbilt University Medical CenterRecruiting40 Years80 YearsAll34Phase 1United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
296NCT02939391September 201611 June 2018A Study of KW-6356 in Subjects With Early Parkinson's DiseaseAn Early Phase 2 Study of KW-6356 in Subject With Early Parkinson's DiseaseParkinson's DiseaseDrug: KW-6356;Drug: PlaceboKyowa Hakko Kirin Co., LtdNot recruiting20 Years80 YearsAll175Phase 2Japan
297NCT03192046September 201611 February 2019Bracing for Walking in Parkinson's DiseaseImpact of Carbon Fiber AFOs on Gait and Resulting Changes in Quality of Life Across Time in Persons With PDGait Disorders, Neurologic;Parkinson DiseaseDevice: Carbon Fiber Ankle Foot Orthosis (AFO)University of Texas Southwestern Medical CenterAmerican Orthotic and Prosthetic AssociationRecruiting30 Years85 YearsAll16N/AUnited States
298EUCTR2015-005814-31-AT29/08/201624 September 2018-A multicenter, international, open-label, safety study of ND0612, a solution of levodopa/carbidopa delivered via a pump system as a continuous subcutaneous infusion in subjects with advanced Parkinson's Disease (BeyoND)Subjects with advanced Parkinson's disease
MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: levodopa/carbidopa solution
Product Code: ND0612
Pharmaceutical Form: Solution for injection/infusion
INN or Proposed INN: Levodopa
CAS Number: 59-92-7
Current Sponsor code: -
Other descriptive name: LEVODOPA
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 60-
INN or Proposed INN: carbidopa
CAS Number: 38821-49-7
Current Sponsor code: -
Other descriptive name: CARBIDOPA
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 7.5-		NeuroDerm Ltd.AuthorisedFemale: yes
Male: yes		210Phase 2France;United States;Hungary;Czech Republic;Belgium;Spain;Poland;Austria;Israel;Germany;Italy
299NCT02365870August 20164 November 2019Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational TreatmentAnxiety in Parkinson's: Use of Quantitative Methods to Guide Rational TreatmentAnxiety Disorders;Parkinson DiseaseDrug: rotigotine transdermal patch;Drug: placeboJohns Hopkins UniversityNational Institute on Aging (NIA)Not recruiting21 Years89 YearsAll4Phase 4United States
300NCT02782481August 20163 December 2018A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor FluctuationsA Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel Group Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor FluctuationsParkinson's DiseaseDrug: ND0612;Drug: PlaceboNeuroDerm Ltd.Not recruiting30 Years80 YearsAll1Phase 3Israel
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
301EUCTR2014-001014-25-ES20/07/20168 August 2016Brain amyloid beta burden as per florbetaben PETBrain Amyloid-Beta burden as per florbetaben (Neuraceq) pet and cognitive outcomes after deep brain stimulation in Parkinsin's diseaseParkinson's Disease
MedDRA version: 19.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Neuraceq
Product Name: Neuraceq
Pharmaceutical Form: Solution for injection
INN or Proposed INN: FLORBETABEN (18F)
CAS Number: 902143-01-5
Current Sponsor code: Piramal Imaging GmbH
Concentration unit: MBq/mg megabecquerel(s)/milligram
Concentration type: equal
Concentration number: 300-		Fundació Clínic per la Recerca BiomèdicaAuthorisedFemale: yes
Male: yes		Phase 4Spain
302NCT02382198July 201611 June 2018Study of Glycopyrrolate for Moderate-to-severe Sialorrhea in Parkinson's DiseaseA Randomized, Placebo-controlled, 2-arm Parallel-group Superiority Phase II Study of GLYCOpyrrolate for Moderate-to-severe Sialorrhea in PARkinson's DiseaseSialorrhea;Parkinson's DiseaseDrug: Glycopyrrolate;Drug: PlaceboOttawa Hospital Research InstituteRecruiting30 YearsN/AAll28Phase 2Canada
303NCT02452723July 201615 April 2019A Study to Evaluate the Safety of Neural Stem Cells in Patients With Parkinson's DiseaseA Single Arm, Open-Label Phase 1 Study to Evaluate the Safety and Tolerability of ISC-hpNSC Injected Into the Striatum and Substantia Nigra of Patients With Parkinson's DiseaseParkinson DiseaseBiological: ISC-hpNSCCyto Therapeutics Pty LimitedNot recruiting30 Years70 YearsAll12Phase 1Australia
304NCT02615873July 201627 August 2018A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004An Open-Label,Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects Who Completed Study IN 11 004Parkinson's DiseaseDrug: Accordion Pill™ Carbidopa/LevodopaIntec Pharma Ltd.Recruiting30 Years100 YearsAll460Phase 3United States;Bulgaria;Germany;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom
305NCT02789592July 201613 June 2016Efficacy and Safety of Melatonin PR and Clonazepam in Patients With REM Sleep Behavior Disorder in Parkinson DiseaseA Randomized Double-Blind, Double-Dummy, Crossover Study to Evaluate the Efficacy and Safety of Prolonged-Release Melatonin and Clonazepam in Patients With Rapid Eye Movement (REM) Sleep Behavior Disorder in Parkinson DiseaseREM Sleep Behavior Disorder;Parkinson DiseaseDrug: Clonazepam placebo;Drug: Melatonin PR placebo;Drug: Clonazepam;Drug: Melatonin PRSeoul National University HospitalKuhnil Pharmaceutical Co., Ltd.Not recruiting30 YearsN/ABoth30Phase 2Korea, Republic of
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
306NCT02818777July 201616 December 2017A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's DiseaseA Randomized, Double Blind, Placebo-controlled Crossover Study of Tolerability and Efficacy of Cannabidiol (CBD) on Tremor in Parkinson's DiseaseParkinson's DiseaseDrug: cannabidiol;Drug: placeboUniversity of Colorado, DenverColorado Department of Public Health and Environment;GW Research LtdRecruiting45 Years78 YearsAll60Phase 2United States
307EUCTR2015-005626-19-CZ23/06/201618 June 2018A study of the safety and effectiveness of levodopa inhalation powder (CVT-301) in Parkinson's Disease Patients with OFF episodesA 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena)
MedDRA version: 20.0 Level: LLT Classification code 10034007 Term: Parkinson's disease NOS System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: CVT-301
Product Code: CVT-301 35mg
Pharmaceutical Form: Inhalation powder, hard capsule
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Current Sponsor code: CVT-301
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 30-
Product Name: CVT-301
Product Code: CVT-301 50mg
Pharmaceutical Form: Inhalation powder, hard capsule
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Current Sponsor code: CVT-301
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 42-		Civitas Therapeutics, Inc.Not RecruitingFemale: yes
Male: yes		440Phase 3United States;Czech Republic;Canada;Poland;Spain
308EUCTR2015-005626-19-ES13/06/201611 June 2018A study of the safety and effectiveness of levodopa inhalation powder (CVT-301) in Parkinson's Disease Patients with OFF episodesA 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena)
MedDRA version: 19.0 Level: LLT Classification code 10034007 Term: Parkinson's disease NOS System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: CVT-301
Product Code: CVT-301 35mg
Pharmaceutical Form: Inhalation powder, hard capsule
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Current Sponsor code: CVT-301
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 30-
Product Name: CVT-301
Product Code: CVT-301 50mg
Pharmaceutical Form: Inhalation powder, hard capsule
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Current Sponsor code: CVT-301
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 42-		Civitas Therapeutics, a wholly owned subsidiary of AcordaNot RecruitingFemale: yes
Male: yes		440Phase 3United States;Czech Republic;Canada;Poland;Spain
309JPRN-jRCTs05118009809/06/201622 July 2019The DAT-SPECT study for the benefit of Selegilline or Zonisamide in Parkinson's DiseaseA comparative randomized study for the evaluation of the overlaying effect of Selegiline or Zonisamide over Levodopa in Parkinson's diseaseParkinson's disease;034034L-Dopa/DCI only : The drug is administered per oral at 300 mg/day. The treatment is started within 14 days after registration and continued until day 365.
L-Dopa/DCI + selegiline : L-Dopa/DCI is administered per oral at 300 mg/day and selegiline is administered at 5 mg/day. The treatment is started within 14 days after registration and continued until day 365.
L-Dopa/DCI + zonisamide : L-Dopa/DCI is administered per oral at 300 mg/day and zonisamide is administered at 25 mg/day. The treatment is started within 14 days after registration and continued until day 365.		Hidefumi ItoRecruiting>=55 age old<80 age oldBoth180Phase 2none
310JPRN-UMIN0000225292016/06/012 April 2019Effects on the pharmacokinetics of L-DOPA formulation by Proton pump inhibitors in patients with Parkinson's diseaseParkinson's disease8-day oral administration of L-DOPA formulation(Menesit100 Tablets or DopacolL100 Tablets,dosage in taking)and Nexium10 Capsules(once a day 2Cap,after breakfast)

Blood concentration measurement date only, oral administration of L-DOPA formulation 1tablet(100mg) and Nexium10 2Cap(20mg)
Washout 6days

8-day oral administration of L-DOPA formulation(Menesit100 Tablets or DopacolL100 Tablets,dosage in taking)and Nexium Placebo Capsules(lactose,once a day 2Cap,after breakfast)

Blood concentration measurement date only, oral administration of L-DOPA formulation 1tablet(100mg) and Nexium Placebo Capsules 2Cap
8-day oral administration of L-DOPA formulation(Menesit100 Tablets or DopacolL100 Tablets,dosage in taking)and Nexium Placebo Capsules(lactose,once a day 2Cap,after breakfast)

Blood concentration measurement date only, oral administration of L-DOPA formulation 1tablet(100mg) and Nexium Placebo Capsules 2Cap
Washout 6days

8-day oral administration of L-DOPA formulation(Menesit100 Tablets or DopacolL100 Tablets,dosage in taking)and Nexium10 Capsules(once a day 2Cap,after breakfast)

Blood concentration measurement date only, oral administration of L-DOPA formulation 1tablet(100mg) and Nexium10 2Cap(20mg)		Utano National Hospital, National Hospital OrganizationNot Recruiting20years-old85years-oldMale and Female8Phase 3Japan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
311JPRN-UMIN0000225332016/06/012 April 2019A comparative randomized study for the evaluation of the overlaying effect of Selegiline or Zonisamide over Levodopa in Parkinson's diseaseParkinson's diseaseL-Dopa/DCI only
The drug is administered per oral at 150 to 300 mg/day. The treatment is started within 14days after registration and continued until day 365.
L-Dopa/DCI + selegiline
L-Dopa/DCI is administered per oral at 150 to 300 mg/day and selegiline is administered at 5mg/day. The treatment is started within 14days after registration and continued until day 365.
L-Dopa/DCI + zonisamide
L-Dopa/DCI is administered per oral at 150 to 300 mg/day and zonisamide is administered at 25mg/day. The treatment is started within 14days after registration and continued until day 365.		Osaka Redcross Hospital Wakayama Prefectural Medical CollegeRecruiting55years-old80years-oldMale and Female180Phase 2Japan
312NCT02642393June 201619 November 2018Study of Urate Elevation in Parkinson's Disease, Phase 3A Randomized, Double-blind, Placebo-controlled Trial of Urate-elevating Inosine Treatment to Slow Clinical Decline in Early Parkinson's DiseaseParkinson's DiseaseDrug: Inosine;Drug: PlaceboMichael Alan SchwarzschildThe Parkinson Study Group;Michael J. Fox Foundation for Parkinson's Research;University of Rochester;National Institute of Neurological Disorders and Stroke (NINDS)Not recruiting30 YearsN/AAll270Phase 3United States;Puerto Rico
313NCT02785978June 201616 December 2017Pilot Study to Evaluate ActiMyo Measured Activity in Parkinson Disease Patients & Healthy VolunteersPilot Study to Evaluate ActiMyo Measured Activity in Parkinson Disease Patients & Healthy VolunteersParkinson Disease;Healthy VolunteersDrug: Levodopa acute challenge;Other: Controlled environment tests (series of tasks of everyday life);Other: Standardized scales: MDS-UPDRS (Part II to IV) and RDRS;Device: ActiMyo recording;Other: Diary completionInstitut de Myologie, FranceNot recruiting18 YearsN/AAll30N/AFrance
314NCT02807675June 201616 December 2017A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)A Phase 1 Study of the Safety and Tolerability of a Single Dose Administration of CVT- 301 (Levodopa Inhalation Powder) When Administered for Early Morning OFF Symptoms in Patients With Parkinson's DiseaseParkinson's DiseaseOther: Placebo;Drug: CVT-301, LIPAcorda TherapeuticsNot recruiting30 Years85 YearsAll36Phase 1United States
315NCT02812394June 20167 November 2016A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) TabletsA Phase 1 Single Dose Pharmacokinetic Bridging Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) TabletsParkinson DiseaseDrug: CVT-301 (Dose Level 1);Drug: CVT-301 (Dose Level 2);Drug: Sinemet®Acorda TherapeuticsNot recruiting25 Years65 YearsBoth24Phase 1United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
316NCT02838797June 201622 October 2019RQ-00000010 for Gastroparesis and Constipation in Parkinson's DiseaseRQ-00000010 for Gastroparesis and Constipation in Parkinson's DiseaseParkinson's Disease;Gastroparesis;ConstipationDrug: RQ-00000010;Drug: PlaceboVirginia Commonwealth UniversityMichael J. Fox Foundation for Parkinson's Research;RaQualia Pharma Inc.Not recruiting18 YearsN/AAll51Phase 1United States
317EUCTR2016-000679-25-ES31/05/201628 February 2019Clinical study for the assessment of security of candesartan in Parkinson?s disease population and its potential benefit in cognitive impairment associated to Parkinson?s disease.A prospective, randomized, double-blind and placebo-controlled, parallel group, phase II study to compare the efficacy and safety of candesartan versus placebo on cognitive impairment associated with Parkinson?s disease. Exploratory study.Parkinson's Disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Parapres
Pharmaceutical Form: Tablet
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use		INSTITUT DE RECERCA HSCSPNot Recruiting Female: yes
Male: yes		56Phase 2Spain
318EUCTR2015-005078-39-AT30/05/20163 April 2017-A multicenter, parallel-group, rater-blinded, randomized clinical study investigating the efficacy, safety, tolerability and pharmacokinetics of 2 dosing regimens of ND0612H, a solution of levodopa/carbidopa delivered via a pump system as a continuous subcutaneous infusion in subjects with advanced Parkinson's diseaseSubjects with advanced Parkinson's disease
MedDRA version: 19.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: levodopa/carbidopa solution
Product Code: ND0612
Pharmaceutical Form: Solution for injection/infusion
INN or Proposed INN: Levodopa
CAS Number: 59-92-7
Current Sponsor code: -
Other descriptive name: LEVODOPA
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 60-
INN or Proposed INN: Carbidopa
CAS Number: 38821-49-7
Current Sponsor code: -
Other descriptive name: CARBIDOPA
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 7.5-		NeuroDerm Ltd.Not RecruitingFemale: yes
Male: yes		47Phase 2United States;Austria;Israel;Germany;Italy
319JPRN-UMIN0000090622016/05/302 April 2019An open-label, single-centered, non-randomized trial of inosine to assess its safety for patients with Parkinson's diseaseParkinson's diseaseTake oral inosine 500-3000mg/day to achieve a serum UA level between 6.0-8.0 mg/dLDept. of Clinical pharmacology and NeurologyNot Recruiting20years-oldNot applicableMale and Female20Phase 1Japan
320EUCTR2016-000636-18-GB12/05/201628 February 2019Phase 3, placebo controlled study to examine the efficacy, safety and tolerability of APL-130277 in patients with Parkinson's disease.A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy, Safety and Tolerability of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (“OFF” Episodes).Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (“OFF” Episodes)
MedDRA version: 19.0 Level: LLT Classification code 10034006 Term: Parkinson's disease aggravated System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10 -
Pharmaceutical form of the placebo: Sublingual film
Route of administration of the placebo: Sublingual use
Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 15-
Pharmaceutical form of the placebo: Sublingual film
Route of administration of the placebo: Sublingual use
Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Sublingual film
Route of administration of the placebo: Sublingual use
Product Name: Apomorphine hydrochloride		Sunuvion Pharmaceuticals IncNot Recruiting Female: yes
Male: yes		126Phase 3United States;Canada;United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
321JPRN-UMIN0000220222016/05/1023 April 2019A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson diseaseA randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease - A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson diseaseParkinson disease Chronic constipationStudy drug group:
A 12-week administration of lubiprostone 24 microrgrum (adjustable) twice daily after switching from magnesium oxide

Control group:
Continuous administration of magnesium oxide at the same dosage regimen as before the enrollment		Dokkyo Medical UniversityNot Recruiting20years-old90years-oldMale and Female64Not selectedJapan
322JPRN-UMIN0000220232016/05/102 April 2019A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease. -to evaluation by change of intestinal bacterial flora-Parkinson disease Chronic constipationStudy drug group:
A 12-week administration of lubiprostone 24 microgrum (adjustable) twice daily after switching from magnesium oxide

Control group:
Continuous administration of magnesium oxide at the same dosage regimen as before the enrollmen		Dokkyo Medical UniversityNot Recruiting20years-old90years-oldMale and Female64Not selectedJapan
323JPRN-UMIN0000221872016/05/062 April 2019Research on Parkinson's disease pathogenesis based on analysis of caffeine absorption in patients with Parkinson's diseaseParkinson&#39;s diseasePD group, 200 mg caffeine administration, qd, 1 day
Control group, 200 mg caffeine administration, qd, 1 day		Department of Neurology, Juntendo UniversityNot Recruiting40years-old60years-oldMale and Female20Not applicableJapan
324NCT02762591May 3, 201616 December 2017Expanded Access of Pimavanserin for Patients With PD PsychosisExpanded Access Program of Pimavanserin in Patients With Parkinson's Disease PsychosisParkinson's Disease PsychosisDrug: Pimavanserin tartrateACADIA Pharmaceuticals Inc.Not recruiting40 YearsN/AAllN/A
325NCT02705755May 20167 October 2019TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)A Phase 2 Study to Assess the Effect of TD-9855 in Subjects With Neurogenic Orthostatic HypotensionNeurogenic Orthostatic Hypotension;Multiple System Atrophy (MSA) With Orthostatic Hypotension;Pure Autonomic Failure;Parkinson Disease;Hypotension, Orthostatic;Orthostatic Hypotension;Pure Autonomic Failure With Orthostatic Hypotension;Parkinson Disease With Orthostatic HypotensionDrug: TD-9855;Drug: PlaceboTheravance BiopharmaNot recruiting40 YearsN/AAll34Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
326NCT02726386May 20163 December 2018A Clinical Study in Advanced Parkinson's Disease Investigating the Long Term Safety of ND0612 Administered as a Continuous SC InfusionA Multicenter, International, Open-label, Safety Study of ND0612, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's DiseaseParkinson's DiseaseDrug: ND0612NeuroDerm Ltd.Not recruiting30 YearsN/AAll210Phase 2United States;Austria;Czechia;France;Germany;Israel;Italy;Poland;Spain
327NCT02728947May 201612 December 2016Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's DiseaseA Single Group and Open-label Study to Evaluate Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's DiseaseParkinson's DiseaseDrug: ROTIGOTINELuye Pharma Group Ltd.Not recruiting18 Years99 YearsBoth28Phase 1United States
328NCT02784145May 201611 June 2018Effects of Resistant Starch on Bowel Habits, Fecal Short Chain Fatty Acids and Gut Microbiota in Parkinson DiseaseEffects of Resistant Starch on Bowel Habits, Fecal Short Chain Fatty Acids and Gut Microbiota in Parkinson DiseaseParkinson DiseaseDietary Supplement: Resistant starch;Other: Recommendation with regard to nutritionSaarland UniversityNot recruiting18 YearsN/AAll95N/AGermany
329NCT02812147May 201625 February 2019Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson DiseaseEffect of L-Dihydoxyphenylserine (L-DOPS, Northera) a Central and Peripheral Norepinephrine Agent on Locomotion, Postural Stability (Balance), and Fall Risk Reduction in Parkinson Disease (PD)Parkinson DiseaseDrug: L-DOPS;Drug: PlaceboSt. Joseph's Hospital and Medical Center, PhoenixArizona State University, TempeNot recruiting30 Years83 YearsAll20Phase 2United States
330EUCTR2015-003512-20-GB28/04/201628 February 2019Clinical Efficacy & Safety of AP CD/LD in Fluctuating Parkinson’s DiseaseA Phase III, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy and Safety of Gastric Retentive, Controlled Release Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD) to Immediate Release CD/LD in Fluctuating Parkinson’s Disease PatientsParkinson's Disease
MedDRA version: 20.0 Level: HLT Classification code 10034005 Term: Parkinson's disease and parkinsonism System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: SINEMET 25-100
Product Name: Immediate Release carbidopa/levodopa 25/100 mg
Pharmaceutical Form: Tablet
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Product Name: Accordion Pill™ Carbidopa/Levodopa 50/400 mg
Pharmaceutical Form: Capsule
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 400-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Product Name: Accordion Pill™ Carbidopa/Levodopa 50/500 mg
Pharmaceutical Form: Capsule
INN or Proposed INN: Carbidopa
Other descriptive name: CARBIDOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
INN or Proposed INN: Levodopa
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)		Intec Pharma, Ltd.Authorised Female: yes
Male: yes		420Phase 3United States;Hungary;Slovakia;Poland;Spain;Ukraine;Russian Federation;Israel;Bulgaria;Germany;Italy;United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
331EUCTR2015-004507-23-DE25/04/20167 January 2019Comparison of two levodopa treatments, ODM-104 and Stalevo, in Parkinson's disease patients who have motor fluctuations.Efficacy and safety of ODM-104 compared to a standard combination (Stalevo®); a randomised, double-blind, crossover proof-of-concept study in patients with Parkinson’s disease and end-of-dose wearing-off. - COMPOCParkinson’s disease (PD) patients with end-of-dose wearing-off (motor fluctuations);Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]Product Name: Levodopa 75 mg A CAP
Pharmaceutical Form: Modified-release capsule, hard
INN or Proposed INN: levodopa
CAS Number: 59-92-7
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 75-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Levodopa 100 mg A CAP
Pharmaceutical Form: Modified-release capsule, hard
INN or Proposed INN: levodopa
CAS Number: 59-92-7
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Levodopa 125 mg A CAP
Pharmaceutical Form: Modified-release capsule, hard
INN or Proposed INN: levodopa
CAS Number: 59-92-7
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 125-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Levodopa 150 mg A CAP
Pharmaceutical Form: Modified-release capsule, hard
INN or Proposed INN: levodopa
CAS Number: 59-92-7
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Carbidopa 65 mg capsule
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Carbidopa
CAS Number: 38821-49-7
Other descriptive name: CARBIDOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 65-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: ODM-104
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: na
Other descriptive name: ODM-104
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-		Orion CorporationNot RecruitingFemale: yes
Male: yes		80Phase 2Hungary;Finland;Latvia;Germany
332NCT02764125April 8, 201611 June 2018Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC)Efficacy and Safety of ODM-104 Compared to a Standard Combination (Stalevo®); a Randomized Double-blind, Crossover Proof-of-concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-offParkinson's DiseaseDrug: Stalevo;Drug: levodopa MROrion Corporation, Orion PharmaNot recruiting30 YearsN/AAll84Phase 2Finland;Germany;Hungary;Latvia
333NCT03034538April 8, 201616 December 2017An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's DiseaseAn Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's DiseaseParkinson Disease;Parkinsonism;DyskinesiasDrug: ZonegranThe Cooper Health SystemRecruiting18 YearsN/AAll20Phase 4United States
334EUCTR2015-005067-17-CZ01/04/201611 April 2016A study of the safety and effectiveness of levodopa inhalation powder (CVT-301) in Parkinson’s Disease Patients with OFF episodesA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients With Motor Response Fluctuations (OFF Phenomena) (SPAN-PD™)Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena)
MedDRA version: 18.1 Level: LLT Classification code 10034007 Term: Parkinson's disease NOS System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: CVT-301
Product Code: CVT-301 35mg
Pharmaceutical Form: Inhalation powder, hard capsule
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Current Sponsor code: CVT-301
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 35-
Pharmaceutical form of the placebo: Inhalation powder, hard capsule
Route of administration of the placebo: Inhalation use
Product Name: CVT-301
Product Code: CVT-301 50mg
Pharmaceutical Form: Inhalation powder, hard capsule
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Current Sponsor code: CVT-301
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Inhalation powder, hard capsule
Route of administration of the placebo: Inhalation use		Civitas Therapeutics, Inc.AuthorisedFemale: yes
Male: yes		345Phase 3United States;Czech Republic;Canada;Poland;Spain
335NCT02719496April 201611 June 2018Prove of Concept Study, to Evaluate the Efficacy, Safety, and Tolerability of IBEROGAST in the Treatment of Bowel Troubles in Patients With Parkinson's DiseaseProve of Concept Study, to Evaluate the Efficacy, Safety, and Tolerability of IBEROGAST in the Treatment of Bowel Troubles in Patients With Parkinson's DiseaseGastrointestinal Disorders in Parkinson's DiseaseDrug: IBEROGASTNantes University HospitalNot recruiting30 Years80 YearsAll45Phase 2France
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
336NCT02729714April 201622 July 2019A Pilot Study of Suvorexant for Insomnia in Parkinson DiseaseA Randomized, Double-Blind, Placebo-Controlled Pilot Study of Suvorexant for Insomnia in Parkinson DiseaseInsomniaDrug: Suvorexant;Drug: PlaceboBurdick, Daniel, M.D.Merck Sharp & Dohme Corp.Recruiting30 Years80 YearsAll20Phase 4United States
337NCT02775591April 20168 April 2019Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal SymptomsEffect of Short-term Motilitone Therapy on Health-related Quality of Life in Parkinson's Disease Patients With Gastrointestinal Symptoms: a Multicenter, Double-blind Randomized, Placebo-controlled TrialParkinson Disease;DyspepsiaDrug: DA-9701;Drug: DA-9701 placeboSeoul National University HospitalSamsung Medical Center;Korea University Guro Hospital;Hanyang University;Seoul Veterans Hospital;SMG-SNU Boramae Medical CenterNot recruiting50 Years80 YearsAll147Phase 4Korea, Republic of
338NCT03173781April 20162 July 2018Effects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's DiseaseEffects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's DiseaseParkinson's DiseaseDrug: Placebo;Drug: droxidopaColorado Springs Neurological AssociatesH. Lundbeck A/SNot recruiting18 YearsN/AAll21N/AUnited States
339EUCTR2015-004344-19-GB31/03/20168 May 2017An international trial of deferiprone in patients with Parkinson’s diseaseA Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients with Parkinson’s Disease - LA48-0215Parkinson’s disease
MedDRA version: 19.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Deferiprone 600 mg delayed release tablet
Pharmaceutical Form: Modified-release tablet
INN or Proposed INN: DEFERIPRONE
CAS Number: 30652-11-0
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 600-
Pharmaceutical form of the placebo: Modified-release tablet
Route of administration of the placebo: Oral use		ApoPharma Inc.AuthorisedFemale: yes
Male: yes		140Phase 2France;Canada;Germany;United Kingdom
340JPRN-jRCTs06118006022/03/201610 September 2019Randomized clinical trial to assess the disease modifying effect of oral inosine for patients with Parkinson's diseaseMulti-centered, placebo-controlled, double-blind, randomized clinical trial to assess the effect of oral inosine on the onset of wearing off in patients with early stage Parkinson's disease - Multi-centered, placebo-controlled, double-blind, randomized clinical trial to assess the effect of oral inosine on the onset of wearing off in patients with early stage Parkinson's diseaseParkinson's disease;D010300Inosine to maintain a serum urate level between 6.0-7.5 mg/dL for 2 years or placebo (500mg/CP)Masahiro NagaiRecruiting20 years oldNoneBoth100Phase 2none
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
341EUCTR2015-004129-15-ES07/03/201618 April 2017Subjects participating in a Parkinson Disease cohort are offered to undergo a PET imaging scan requiring an intravenous diagnostic drug (florbetaben) with the aim of identifying markers of disease progressionEvaluation of [18F] florbetaben in subjects participating in the Parkinson?s Progression Markers Initiative (PPMI) ProtocolParkinson's Disease
MedDRA version: 18.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Neuraceq
Product Name: 18F florbetaben
Pharmaceutical Form: Solution for injection
INN or Proposed INN: FLORBETABEN (18F)
CAS Number: 902143-01-5
Concentration unit: MBq megabecquerel(s)
Concentration type: equal
Concentration number: 300-		Institute for Neurodegenerative DisordersNot RecruitingFemale: yes
Male: yes		Phase 2Spain
342NCT02687542March 3, 20165 March 2018Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor FluctuationsA 15-week, Phase 2, Double Blind, Randomized, Placebo-controlled, Dose Ranging Study To Investigate The Efficacy, Safety And Tolerability Of Pf-06649751 In Subjects With Motor Fluctuations Due To Parkinson's DiseaseParkinson DiseaseDrug: Placebo;Drug: PF-06649751 low dose (1 mg QD);Drug: PF-06649751 middle dose 1 (3 mg QD);Drug: PF-06649751 middle dose 2 (7 mg QD);Drug: PF-06649751 high dose (15 mg QD)PfizerNot recruiting40 Years85 YearsAll108Phase 2United States;Canada;France;Germany;Japan;Spain
343JPRN-UMIN0000212362016/03/012 April 2019Investigation in effect of aroma therapy using magnetoencepharographyNormal volunteer, Epilepsy patients, Parkinson disease patientsaroma 1
Trans-nasal administration of lavender essence
Subject hold a cup with 0.05ml essence in front of the nose for 2 minutes
After the administration, MEG signals will be recorded for 4 minutes
Also, the subjects were evaluated their moods and awareness.
aroma 2
Trans-nasal administration of grapefruit essence
Subject hold a cup with 0.05ml essence in front of the nose for 2 minutes
After the administration, MEG signals will be recorded for 4 minutes
Also, the subjects were evaluated their moods and awareness.
fragrant
Trans-nasal administration of fragrant
Subject hold a cup with 0.05ml essence in front of the nose for 2 minutes
After the administration, MEG signals will be recorded for 4 minutes
Also, the subjects were evaluated their moods and awareness.		Osaka University Graduate School of Medicine Department of NeurosurgeryNot Recruiting20years-old80years-oldMale and Female10Phase 1Japan
344NCT02994719March 1, 201618 December 2018Gait Analysis in Neurological DiseaseGait Pattern Analysis in Neurological DiseaseParkinson's Disease;Parkinsonian Disorders;Atypical Parkinson Disease;Progressive Supranuclear Palsy;Multiple System Atrophy;Corticobasal Degeneration;Gait, FrontalDrug: Anti-Parkinson medication;Device: Deep Brain StimulationBeth Israel Deaconess Medical CenterRecruiting18 Years85 YearsAll110N/AUnited States
345NCT02462603March 201629 July 2019Safety and Biomarker Study of EPI-589 in Parkinson's DiseaseA Phase 2A Safety and Biomarker Study of EPI-589 in Mitochondrial Subtype and Idiopathic Parkinson's Disease SubjectsParkinson's DiseaseDrug: EPI-589Edison Pharmaceuticals IncNot recruiting21 Years75 YearsAll44Phase 2United States;Germany;United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
346NCT02605434March 201626 August 2019A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's PatientsPhase 3 Multicenter Randomized Double-Blind, Double-dummy, Active-Controlled Study Comparing Efficacy/Safety of Gastric-retentive, Controlled-release Accordion Pill Carbidopa/Levodopa to Immediate Release in Fluctuating Parkinson's PatientsParkinson's DiseaseDrug: Accordion Pill™ Carbidopa/Levodopa;Drug: Sinemet®;Drug: Placebo -AP-CD/LD;Drug: Placebo- SinemetIntec Pharma Ltd.Not recruiting30 YearsN/AAll420Phase 3United States;Bulgaria;Germany;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;Hungary
347NCT02668497March 20166 May 2019Kinematic-based BoNT-A Bilateral Upper Limb PD TherapyKinematic Characterization of Upper Limb Parkinson's Disease Tremor for Optimized Botulinum Toxin Type A TherapyParkinson's DiseaseDrug: Botulinum Toxin Type AWestern University, CanadaNot recruiting18 Years80 YearsAll50Phase 2Canada
348NCT02708186March 20165 November 2018Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)A Phase 2, Double-blind, Randomized, Placebo-controlled Study of Nelotanserin Versus Placebo in Subjects With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) Who Have REM Sleep Behavior Disorder (RBD)Dementia With Lewy Bodies;REM Sleep Behavior Disorder;Parkinson's Disease DementiaDrug: Nelotanserin;Drug: PlaceboAxovant Sciences Ltd.Not recruiting50 YearsN/AAll29Phase 2United States
349NCT02618941February 2, 201616 December 2017Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity (AFF008AA)Phase IB Follow-up, Controlled, Parallel Group, Single-center Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety/Tolerability, Immunological and Clinical Activity in Patients Who Have Participated in the AFF008 ProgramParkinson's DiseaseBiological: AFFITOPE® PD01AAffiris AGNot recruiting40 Years68 YearsAll26Phase 1Austria
350JPRN-UMIN0000202882016/02/012 April 2019Intervention Study of Istradefylline for the Treatment of Gait Disorders in Patients with Parkinson's Disease.Parkinson's diseaseIn this research, the duration of evaluation will be 12 weeks.
Treatment with istradefylline will be started at a dose of 20 mg administered once daily. The dose of istradefylline will be increased to 40 mg once daily if the patient has no tolerability issues and still has motor symptoms at Week 4. After the Week 4, the dose will be allowed to be reduced to 20 mg once daily, if the patient exhibits any tolerability issues such as the occurrence of adverse drug reactions caused by istradefylline.		Juntendo University Shizuoka HospitalNot Recruiting20years-oldNot applicableMale and Female30Not selectedJapan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
351JPRN-UMIN0000205272016/02/012 April 2019Multi-centered, placebo-controlled, double-blind, randomized clinical trial to assess the effect of oral inosine on the onset of wearing off in patients with early stage Parkinson's diseaseParkinson's diseaseInosine to maintain a serum urate level between 6.0-7.5 mg/dL for 2 years
Lactose as a placebo for 2 years		Ehime University Graduate School of MedicineRecruiting20years-oldNot applicableMale and Female100Phase 2Japan
352NCT02524405February 201630 September 2019BEAM: Brain-Eye Amyloid Memory StudyThe Brain Eye Amyloid Memory (BEAM) Study: Validation of Ocular Measures as Potential Biomarkers for Early Detection of Brain Amyloid and NeurodegenerationAlzheimer's Disease;Mild Cognitive Impairment;Vascular Cognitive Impairment;Parkinson's Disease;Lewy Body DiseaseOther: Pittsburgh Compound B [11C]-PIBSunnybrook Health Sciences CentreBrain Canada;Weston Brain Institute;GE Healthcare;University Health Network, Toronto;Centre for Addiction and Mental Health;Baycrest;St. Michael's Hospital, Toronto;Kensington Eye InstituteRecruiting50 Years90 YearsAll345N/ACanada
353NCT02641054February 201616 December 2017Efficacy Phase IIa Study of CVXL-0107 in Advanced Parkinson's DiseaseDouble-Blind Randomized Placebo-Controlled Cross-Over Phase IIa Trial to Evaluate Efficacy of CVXL-0107 on Parkinson-Related Symptoms and Levodopa-Induced Dyskinesia in Advanced Parkinson's Disease Patients Using a Levodopa Challenge TestIdiopathic Parkinson DiseaseDrug: CVXL-0107;Drug: Placebo;Drug: LevodopaCleveXel PharmaNot recruiting40 Years75 YearsAll21Phase 2France
354NCT02655315February 201619 November 2018Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's DiseaseConservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease. European Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of DeferiproneParkinson DiseaseDrug: Deferiprone;Drug: PlaceboUniversity Hospital, LilleEuropean Commission;ApoPharmaRecruitingN/A80 YearsAll338Phase 2Austria;Czechia;France;Germany;Netherlands;Portugal;Spain;United Kingdom;Czech Republic
355NCT02680977February 201617 October 2016Mucuna Pruriens Therapy in Parkinson's DiseaseMucuna Pruriens Therapy in Parkinson's Disease: a Double-blind, Placebo-controlled, Randomized, Crossover Study.Parkinson's DiseaseOther: MP-Equivalent;Other: MP-Low;Other: MP+DDCI;Drug: LD+DDCI;Drug: LD-DDCI;Other: PlaceboASST Gaetano Pini-CTOFondazione Grigioni per il Morbo di Parkinson;Fondazione Grigioni per il Morbo di ParkinsonNot recruiting21 YearsN/ABoth18Phase 2Bolivia
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
356NCT02683629February 201627 May 2019Investigation of the Safety and Efficacy of NTCELL® [Immunoprotected (Alginate-Encapsulated) Porcine Choroid Plexus Cells for Xenotransplantation] in Patients With Parkinson's DiseaseA Phase IIb, Randomised, Double-blind, Placebo-controlled, Dose-range Investigation of the Safety and Efficacy of NTCELL® [Immunoprotected (Alginate-Encapsulated) Porcine Choroid Plexus Cells for Xenotransplantation] in Patients With Parkinson's DiseaseParkinson's DiseaseBiological: NTCELL Implantation;Other: Sham SurgeryLiving Cell TechnologiesStatistecol Consultants LimitedNot recruiting40 Years65 YearsAll18Phase 2New Zealand
357EUCTR2015-004238-85-ES27/01/201622 January 2018Brain SPECT in premotor stage of Parkinson diseaseIctal brain SPECT in the premotor stage of Parkinson diseaseParkinson disease
MedDRA version: 18.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: CERETEC (TM) Estabilizado
Product Name: Ceretec
Pharmaceutical Form: Powder for solution for injection
INN or Proposed INN: Ceretec
CAS Number: 100504-35-6
Other descriptive name: TECHNETIUM (99MTC) EXAMETAZIME
Concentration unit: mCi millicurie(s)
Concentration type: equal
Concentration number: 25-		IDIBAPSNot RecruitingFemale: yes
Male: yes		30Phase 2Spain
358JPRN-JapicCTI-15311222/1/201616 July 2019ONO-2370 Phase 2 studyONO-2370 a Phase 2 Double-Blind, Randomised, Placebo-Controlled, Parallel-Group study, and an Open-Label, Uncontrolled, Multicenter, Long-term, Extension studyParkinson's diseaseIntervention name : ONO-2370
INN of the intervention : Opicapone
Dosage And administration of the intervention : ONO-2370 once-daily
Control intervention name : Placebo
INN of the control intervention : -
Dosage And administration of the control intervention : Once-daily placebo equivalent to active control		ONO PHARMACEUTICAL CO.,LTD.Not Recruiting3083BOTH399Phase 2Japan
359NCT03258294January 13, 201616 December 2017Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's DiseaseEffect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease: Double Blind, Randomized, Placebo Controlled TrialParkinson's DiseaseDrug: Melatonin(Circadin®);Drug: Placebo Oral TabletKIMJisunKuhnil Pharmaceutical Co., Ltd.Recruiting55 YearsN/AAll82Phase 4
360ChiCTR-CPC-150072232016-01-0118 April 2017Characteristics andAffecting Factors Amalysis of Sleep Disorder in Parkinsons DiseaseCharacteristics andAffecting Factors Amalysis of Sleep Disorder in Parkinsons DiseaseParkinsons Disease; Sleep DisorderThe treatment group; The control group:Rotigotine patch;Department of Neurology, Changzheng Hospital, Second Military Medical UniversityNot RecruitingBothThe treatment group; The control group:100;Post-marketChina
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
361NCT02549573January 201616 December 2017Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®Outpatient Physical Therapy Intervention in Subjects With Parkinson's DiseaseCurrently Using APOKYN®: A Phase IV Study of Outcome Assessments of Physical Therapy in Subjects in an On Versus End-of-Dose-Off Motor StateParkinson's Disease;Motor SymptomsDrug: APOKYN;Behavioral: Physical TherapyUS WorldMeds LLCNot recruiting18 Years78 YearsAll13Phase 4United States
362NCT02579473January 201630 September 2019A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214A Multi-center, Open-label, Multiple Ascending Dosage-ranging Cohort (MAD) Study in Early, Untreated or Stably Treated Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetics (PK) of Injections of SER-214 Administered Subcutaneously Once a Week for Two Weeks After 0-2 Weeks of Dose TitrationParkinson's DiseaseDrug: SER-214Serina TherapeuticsNot recruiting40 Years80 YearsAll20Phase 1United States
363NCT02589340January 201615 April 2019Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced DyskinesiaBuspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced DyskinesiaParkinson's Disease;Dyskinesias;Movement DisordersDrug: Buspirone;Drug: PlaceboOregon Health and Science UniversityPortland VA Medical CenterRecruiting18 Years99 YearsAll15Phase 1United States
364NCT02639221January 201610 October 2016A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female SubjectsPXT002331 A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female SubjectsParkinson's DiseaseDrug: PXT002331Prexton TherapeuticsNot recruiting18 Years60 YearsBoth64Phase 1United Kingdom
365NCT02649608January 201611 June 2018An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease PatientsInterventional, Open-label, Exploratory Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AE04621 and the Active Metabolite Lu AA40326 After Ascending Oral Doses of Lu AE04621 to Patients With Parkinson's DiseaseParkinson DiseaseDrug: Lu AE04621H. Lundbeck A/SNot recruiting45 Years75 YearsAll15Phase 1United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
366NCT02768077January 201630 May 2016Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's DiseaseEffect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease: Double Blind, Randomized, Placebo Controlled TrialParkinson's DiseaseDrug: Melatonin(Circadin®);Drug: PlaceboKuhnil Pharmaceutical Co., Ltd.Recruiting55 YearsN/ABoth100Phase 4
367EUCTR2014-002600-24-SE03/12/201520 February 2017Safinamide versus placebo in patients with Parkinson’s disease for improvement of motor complicationsA TWO YEAR, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF SAFINAMIDE 100 MG, ONCE DAILY, AS ADD ON THERAPY, IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS - EVERESTIdiopathic Parkinson's Disease
MedDRA version: 18.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Xadago
Product Name: safinamide
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: SAFINAMIDE
CAS Number: 133865-89-1
Other descriptive name: SAFINAMIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Trade Name: Xadago
Product Name: safinamide
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: SAFINAMIDE
CAS Number: 133865-89-1
Other descriptive name: SAFINAMIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-		Zambon S.P.A.Not RecruitingFemale: yes
Male: yes		556Phase 3France;Spain;Austria;Russian Federation;Germany;Italy;United Kingdom;Switzerland;Sweden
368NCT02470780December 201516 December 2017Treating Bacterial Overgrowth in Parkinson's DiseaseTreating Bacterial Overgrowth in Parkinson's DiseaseParkinson's Disease;Small Intestinal Bacterial OvergrowthDrug: Rifaximin;Drug: PlaceboUniversity of CincinnatiNot recruiting18 YearsN/AAll24Phase 2/Phase 3United States
369NCT02610231December 20151 April 2019Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's DiseaseA Phase 3, Long-term, Open-label Study of Istradefylline in Subjects With Moderate to Severe Parkinson's DiseaseIdiopathic Parkinson's DiseaseDrug: Istradefylline 20 mg or 40 mgKyowa Hakko Kirin Pharma, Inc.Kyowa Hakko Kirin Co., LtdNot recruiting30 YearsN/AAll243Phase 3United States;Canada;Czechia;Germany;Israel;Italy;Poland;Serbia;Czech Republic
370NCT02702102December 201522 October 2019Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy BodiesImaging Inflammation in Patients With Diffuse Lewy Body DiseaseDiffuse Lewy Body Disease;Dementia With Lewy Bodies;Parkinson's Disease DementiaDrug: 11C-PBR28William Charles KreislNational Institute on Aging (NIA)Not recruiting60 YearsN/AAll5Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
371EUCTR2015-002631-17-ES19/11/201528 February 2019A study comparing immediate-release oral Levodopa and L-dopa/carbidopa intestinal gel over cognition and mood in non-demented Parkinson?s disease (PD) patientsAn intra-subject, randomized, double blind, crossover study comparing immediate-release oral LD (IR-LD) and L-dopa/carbidopa intestinal gel (LCIG) over cognition and mood in non-demented advanced Parkinson?s disease (PD) patientsParkinson disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Duodopa
Product Name: Duodopa
Pharmaceutical Form: Intestinal gel
Trade Name: Sinemet Plus
Product Name: Sinemet Plus
Pharmaceutical Form: Tablet		Institut de Recerca del Hospital de la Santa Creu i Sant PauNot Recruiting Female: yes
Male: yes		18Phase 4Spain
372NCT02565628November 16, 201516 December 2017PF-06669571 In Subjects With Idiopathic Parkinson's DiseaseA Phase 1b, Double Blind, Sponsor Open, Randomized, Parallel, Group Multiple Dose Study Examining The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06669571 In Subjects With Idiopathic Parkinson's Disease.Idiopathic Parkinson's DiseaseDrug: PF-06669571;Drug: PlaceboPfizerNot recruitingN/AN/AAll20Phase 1United States
373JPRN-UMIN0000196762015/11/1023 April 2019The double blind, placebo controlled trial of modafinil for excessive daytime sleepiness in Parkinson's diseaseThe double blind, placebo controlled trial of modafinil for excessive daytime sleepiness in Parkinson's disease - The double blind, placebo controlled trial of modafinil for excessive daytime sleepiness in Parkinson's diseaseParkinson's diseasetaking modafinil (200 mg/day) after breakfast for 4 weeks, wash out for 2 weeks, taking matching placebo after breakfast for 4 weeks
taking matching placebo after breakfast for 4 weeks, wash out for 2 weeks, taking modafinil (200 mg/day) after breakfast for 4 weeks		Department of Neurology and Clinical Pharmacology, Ehime University Graduate School of MedicineNot Recruiting20years-old100years-oldMale and Female20Not selectedJapan
374EUCTR2015-000148-40-GB09/11/201518 April 2016A trial comparing simvastatin to placebo as a neuronal protective treatment for Parkinson's disease.Simvastatin as a neuroprotective treatment for Parkinson's disease: a double-blind, randomised, placebo controlled futility study in patients of moderate severity. - Simvastatin as a neuroprotective treatment for moderate PD (PD STAT)Parkinson's disease
MedDRA version: 18.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 18.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Simvastatin
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Simvastatin
CAS Number: 79902-63-9
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 40-
Pharmaceutical form of the placebo: Capsule, soft
Route of administration of the placebo: Oral use		Plymouth Hospitals NHS TrustAuthorisedFemale: yes
Male: yes		198United Kingdom
375JPRN-UMIN0000196542015/11/062 April 2019The effect of rich-hydrogen water drinking to gut peptideParkinson's disease, healthy controlhydrogen water
natural water		Nagoya graduate school of medicine universityNot Recruiting20years-old80years-oldMale and Female40Not applicableJapan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
376JPRN-UMIN0000190902015/11/042 April 2019Reduced form of CoenzymeQ10 for Parkinson's disease - open trial of dose finding test and combination with hydrogen waterParkinson's diseasereduced form of CoQ10 300mg 16weeks
reduced form of CoQ10 600mg 16weeks
reduced form of CoQ10 600mg 16weeks
hydrogen water 500ml(Suisosui 7.0) 16weeks		Juntendo University Koshigaya HospitalNot Recruiting20years-old80years-oldMale and Female45Not selectedJapan
377JPRN-jRCTs04118007004/11/201510 September 2019Trerief Impact in PD PET StudyRandomized, multicenter, open-label, comparative study on neuroprotective effects of zonisamide (Trerief), anti-parkinsonian drug, in patients with early Parkinson's disease: Evaluation by functional PET (positron emission tomography) images - TIPPSParkinson's disease
Parkinson's disease;D010300		[1] Zonisamide treatment group
Zonisamide (25 mg) once daily in addition to levodopa/DCI with fixed dosage and administration.
Note that after one-year fixed protocol period, the followings are allowed; 1) one or two tablets per day in case of developing wearing off phenomenon, 2) change of dose and/or administration of levodopa/DCI, and 3) addition of other anti-parkinsonian drugs due to exacerbation of symptoms.
[2] Zonisamide non-treatment group
Only levodopa/DCI with fixed dosage and administration.
Note that after one-year fixed protocol period, the followings are allowed; 1) change of dose and/or administration of levodopa/DCI and 2) addition of other anti-parkinsonian drugs except for zonisamide due to exacerbation of symptoms.		Yasuomi OuchiNot RecruitingnoneUnder 80 years oldBoth20N/Anone
378JPRN-JapicCTI-15305601/11/20152 April 2019ME2125 Phase II/III (ME2125-3)A Phase II/III, Double-Blind, Placebo-Controlled Study of ME2125 in Patients with Parkinson's Disease with Wearing-Off PhenomenonParkinson's diseaseIntervention name : ME2125
INN of the intervention : safinamide
Dosage And administration of the intervention : Orally administer a dose of 2 tablets once a daily in morning.
Control intervention name : Placebo
Dosage And administration of the control intervention : Orally administer a dose of 2 tablets once a daily in morning.		Meiji Seika Pharma Co., Ltd.30BOTH410Phase 2-3
379JPRN-JapicCTI-15305701/11/20152 April 2019ME2125 Phase III (ME2125-4)A Phase III, Long-Term Treatment Study of ME2125 in Patients with Parkinson's Disease with Wearing-Off PhenomenonParkinson's diseaseIntervention name : ME2125
INN of the intervention : safinamide
Dosage And administration of the intervention : Orally administer a dose of 2 tablets once a daily in morning.
Control intervention name : Placebo
Dosage And administration of the control intervention : Orally administer a dose of 2 tablets once a daily in morning.		Meiji Seika Pharma Co., Ltd.30BOTH200Phase 3
380NCT04110678November 1, 201514 October 2019Tolerance to NeuroEPO in Parkinson DiseaseNasal Administration of the NeuroEPO in Parkinson Disease: Short-term Tolerance Physician Lead TrialParkinson DiseaseDrug: NeuroEPOInternational Center for Neurological Restoration, CubaCenter of Molecular Immunology, Cuba;University of Electronic Science and Technology of ChinaNot recruiting40 Years70 YearsAll26Phase 1/Phase 2Cuba
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
381NCT02271503November 201516 December 2017A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's DiseaseA Study to Assess the Pharmacokinetics and Pharmacodynamics of a Single Dose of IPX203 in Patients With Advanced Parkinson's DiseaseParkinson's DiseaseDrug: CD-LD IR;Drug: IPX203 180 mg;Drug: IPX203 270 mg;Drug: Rytary 195 mg;Drug: Rytary 145 mgIMPAX Laboratories, Inc.Not recruiting40 YearsN/AAll26Phase 2United States
382NCT02577523November 201523 April 2019A Clinical Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of ND0612H, a Solution of Levodopa/Carbidopa Administered as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's DiseaseA Multicenter, Parallel-group, Rater-blinded, Randomized Clinical Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of 2 Dosing Regimens of ND0612H, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's DiseaseParkinson's DiseaseDrug: ND0612 (Levodopa/Carbidopa solution)NeuroDerm Ltd.Not recruiting30 Years80 YearsAll38Phase 2United States;Austria;Israel;Italy
383NCT02632279November 20153 September 2018Tryptophan Depletion in PD Patients Treated With STN DBSTryptophan Depletion in Parkinson's Disease Patients Treated With Deep Brain Stimulation of the Subthalamic Nucleus: Effects on Mood and Motor FunctionsParkinson's DiseaseDietary Supplement: Tryptophan (TRP) depletion;Dietary Supplement: Placebo;Device: Stimulator ON;Device: Stimulator OFFMaastricht University Medical CenterNetherlands Brain FoundationNot recruitingN/AN/AAll7N/ANetherlands
384NCT02758730November 201515 August 2016Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA PatientsA Randomized, Placebo-controlled, Parallel Group, Patient-blind, Single-center Phase I Pilot Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A, a New Vaccine Against Alpha-synuclein, in Patients With PD-GBAParkinson's DiseaseBiological: AFFITOPE® PD01A + Adjuvant;Biological: Adjuvant without active componentAffiris AGUniversity Hospital TuebingenNot recruiting40 Years80 YearsBoth0Phase 1Germany
385NCT02914366November 20151 April 2019Ambroxol as a Treatment for Parkinson's Disease DementiaAmbroxol as a Novel Disease Modifying Treatment for Parkinson's Disease DementiaParkinson's Disease DementiaDrug: Ambroxol;Other: PlaceboLawson Health Research InstituteWeston Brain Institute;University of Western Ontario, Canada;London Health Sciences CentreRecruiting50 YearsN/AAll75Phase 2Canada
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
386EUCTR2015-003045-26-SE23/10/201516 November 2015Study of Dopamine Transporters (signal substance in central nervous system)in patients with early signs of Parkinson´s disease.[18F] FE-PE2I PET/CT study of Dopamine Transporters in Early Parkinsonian disease.Patients with newly clinically diagnosed untreated idiopathic parkinsonism
MedDRA version: 18.0 Level: HLT Classification code 10034005 Term: Parkinson's disease and parkinsonism System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: [18F]FE-PE2I
Pharmaceutical Form: Solution for injection
INN or Proposed INN: [18F]-(E)-N-(3-iodoprop-2-enyl)-2b-carbofluoroethoxy-3b-(4'-methylphenyl)nortropane
Current Sponsor code: [18F]-(E)-N-(3-iodoprop-2-enyl)-2b-carbofluoroethoxy-3b-(4'-methylphenyl)nortropane
Concentration unit: MBq/kg megabecquerel(s)/kilogram
Concentration type: equal
Concentration number: 2.86-
Trade Name: DaTSCAN
Pharmaceutical Form: Solution for injection
INN or Proposed INN: IOFLUPANE (123I)
CAS Number: 155798-07-5
Concentration unit: MBq megabecquerel(s)
Concentration type: equal
Concentration number: 185-
Product Name: 15O H2O
Pharmaceutical Form: Solution for injection
INN or Proposed INN: [15O]H2O
Current Sponsor code: [15O]H2O
Concentration unit: MBq megabecquerel(s)
Concentration type: equal
Concentration number: 800-		Umeå University HospitalAuthorisedFemale: yes
Male: yes		Sweden
387JPRN-UMIN0000190822015/10/102 April 2019the effect of smell dysfunction using hydrogen gas for parkinson diseaseparkinson's diseasewe measured smell test and urine 8-OHdG before and after 3.5% hydrogen gas. After two month discontinuation of administration. we measured smell test and urine 8-OHdG before and after room air.
we measured smell test and urine 8-OHdG before and after room air. After two month discontinuation of administration. we measured smell test and urine 8-OHdG before and after 3.5% hydrogen gas.		Nagoya University Graduate School of MedicineNot RecruitingNot applicableNot applicableMale and Female20Not selectedJapan
388JPRN-UMIN0000195242015/10/012 April 2019Randomized, multicenter, open-label, comparative study on neuroprotective effects of zonisamide (Trerief), anti-parkinsonian drug, in patients with early Parkinson's disease: Evaluation by functional PET (positron emission tomography) imagesRandomized, multicenter, open-label, comparative study on neuroprotective effects of zonisamide (Trerief), anti-parkinsonian drug, in patients with early Parkinson's disease: Evaluation by functional PET (positron emission tomography) images - Trerief Impact in PD PET Study (TIPPS)Parkinson's DiseaseZonisamide treatment group:

Zonisamide (25 mg) once daily in addition to levodopa/DCI with fixed dosage and administration.
Note that after one-year fixed protocol period, the followings are allowed; 1) one or two tablets per day in case of developing wearing off phenomenon, 2) change of dose and/or administration of levodopa/DCI, and 3) addition of other anti-parkinsonian drugs due to exacerbation of symptoms.
Zonisamide non-treatment group:

Only Levodopa/DCI with fixed dosage and administration.
Note that after one-year fixed protocol period, the followings are allowed; 1) change of dose and/or administration of levodopa/DCI and 2) addition of other anti-parkinsonian drugs except for zonisamide due to exacerbation of symptoms.		Hamamatsu University School of MedicineNot RecruitingNot applicable80years-oldMale and Female20Not applicableJapan
389NCT02572713October 201516 December 2017Systemic Synuclein Sampling Study (S4)Systemic Synuclein Sampling Study (S4)Parkinson's DiseaseProcedure: Biofluid samplings;Procedure: Tissue samplings;Drug: DaTSCAN™Michael J. Fox Foundation for Parkinson's ResearchIndiana University;University of Iowa;Banner Health;Paracelsus Elena KlinikNot recruiting40 YearsN/AAll80N/AUnited States;Canada
390NCT02562768September 30, 201516 December 2017A Study of LY3154207 in Healthy Participants and Participants With Parkinson's DiseaseMultiple-Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of LY3154207 in Healthy Subjects and Subjects With Parkinson's DiseaseParkinson's DiseaseDrug: LY3154207;Drug: PlaceboEli Lilly and CompanyNot recruiting20 YearsN/AAll80Phase 1United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
391NCT02549092September 9, 20157 October 2019A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) THerapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects With Advanced Parkinson's Disease - INSIGHTS StudyAdvanced Parkinson's DiseaseDrug: ABT-SLV187AbbVieRecruiting30 Years99 YearsAll88Phase 3United States;Australia;Canada;Germany;Greece;Italy;Korea, Republic of;Spain;Sweden
392NCT02542696August 31, 201514 October 2019An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's DiseaseAn Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)Parkinson DiseaseDrug: APL-130277SunovionRecruiting18 YearsN/AAll226Phase 3United States;Austria;Canada;France;Germany;Italy;Spain;United Kingdom
393EUCTR2014-004865-26-DE27/08/201521 November 201626-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Subjects with Advanced Parkinson's DiseaseAn Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) Therapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects with Advanced Parkinson's Disease – INSIGHTS Study - INSIGHTS StudyNon-motor symptoms in advanced Parkinson's disease
MedDRA version: 19.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Duodopa
Pharmaceutical Form: Intestinal gel
INN or Proposed INN: Levodopa
CAS Number: 59-92-7
Other descriptive name: LEVODOPA
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 20-
INN or Proposed INN: Carbidopa
CAS Number: 38821-49-7
Other descriptive name: CARBIDOPA MONOHYDRATE
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 5-		AbbVie Deutschland GmbH & Co. KGNot RecruitingFemale: yes
Male: yes		88Phase 3European Union;Canada;Spain;Australia;Germany;Italy;Sweden
394EUCTR2015-000373-13-DE18/08/201519 October 2015A study to examine the effectiveness and safety of a new drug for involuntary muscle movements in patients with Parkinson’s diseasePhase 2, multicenter, randomized, double-blind, placebo-controlled, four-period cross-over, dose-range finding study to evaluate the safety, tolerability and efficacy of Eltoprazine in the treatment of levodopa induced dyskinesia in patients with Parkinson's disease.Parkinson’s disease levodopa induced dyskinesia (PD-LID)
MedDRA version: 18.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Eltoprazine Hydrochloride
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: ELTOPRAZINE
CAS Number: 98224-03-4
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 7.5-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Eltoprazine Hydrochloride
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: ELTOPRAZINE
CAS Number: 98224-03-4
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: Eltoprazine Hydrochloride
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: ELTOPRAZINE
CAS Number: 98224-03-4
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2.5-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use		Amarantus BioScience Holdings, Inc.Not RecruitingFemale: yes
Male: yes		60Phase 2France;United States;Germany;Sweden
395NCT02554734August 201525 January 2016Pharmacokinetic Study in Healthy VolunteersPharmacokinetics of Levodopa After Repeated Doses of Carbidopa, ODM-104 and Levodopa: an Open, Randomised Study With Crossover Design in Healthy Males and FemalesParkinson's DiseaseDrug: levodopa, carbidopa, ODM-104;Drug: levodopa, carbidopa, entacaponeOrion Corporation, Orion PharmaNot recruiting18 Years65 YearsBoth15Phase 1Finland
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
396NCT02599753August 201522 October 2018Investigating the Microstructural and Functional Alterations of Brain in Parkinson's Disease PatientsInvestigating the Microstructural and Functional Alterations of Brain in Parkinson's Disease Patients With Neuropsychiatric Disorders by Multimodal NeuroimagingParkinson's DiseaseDrug: 18-FDTBZChang Gung Memorial HospitalNot recruiting20 Years80 YearsAll35Phase 2Taiwan
397NCT02917122August 201510 October 2016The Therapeutic Effect of Transcranial Direct Current Stimulation on Depression in Parkinson's DiseaseThe Therapeutic Effect of Transcranial Direct Current Stimulation on Depression in Parkinson's DiseaseParkinson Disease;DepressionDevice: active tDCS;Drug: Sertraline;Device: sham tDCSNational Cheng-Kung University HospitalNot recruiting18 Years75 YearsBoth40Phase 1/Phase 2
398NCT02337751July 31, 201516 December 2017A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease ParticipantsA Multicenter, Open-label, Long-term, Extension, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With LevodopaParkinson's DiseaseDrug: TVP-1012 1mgTakedaNot recruiting30 Years79 YearsAll198Phase 3Japan
399NCT02459886July 1, 201526 August 2019Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's DiseaseA Phase 1 Randomized, Double-Blinded, Placebo-Controlled Single-Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB054 in Healthy Subjects and Subjects With Early Parkinson's DiseaseParkinson's Disease;HealthyDrug: BIIB054;Drug: PlaceboBiogenNot recruiting40 Years80 YearsAll66Phase 1United States
400NCT02488265July 1, 201512 November 2018Protocol: Balance Training in Parkinson's DiseaseRandomized Controlled Trial Protocol: Balance Training With Rhythmical Cues to Improve and Maintain Balance Control in Parkinson's DiseaseParkinson DiseaseOther: Balance Training;Other: Screening to prevent fallsUniversity of Sao Paulo General HospitalNot recruiting50 Years70 YearsAll150N/ABrazil
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
401NCT02415062July 201517 August 2015The Efficacy and Safety Study of High Dose Donepezil in Parkinson's Disease With DementiaThe Efficacy of 23mg Versus 10mg of Donepezil in ParkInson's Disease With DementiaParkinson's DiseaseDrug: DonepezilInje UniversityRecruiting50 Years80 YearsBoth150Phase 2Korea, Republic of
402NCT02453386July 20158 April 2019Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's PatientsA Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose Wearing-Off (TOZ-PD)Idiopathic Parkinson's DiseaseDrug: tozadenant;Drug: placeboBiotie Therapies Inc.Not recruiting30 Years80 YearsAll449Phase 3United States;Austria;Canada;Czechia;Germany;Italy;Spain;Czech Republic
403NCT02469090June 30, 20153 December 2018Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's DiseaseRandomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy, Safety and Tolerability of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)Parkinson Disease, Off EpisodesDrug: APL-130277;Drug: PlaceboSunovionNot recruiting18 YearsN/AAll219Phase 3United States;Canada;United Kingdom
404EUCTR2014-000657-36-NL22/06/201510 July 2015Trial to investigate the efficacy of treatments in apomorphine-induced skin reactionsOpen-label crossover trial to investigate the efficacy of treatments in apomorphine-induced skin reactions - Treatment of apomorphine-induced skin reactions: a pilot studyParkinson's disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Hydrocortisone cream 10mg/g FNA Fagron
Product Name: Hydrocortisone cream
Pharmaceutical Form: Cream
Trade Name: Solu-Cortef, powder for solution for injection, 100mg, and 'Act-O-Vial'
Product Name: Solu-Cortef
Pharmaceutical Form: Powder and solvent for solution for injection
Trade Name: APO-go
Product Name: Apomorphine
Pharmaceutical Form: Solution for infusion in pre-filled syringe		University Medical Center GroningenAuthorisedFemale: yes
Male: yes		Netherlands
405NCT02230930June 201516 December 2017Treatment of Apomorphine-induced Skin Reactions: a Pilot StudyOpen-label Crossover Trial to Investigate the Efficacy of Treatments in Apomorphine-induced Skin ReactionsParkinson's Disease;Apomorphine-induced Skin ReactionsDrug: Apomorphine 0.25% (2.5mg/ml);Device: Massage with a spiky ball;Drug: Hydrocortisone cream 1%;Drug: Subcutaneous hydrocortisone 10mgUniversity Medical Center GroningenRecruiting30 YearsN/AAll20Phase 2Netherlands
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
406NCT02450786June 201511 February 2019Effect of Donepezil on Cognition in Parkinson's Disease With Mild Cognitive Impairment (PD-MCI)Parkinson's DiseaseDrug: DonepezilYonsei UniversityNot recruiting40 YearsN/AAll80Phase 2Korea, Republic of
407NCT02604914June 201513 June 2016A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects1) To Identify the Concentration of CD That Provides Optimal Bioavailability of a Concomitant Fixed Concentration of LD Infused SC Continuously; 2) To Compare the Bioavailability of the Optimal LD/CD Solution to That of LD/CD Intestinal GelParkinson's DiseaseDrug: ND0612;Drug: LCIGNeuroDerm Ltd.Quotient ClinicalNot recruiting40 Years65 YearsBoth36Phase 1United Kingdom
408NCT02769793June 201511 June 2018Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in PD Patients With Delayed ONEfficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in Parkinson's Disease Patients With Delayed ON: a Multicenter Randomized Open-label Cross-over TrialParkinson DiseaseDrug: Levodopa dispersible;Drug: LevodopaSeoul National University HospitalSMG-SNU Boramae Medical Center;Samsung Medical CenterRecruiting31 Years80 YearsAll40Phase 4Korea, Republic of
409EUCTR2014-005422-35-GB28/05/201530 April 2019The role of Buspirone in attenuating involuntary movements (Dyskinesias) in patients with Parkinson's disease.THE ROLE OF BUSPIRONE IN ATTENUATING LEVODOPA-INDUCED DYSKINESIAS IN PATIENTS WITH PARKINSON'S DISEASE: A CLINICAL AND POSITRON EMISSION TOMOGRAPHY STUDY WITH 11C-PHNO. - The role of buspirone in LIDs in patients with Parkinson’s disease.Levodopa induced dyskinesias within Parkinson's disease.
MedDRA version: 17.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Buspirone Hydrochloride
Product Name: Buspirone Hydrochloride
Pharmaceutical Form: Tablet
INN or Proposed INN: Buspirone Hydrochloride
Concentration type: equal
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use		Imperial College London-Imperial College Healthcare NHS TrustNot Recruiting Female: yes
Male: yes		24Phase 4United Kingdom
410JPRN-jRCTs06118002811/05/201510 September 2019Pain reduction in PD patients with depression: double blind, randomized clinical trial of duloxetineA double-blind, randomized clinical trial to evaluate the efficacy of Duloxetine against pain associated with Parkinson's disease with depression - Pain reduction in PD patients with depression: double blind, randomized clinical trial of duloxetineParkinson's disease;D010300The treatment groups consist of an active treatment arm (40mg/day Duloxetine) and a placebo arm. During the Titration Period (2 weeks), all subjects will be started on 1 capsule (10mg or placebo). During the Maintenance Period (10 weeks), subjects will take 2 capsules. Subjects who are unable to increase their dose can stay at 1 capsule.Rina AndoRecruiting20 years oldNoneBoth50Phase 2none
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
411EUCTR2010-024424-26-SK05/05/201512 November 2018Clinical study for the evaluation of the safety and efficacy of masitinib in patients suffering from parkinson's diseaseA prospective, multicenter, randomised, double-blind, placebo-controlled, parallel group, phase 2 study to compare the efficacy and safety of masitinib versus placebo on cognitive impairment associated with Parkinson's diseaseParkinson's disease
MedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: masitinib
Product Code: AB1010
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: masitinib mesylate
CAS Number: 790-299-79-5
Current Sponsor code: AB1010
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Product Name: masitinib
Product Code: AB1010
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: masitinib mesylate
CAS Number: 790-299-79-5
Current Sponsor code: AB1010
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use		AB ScienceNot RecruitingFemale: yes
Male: yes		45Phase 2France;United States;Hungary;Czech Republic;Slovakia;Spain;Romania;Bulgaria;South Africa;Germany
412NCT02439125May 20152 May 2016A Study of Efficacy and Safety of Eltoprazine HCl for Treating Levodopa-induced Dyskinesia in Parkinson's Disease PatientsPhase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, 4-way Crossover, Dose-finding Study, of Eltoprazine Safety, Tolerability and Efficacy in the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson's DiseaseParkinson's Disease;DyskinesiaDrug: Eltoprazine HCl;Drug: PlaceboAmarantus BioScience Holdings, Inc.Not recruiting30 Years85 YearsBoth60Phase 2United States
413NCT02439203May 201525 January 2016Efficacy and Safety of JM-010 in PD With Levodopa-Induced DyskinesiaA Randomized, Double-blind, Placebo-controlled, 2-way Crossover Study in Subjects With Parkinson's Disease With Moderate to Severe Levodopa-induced Dyskinesia, to Assess the Efficacy, Safety/Tolerability and Pharmacokinetics of JM-010Parkinson's Disease;Levodopa Induced Dyskinesia (LID)Drug: JM-010;Drug: PlaceboBukwang PharmaceuticalContera Pharma ApSNot recruiting18 YearsN/ABoth30Phase 2South Africa
414NCT02448914May 201519 October 2017A Study to Compare Plasma Levels of Levodopa, Carbidopa and Entacapone After TRIGEL or Duodopa Infusion in PD PatientsA Single Centre, Two-period, Open Label, Randomised, Cross-over Study to Assess Plasma Levodopa, Carbidopa and Entacapone Concentrations After Continuous Infusion of TRIGEL or Duodopa in Patients With Advanced Parkinson´s DiseaseParkinson's DiseaseDrug: TRIGEL;Drug: DuodopaLobSor Pharmaceuticals ABTFS Trial Form SupportNot recruiting30 YearsN/AAll11Phase 1Sweden
415NCT02452125May 201516 December 2017The Effects of Nicotine Chewing Gum in Parkinson's DiseaseThe Effects of Nicotine Chewing Gum on Acute Low Blood Pressure in Parkinson's DiseaseLow Blood Pressure;Parkinsons DiseaseDietary Supplement: Nicotine gumNew York Institute of TechnologyNot recruitingN/AN/AAll10N/AUnited States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
416NCT02616120May 20155 November 2018Effect of SQJZ Herbal Mixtures on Non-motor Symptoms of Parkinson's DiseaseEfficacy and Safety of SQJZ Herbal Mixtures on Non-motor Symptoms in Parkinson's Disease PatientsParkinson's DiseaseDrug: SQJZ herbal mixtures;Drug: PlaceboDongzhimen Hospital, BeijingRecruiting18 Years80 YearsAll240Phase 2China
417JPRN-JapicCTI-15287011/4/201523 April 2019A parallel group comparison study of HP-3000 in patients with Parkinson's disease using L-DOPAA phase III parallel group comparison study of HP-3000 in patients with Parkinson's disease using L-DOPAParkinson's diseaseIntervention name : HP-3000 (ropinirole hydrochloride patch)
Dosage And administration of the intervention : Transdermal, once daily
Control intervention name : HP-3000 placebo
Dosage And administration of the control intervention : Transdermal, once daily
Control intervention name : Ropinirole hydrochloride extended-release tablet
Dosage And administration of the control intervention : Oral, once daily
Control intervention name : Ropinirole hydrochloride extended-release tablet placebo
Dosage And administration of the control intervention : Oral, once daily		Hisamitsu Pharmaceutical Co.,Inc.2079BOTHPhase 3
418JPRN-UMIN0000170362015/04/032 April 2019Association of ghrelin and leptin in cardiovascular autonomic dysfunction in patients with primary dysautonomia.autonomic failure such as Parkinson's diseaseblood test of Leptin and Ghrelin
blood test of Leptin and Ghrelin		Nagoya University Graduate School of MedicineNot Recruiting40years-oldNot applicableMale and Female50Not applicableJapan
419JPRN-UMIN0000165912015/04/012 April 2019Clinical trial of balance exercise "Assist"Stroke, Parkinson disease, Osteoarthrosisuse of balance exercise assist
ordinary balance exercise		Juntendo UniversityNot Recruiting20years-old75years-oldMale and Female40Not applicableJapan
420JPRN-UMIN0000167342015/04/012 April 2019The evaluation of duloxetine effect for the parkinsonism and gait freezingParkinson's diseaseDrug ; Duloxetine
Duraion; SEP012014-AUG312016
Doseage; 20mg/day or 40mg/day
Times; one time per day P.O.		Department of Neurology, Juntendo University School of MedicineNot Recruiting20years-old85years-oldMale and Female30Not selectedJapan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
421NCT02359448April 201519 February 2015Melatonin for Nocturia in Parkinson's DiseaseSingle-centre Open Label Exploratory Phase IIb Pilot Study of Exogenous Oral Melatonin for the Treatment of Nocturia in Adults With Parkinson's DiseaseParkinson's Disease;NocturiaDrug: MelatoninUniversity College, LondonNot recruiting18 YearsN/ABoth20Phase 2United Kingdom
422NCT02390089April 201525 February 2019Cough According to Stimulus Type in PDAirway Protection Deficits According to Stimulus Type in Parkinson's DiseaseParkinson's DiseaseDrug: Capsaicin vapor;Other: fog;Radiation: Videofluoroscopic swallow evaluation;Device: NebulizerUniversity of FloridaNational Institute on Deafness and Other Communication Disorders (NIDCD)Not recruiting50 Years80 YearsAll158Phase 1United States
423NCT02424708April 20154 July 2016Phase IIb Study of Intranasal Glutathione in Parkinson's DiseasePhase IIb Study of Intranasal Glutathione in Parkinson's DiseaseParkinson's DiseaseDrug: Reduced Glutathione 100mg;Drug: Reduced Glutathione 200mg;Drug: PlaceboBastyr UniversityMichael J. Fox Foundation for Parkinson's ResearchNot recruiting21 YearsN/ABoth45Phase 2United States
424NCT02486432April 20153 August 2015A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa)A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa) Doses Administered Using a Divided Dose ApproachParkinson's DiseaseDrug: Levodopa/Carbidopa (Sinemet)NeuroDerm Ltd.Quotient ClinicalNot recruiting40 Years65 YearsBoth6Phase 1
425JPRN-UMIN0000166592015/03/012 April 2019Comparative study of the effects on L-dopa formulation absorption by the acid secretion inhibitorhealty adult Parkinson's diseaseMENESIT100 1tablet once a day (p.o.)

famotidine 40mg/day for previous 1day (p.o.)
MENESIT100 1tablet once a day (p.o.)

esomeprazole 20mg for previous three days or more (p.o.)
MENESIT100 1tablet once a day (p.o.)		Utano National Hospital, National Hospital OrganaizationNot Recruiting20years-old75years-oldMale and Female3Phase 1Japan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
426JPRN-UMIN0000166642015/03/012 April 2019Effect of nicotine patch in Cognitive function improvement in Parkinson's diseaseParkinson's diseasenicotine patchDepartment of Clinical Pharmacology and Neurology Ehime University graduated School of MedicineRecruitingNot applicableNot applicableMale and Female20Not selectedJapan
427NCT02066571March 201514 November 2016Study to Assess the Clinical Benefit and Safety of Droxidopa in Parkinson's DiseaseA Phase II, Double-Blind, Placebo-Controlled, Crossover Study to Assess Clinical Benefit and Safety of Droxidopa in the Treatment of Parkinson's DiseaseParkinson's Disease;Freezing of Gait;Cognitive Ability, GeneralDrug: Droxidopa;Drug: sugar pillHenry Ford Health SystemRecruiting30 YearsN/ABoth20Phase 2United States
428NCT02242487March 201526 August 2019Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF EpisodesA 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)Idiopathic Parkinson's DiseaseDrug: CVT-301Acorda TherapeuticsNot recruiting30 Years86 YearsAll325Phase 3United States;Canada;Czechia;Poland;Spain;Czech Republic
429NCT02373072March 201516 December 2017A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's DiseaseA Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Idiopathic Parkinson's DiseaseIdiopathic Parkinson DiseaseDrug: PF-06649751;Drug: Trimethobenzamide Hydrochloride;Drug: PlaceboPfizerNot recruitingN/AN/AAll18Phase 1United States;Belgium
430NCT02393027March 201516 December 2017Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999Idiopathic Parkinson DiseaseDrug: [18F] LBT-999 PETUniversity Hospital, ToursNot recruiting45 Years75 YearsAll16Early Phase 1France
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
431NCT02452606March 20158 August 2016Clock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa/Carbidopa/Entacapone) on Sleep Disorders in Parkinson's DiseaseClock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa/Carbidopa/Entacapone) on Sleep Disorders in Parkinson's DiseaseParkinson Disease;Sleep DisordersDrug: Stalevo®Asan Medical CenterRecruiting20 Years79 YearsBoth100N/AKorea, Republic of
432NCT02696603March 201516 December 2017Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower)Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower)Parkinson Disease;Neurodegenerative Diseases;Movement Disorders;Central Nervous System Diseases;Brain Diseases;Basal Ganglia Diseases;Parkinsonian DisordersBehavioral: Participant self-assessment surveys;Behavioral: Phonation;Behavioral: Gait and balance;Behavioral: Memory;Behavioral: Dexterity;Behavioral: Participant open-response writing;Other: Parkinson mPower mobile applicationSage BionetworksRobert Wood Johnson FoundationRecruiting18 YearsN/AAll20000N/AUnited States
433JPRN-UMIN0000164852015/02/252 April 2019Pilot study about imaging method of 18F-fluoro-dopa and 11C-raclopride in Parkinson's disease and Parkinson's syndromeHealthy subjects, Parkinson's disease patients and Parkinson's syndrome patientsIntravenous injection of 18F-fluoro-dopa and 11C-raclopride
PET imaging		Institute of Biomedical Research and InnovationNot Recruiting35years-oldNot applicableMale and Female20Not selectedJapan
434EUCTR2014-003799-22-HU11/02/20153 July 2017A study of the safety and drug effects of levodopa inhalation powder (CVT-301) compared to Standard of Care Observational Cohort in patients with Parkinson’s diseaseA Phase 3, Randomized Study Investigating the Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients With Motor Response Fluctuations (OFF Phenomena) Compared to an Observational Cohort ControlParkinson's Disease With Motor Response Fluctuations (OFF Phenomena)
MedDRA version: 17.1 Level: LLT Classification code 10034007 Term: Parkinson's disease NOS System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: CVT-301
Product Code: CVT-301
Pharmaceutical Form: Inhalation powder, hard capsule
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Current Sponsor code: CVT-301
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 30-
Product Name: CVT-301
Product Code: CVT-301
Pharmaceutical Form: Inhalation powder, hard capsule
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Current Sponsor code: CVT-301
Other descriptive name: LEVODOPA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 42-		Civitas Therapeutics, Inc.Not RecruitingFemale: yes
Male: yes		365Phase 3Serbia;Spain;Austria;Israel;United Kingdom;Italy;France;Hungary;Czech Republic;Belgium;Poland;Romania;Germany
435NCT02337725February 201510 October 2016A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease PatientsA Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With LevodopaParkinson's DiseaseDrug: Placebo;Drug: TVP-1012TakedaNot recruiting30 Years80 YearsBoth244Phase 3Japan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
436NCT02337764February 20157 November 2016A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease ParticipantsA Multicenter, Open-label, Long-term, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Levodopa Treated Parkinson's Disease PatientsParkinson's DiseaseDrug: TVP-1012 1mg with levodopaTakedaNot recruiting30 Years79 YearsBoth222Phase 3Japan
437NCT02339064February 201514 October 2019Infusion of Apomorphine: Long-term Safety StudyA Phase 3, Open-Label Study of the Safety, Efficacy and Tolerability of Apomorphine Administered by Continuous Subcutaneous Infusion in Advanced Parkinson's Disease Patients With Unsatisfactory Control on AvailableIdiopathic Parkinson's DiseaseDrug: apomorphine infusionUS WorldMeds LLCNot recruiting30 YearsN/AAll99Phase 3United States
438NCT02409823February 20152 November 2015Clinical Registry of Patients Under Treatment With Atypical AntipsychoticsClinical Registry of Patients Under Treatment With Atypical AntipsychoticsSchizophrenia;Major Depressive Disorder;Bipolar Depressive Disorder;Parkinson's Disease With HallucinationsDrug: Atypical AntipsychoticsPontifical Catholic University of ArgentinaNot recruiting18 YearsN/ABoth665N/A
439NCT02933372February 201515 July 2019Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease - Proj#3Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease - Proj#3Parkinson's DiseaseDrug: Varenicline;Radiation: PET Scan;Other: Evaluation by InvestigatorUniversity of MichiganNot recruiting45 YearsN/AAll58Phase 2
440JPRN-JapicCTI-15276227/1/20152 April 2019A long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease PatientsA Multicenter, Open-label, Long-term, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Levodopa Treated Parkinson's Disease PatientsParkinson's diseaseIntervention name : TVP-1012 (1 mg/day) with levodopa
Dosage And administration of the intervention : TVP-1012 (1 mg/day) once daily, before or after breakfast. A levodopa combination drug will be concomitantly administered in principle without change in the dose regimen throughout the study period from the start of the screening period.
Control intervention name : null		TAKEDA PHARMACEUTICAL COMPANY LTD.3079BOTH215Phase 3
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
441NCT02337738January 201510 October 2016A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease ParticipantsA Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2/3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Patients With Wearing OffParkinson's DiseaseDrug: TVP-1012 1mg;Drug: TVP-1012 0.5mg;Drug: PlaceboTakedaNot recruiting30 Years79 YearsBoth404Phase 2/Phase 3Japan
442NCT02347059January 201519 February 2015L-dopa Versus Dopamine Agonists After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's DiseaseA Randomized, Single-blind Trial on the Efficacy and Safety of L-dopa Monotherapy Versus Dopamine Agonists Monotherapy After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's DiseaseParkinson's DiseaseDrug: L-dopa;Drug: Dopamine Agonists (pramipexole, ropirinole)University of TorontoMichael J. Fox Foundation for Parkinson's ResearchRecruitingN/AN/ABoth40Phase 2Canada
443NCT02406105January 201513 April 2015An Effectiveness and Toxicity of CyberKnife Based Radiosurgery for Parkinson DiseaseAn Evaluation of Effectiveness and Toxicity of CyberKnife Based Functional Radiosurgery for Parkinson Disease Patients Suffering From Tremor and Its Implementation in PolandParkinson DiseaseRadiation: Radiosurgical thalamotomy;Drug: CyberKnifeMaria Sklodowska-Curie Memorial Cancer Center, Institute of OncologyRecruiting18 YearsN/ABoth27Phase 2Poland
444NCT02763137January 201517 May 2016Intermittent Oral Administration vs. Semi-continuous Intra-oral Administration of Levodopa/Carbidopa in Fluctuating Parkinsonian PatientsA Phase IIa Study to Assess the Safety, Tolerability, Plasma Pharmacokinetics and Efficacy of Intermittent Oral Administration of Standard Levodopa/Carbidopa vs. Semi-continuous Intra-oral Administration of Levodopa/Carbidopa in Patients With Advanced Parkinson's Disease Who Suffer Motor FluctuationsParkinson DiseaseDrug: Standard LD/CD;Drug: Semi continuous intra-oral administration of LD/CDIRCCS San RaffaeleSynAgile CorporationNot recruiting35 Years75 YearsBoth18Phase 2Italy
445NCT02258152December 22, 201429 April 2019SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)Parkinson's Disease Dementia (PDD)Drug: SYN120;Drug: PlaceboBiotie Therapies Inc.Michael J. Fox Foundation for Parkinson's Research;Massachusetts General Hospital;Acorda TherapeuticsNot recruiting50 YearsN/AAll82Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
446JPRN-JapicCTI-14274811/12/201423 April 2019Long-term study of HP-3000 in patients with Parkinson's diseaseA phase III long-term study of HP-3000 in patients with Parkinson's diseaseParkinson's diseaseIntervention name : HP-3000(ropinirole hydrochloride patch)
Dosage And administration of the intervention : Transdermal, once daily		Hisamitsu Pharmaceutical Co.,Inc.2079BOTHPhase 3
447NCT02267434December 20147 November 2016Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's DiseaseA Randomized, Placebo-controlled, Parallel Group, Patient-blinded, Multi-center, Phase I Pilot Study to Assess Tolerability and Safety of Two Doses of AFFITOPE® PD03A Formulated With Adjuvant to Patients With Early Parkinson's DiseaseParkinson Disease;Neurodegenerative DiseasesBiological: Low dose AFFITOPE® PD03A + Adjuvant;Biological: High dose AFFITOPE® PD03A + Adjuvant;Biological: Adjuvant without active componentAffiris AGPROSENEX AmbulatoriumbetriebsGMBH;Medical University Innsbruck;Forschungszentrum JuelichNot recruiting45 Years70 YearsBoth36Phase 1Austria
448NCT02324426December 201411 May 2015CNS Uptake of Intranasal GlutathioneCentral Nervous System Uptake of Intranasal Glutathione in Parkinson's DiseaseParkinson's DiseaseDrug: Reduced GlutathioneUniversity of WashingtonMichael J. Fox Foundation for Parkinson's ResearchNot recruiting18 YearsN/ABoth15Phase 1United States
449NCT02480803December 20144 February 2019INfusion VErsus STimulation in Parkinson's DiseaseTreatment in Advanced Parkinson's Disease: Continuous Intrajejunal Levodopa INfusion VErsus Deep Brain STimulationParkinson's DiseaseDrug: Continuous intrajejunal infusion of levodopa-carbidopa;Device: deep brain stimulationAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)ZonMw: The Netherlands Organisation for Health Research and DevelopmentRecruiting18 YearsN/AAll66Phase 4Netherlands
450NCT03116308November 21, 201416 December 2017Effect of Food on OpicaponeEffect of Food on Opicapone Bioavailability and Pharmacodynamics in Healthy SubjectsParkinson DiseaseDrug: Opicapone (OPC)Bial - Portela C S.A.Not recruiting18 Years45 YearsAll28Phase 1
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
451ChiCTR-DDD-170107942014-11-0818 April 2017The study on early diagnosis of Parkinson 's disease by transcranial ultrasonographythe study on early diagnosis of Parkinson 's disease by transcranial ultrasonographyParkinson's DiseaseGold Standard:Diagnosis of Parkinson disease needs to meet 3 or more: unilateral onset;resting tremor;progressive course; long term asymmetry, the most obvious symptoms is the onset side; a good response to levodopa (70% ~ 100%); levodopa induced chorea; a reaction of levodopa lasts 5 years or more; clinical course last;Index test:Laboratory apparatus
As shown in Figure 1, The ultrasound equipment, Philips IE33-BOMJH1 color Doppler ultrasonography, Model IE-ELite, with 2-4MHz phased array probe (S5-1 probe) was used for TCS to examine SN in our study.
Transcranial ultrasound study
Ultrasonography through temporal window, alon;		Department of Neurology, Fujian Institute of Geriatrics, Fujian Medical University Union HospitalNot Recruiting3684BothTarget condition:135;Difficult condition:0Diagnostic New Technique Clincal StudyChina
452JPRN-JapicCTI-14270201/11/201423 April 2019A Phase 1 Study of ONO-2160/CDA Phase 1 study on single and multiple oral dose administration of ONO-2160/CD in healthy adult male subjects and on multiple oral dose administration of ONO-2160/CD in Parkinson's disease patientsParkinson's diseaseIntervention name : ONO-2160/CD
Dosage And administration of the intervention : Oral administration
Control intervention name : Levodopa/carbidopa hydrate
INN of the control intervention : Levodopa/carbidopa hydrate
Dosage And administration of the control intervention : Oral administration		ONO PHARMACEUTICAL CO.,LTD.BOTH34Phase 1
453NCT02240030November 20143 June 2019Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF EpisodesA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena) (SPAN-PD™)Idiopathic Parkinson's DiseaseDrug: CVT-301 Low Dose;Drug: CVT-301 High Dose;Other: PlaceboAcorda TherapeuticsNot recruiting30 Years85 YearsAll351Phase 3United States;Canada;Czechia;Poland;Spain;Czech Republic
454NCT02278588November 201429 April 2019Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.Parkinson's DiseaseDrug: RasagilineThomas GuttusoNot recruitingN/AN/AAll45Phase 4United States
455NCT02281474November 201428 December 2015Nilotinib in Cognitively Impaired Parkinson Disease Patients 001Open Label Dose Escalation of Nilotinib in Cognitively Impaired Parkinson Disease Patients With Elevated Cerebrospinal Fluid and Blood a-SynucleinParkinson's Disease;Parkinson's Disease Dementia;Diffuse Lewy Body DiseaseDrug: NilotinibGeorgetown UniversityNot recruiting40 Years90 YearsBoth12Phase 1United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
456NCT02312232November 20142 March 2015Pharmacokinetic Study in Healthy MalesPharmacokinetics of Levodopa, Carbidopa, 3-OMD and ODM-104 After Repeated Doses of Different Formulations: an Open, Randomised, Multicentre Study With Crossover Design in Healthy MalesParkinson's DiseaseDrug: levodopa, carbidopa, ODM-104Orion Corporation, Orion PharmaNot recruiting18 Years65 YearsMale20Phase 1Finland
457EUCTR2014-000335-17-GB28/10/20144 August 2015Rotigotine and memory in Parkinson's.The Effect of Rotigotine on Memory in Idiopathic Parkinson's Disease without Cognitive Impairment - Rotigotine and Memory in Parkinson's.Idiopathic Parkinson's Disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: rotigotine
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: 92206-54-7
Concentration unit: Other
Concentration type: up to
Concentration number: -16 mg/24 h
Product Name: levodopa CR (controlled release)
Pharmaceutical Form: Tablet
INN or Proposed INN: levodopa
CAS Number: 59-92-7
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: -1000
Product Name: Rasagiline
Pharmaceutical Form: Tablet
INN or Proposed INN: Rasagiline
CAS Number: 1875-50-9
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: -1 mg/24h
Product Name: Selegiline
Pharmaceutical Form: Tablet
INN or Proposed INN: selegiline
CAS Number: 14611-51-9
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: -12mg/24hs		Research and Development University Hospital of North StaffordshireKeele UniversityNot RecruitingFemale: yes
Male: yes		0United Kingdom
458EUCTR2014-001131-36-ES23/10/20148 August 2016A 16 Week Clinical Study to Evaluate the Use of Long-Acting Amantadine to Treat Parkinson's Disease Patients with Abnormal Involuntary Movements caused by LevodopaA Multicenter, Randomized, Placebo-controlled, Double-blind, 16 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects with Levodopa-Induced DyskinesiasParkinson's Disease Subjects with Levodopa-Induced Dyskinesias
MedDRA version: 17.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Amantadine HCl Extended Release
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Amantadine hydrochloride
Other descriptive name: AMANTADINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 160-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Product Name: Amantadine HCl Extended Release
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Amantadine hydrochloride
Other descriptive name: AMANTADINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 240-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Product Name: Amantadine HCl Extended Release
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Amantadine hydrochloride
Other descriptive name: AMANTADINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 320-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use		Osmotica Pharmaceutical Corp.Not RecruitingFemale: yes
Male: yes		162Phase 3France;United States;Canada;Spain;Germany
459EUCTR2014-001132-10-ES23/10/20148 August 2016A 26 Week Clinical Study to Evaluate the Use of Long-Acting Amantadine to Treat Parkinson's Disease Patients with Abnormal Involuntary Movements caused by LevodopaA Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects with Levodopa-Induced DyskinesiasParkinson's Disease Subjects with Levodopa-Induced Dyskinesias
MedDRA version: 17.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Amantadine HCl Extended Release
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Amantadine hydrochloride
Other descriptive name: AMANTADINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 160-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Product Name: Amantadine HCl Extended Release
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Amantadine hydrochloride
Other descriptive name: AMANTADINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 240-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Product Name: Amantadine HCl Extended Release
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Amantadine hydrochloride
Other descriptive name: AMANTADINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 320-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use		Osmotica Pharmaceutical Corp.Not RecruitingFemale: yes
Male: yes		162Phase 3France;United States;Canada;Spain;Germany
460EUCTR2014-002295-87-IT13/10/201419 February 2018A Phase IIa study to assess the safety, tolerability, plasma pharmacokinetics and efficacy of intermittent oral administration of standard levodopa/carbidopa vs. semi-continuous intra-oral administration of levodopa/carbidopa in patients with advanced Parkinson’s disease who suffer motor fluctuations.A Phase IIa study to assess the safety, tolerability, plasma pharmacokinetics and efficacy of intermittent oral administration of standard levodopa/carbidopa vs. semi-continuous intra-oral administration of levodopa/carbidopa in patients with advanced Parkinson’s disease who suffer motor fluctuations.Parkinson's disease patients who suffer motor fluctuations will participate in the study
MedDRA version: 17.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: SINEMET 100 mg + 25 mg compresse
Product Name: SINEMET 100 mg + 25 mg compresse
Product Code: NA
Pharmaceutical Form: Oral suspension		SynAgile CorporationNot RecruitingFemale: yes
Male: yes		18Phase 2Italy
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
461NCT02183519October 201416 December 2017Respiratory Kinematics of Cough in Healthy Older Adults and Parkinson's DiseaseRespiratory Kinematics of Reflex and Voluntary Cough in Healthy Older Adults and Parkinson's DiseaseCough;Parkinson's DiseaseDrug: Capsaicin;Other: Voluntary cough testUniversity of FloridaNot recruiting55 Years85 YearsAll44Phase 1/Phase 2United States
462NCT02224664October 201416 December 2017Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s DiseaseA Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor FluctuationsParkinson`s DiseaseDrug: PF-06649751PfizerNot recruiting30 Years80 YearsAll50Phase 1United States;Belgium
463NCT02259049October 20141 February 2016The Effects of L-Tyrosine on 24 Hour Blood Pressure and Heart Rate in Parkinson's DiseaseThe Effects of L-Tyrosine on Non-invasive Ambulatory Blood Pressure and Heart Rate Monitoring in Parkinson's DiseaseBlood PressureDietary Supplement: L-tyrosine;Dietary Supplement: Sugar PillNew York Institute of TechnologyNot recruiting40 Years84 YearsBoth6Phase 0United States
464NCT02274324October 201419 February 2015Dietary Modifications Effect on Continuous LCIG Infusion Outcomes in Patients With Advanced Parkinson&Apos;s DiseaseDietary Modifications Effect on Continuous LCIG Infusion Outcomes in Patients With Advanced Parkinson's DiseaseParkinson DiseaseDietary Supplement: different dietsSheba Medical CenterTel Aviv UniversityNot recruiting40 Years80 YearsBoth20N/A
465NCT02274766October 201422 January 2018Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced DyskinesiaADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study)Dyskinesia;Levodopa-Induced Dyskinesia (LID);Parkinson's Disease (PD)Drug: ADS-5102;Other: PlaceboAdamas Pharmaceuticals, Inc.Not recruiting30 Years85 YearsAll77Phase 3United States;Austria;France;Germany;Spain
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
466JPRN-UMIN0000168932014/09/2221 May 2019A double-blind, randomized clinical trial to evaluate the efficacy of Duloxetine against pain associated with Parkinson's disease with depression.A double-blind, randomized clinical trial to evaluate the efficacy of Duloxetine against pain associated with Parkinson's disease with depression. - Pain reduction in PD patients with depression: double blind, randomized clinical trial of duloxetine.PD patientsThe treatment groups consist of an active treatment arm (40mg/day Duloxetine) and a placebo arm. During the Titration Period (2 weeks), all subjects will be started on 1 capsule (10mg or placebo). During the Maintenance Period (10 weeks), subjects will take 2 capsules. Subjects who are unable to increase their dose can stay at 1 capsule.
The treatment groups consist of an active treatment arm (40mg/day Duloxetine) and a placebo arm. During the Titration Period (2 weeks), all subjects will be started on 1 capsule (10mg or placebo). During the Maintenance Period (10 weeks), subjects will take 2 capsules. Subjects who are unable to increase their dose can stay at 1 capsule.		Ehime University Hospital Dept. of Clinical pharmacology and NeurologyNot Recruiting20years-oldNot applicableMale and Female50Phase 2Japan
467NCT02236260September 3, 201416 December 2017Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain StimulationEvaluation of the Benefit Provided by the Addition of Acupunctural Analgesia With Electrostimulation to Conventional Local Anesthesia Compared to Conventional Local Anesthesia Alone in Surgery of Deep Brain Stimulation for Movement Disorders.Parkinson's DiseaseProcedure: Electroacupuncture;Drug: Local Anesthesia (lidocaine hydrochloride)Nantes University HospitalNot recruiting18 Years74 YearsAll20N/AFrance
468NCT02168842September 20144 March 2019Efficacy of Isradipine in Early Parkinson DiseasePhase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson DiseaseParkinson DiseaseDrug: Isradipine;Drug: Placebo (for Isradipine)University of RochesterNational Institute of Neurological Disorders and Stroke (NINDS);Michael J. Fox Foundation for Parkinson's Research;The Parkinson Study GroupNot recruiting30 YearsN/AAll336Phase 3United States;Canada
469NCT02212678September 201414 March 2016Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's DiseaseRepeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's DiseaseParkinson DiseaseDrug: N-acetylcysteine capsuleUniversity of Minnesota - Clinical and Translational Science InstituteParkinson's Disease Society of the United KingdomNot recruiting18 YearsN/ABoth9Phase 2United States
470NCT02225548September 20148 January 2018Sagene 2014 - Parkinson's Disease and Erectile DysfunctionAn Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction.Parkinson's Disease;Erectile DysfunctionDrug: Selegiline;Drug: TadalafilUniversity of South FloridaRecruiting40 Years64 YearsMale10Phase 4United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
471NCT02230904September 201419 October 2017A Study to Compare the Adhesiveness of 2 Different Rotigotine Patches Used for the Treatment of Parkinson's DiseaseA Multicenter, Randomized, Double-blind, 2-way Cross-over Study to Compare the Adhesiveness of 2 Different Rotigotine Patch Formulations in Subjects With Parkinson's DiseaseParkinson's DiseaseDrug: Rotigotine (Test product PR 2.3.1);Drug: Rotigotine (Reference product PR 2.1.1)UCB BIOSCIENCES GmbHPharmaceutical Health Sciences;Bracket GlobalNot recruiting18 YearsN/AAll57Phase 1Germany
472NCT02256319September 201428 December 2015Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity Measured Through Implanted StimulatorsEffects of Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity (Local Field Potentials) Measured Through Implanted StimulatorsParkinson's DiseaseDrug: Dexmedetomidine;Drug: PropofolClinica Universidad de Navarra, Universidad de NavarraNot recruiting18 YearsN/ABoth12Phase 4Spain
473NCT02777060September 201430 May 2016Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome MeasuresExploring the Effectiveness of Sensor-based Balance Training on Patient Outcome MeasuresDiabetes;Cancer;Multiple Sclerosis;Arthritis;Parkinson's Disease;Cognitive Disorders;Brain Injury;StrokeProcedure: Exergame;Procedure: Home based balance trainingUniversity of ArizonaRecruiting18 YearsN/ABoth200N/AUnited States
474NCT03151460September 201416 December 2017Dopaminergic Modulation of Declarative MemoryDopaminergic Modulation of Declarative MemoryParkinson's DiseaseDrug: Dopamine AgentI.R.C.C.S. Fondazione Santa LuciaNot recruitingN/AN/AAll40Phase 4Italy
475ChiCTR-TRC-140051432014-08-2518 April 2017A traditional chinese medicine clinical intervention study of depressed Parkinson's disease - based on the Wenyang Jieyu methodA traditional chinese medicine clinical intervention study of depressed Parkinson's disease - based on the Wenyang Yieyu methodDepressed Parkinson's diseaseChinese Medicines:Formula granule;Western Medicine group:Venlafaxine hydrochloride sustained-release capsules ;The Third Affiliated Hospital of Beijing University of Traditional Chinese MedicineRecruiting5575BothChinese Medicines:60;Western Medicine group:60;Phase 2 studyChina
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
476NCT02153645August 18, 201415 April 2019Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.A Multicenter, Randomized, Placebo-controlled, Double-blind, 16 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced DyskinesiasParkinson's Disease;Levodopa Induced Dyskinesias (LID)Drug: 240mg Amantadine HCl ER tablets;Drug: Placebo tablets;Drug: 320mg Amantadine HCl ER tabletsOsmotica Pharmaceutical US LLCNot recruiting30 Years85 YearsAll87Phase 3United States;Canada;France;Germany;Spain
477NCT02216188August 201424 August 2015Follow-up Study to Assess One Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical ActivityPhase IB Follow-up, Randomized, Controlled, Parallel Group, Patient-blinded, Single-center Study to Assess One Boost With AFFITOPE® PD01A With Regard to Safety/Tolerability, Immunological + Clinical Activity in Patients Who Have Received the Vaccine Within the Study AFF008Parkinson's DiseaseBiological: AFFITOPE® PD01A;Other: ControlAffiris AGNot recruiting40 Years68 YearsBoth28Phase 1Austria
478NCT02228590August 201416 December 2017A Study to Examine APL-130277 in Patients With Parkinson's DiseaseA Phase 2 Study to Examine the Safety, Tolerability and Efficacy of APL-130277 in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: APL-130277SunovionNot recruiting18 Years80 YearsAll19Phase 2United States
479NCT02230267August 201423 May 2016High-intensity Exercise and Fall Prevention Boot Camp for Parkinson's DiseaseHigh-intensity Exercise and Fall Prevention Boot Camp for Parkinson's DiseaseParkinson's DiseaseOther: High intensity exercise and balance training;Other: Usual care arm exerciseUniversity of Nevada, Las VegasNot recruiting45 Years85 YearsBoth27Phase 2United States
480NCT02236065August 201416 December 2017Combination Therapy of Cord Blood and G-CSF for Patients With Brain Injury or Neurodegenerative DisordersA Pilot Study of Combination Therapy of Allogeneic Umbilical Cord Blood and Granulocyte-colony Stimulating Factor for Patients With Brain Injury or Neurodegenerative DisordersBrain Injury;Cerebral Palsy;Amyotrophic Lateral Sclerosis;Parkinson's DiseaseProcedure: Umbilical cord blood therapy;Biological: FilgrastimMinYoung Kim, M.D.Not recruiting19 Years75 YearsAll10N/AKorea, Republic of
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
481NCT02438215August 201425 May 2015Study of IRX4204 for Treatment of Early Parkinson's DiseaseAn Open-Label, Single Site Study Using [123I]ß-CIT Single Photon Emission Tomography (SPECT) to Evaluate Dopamine Transporter Binding Following Treatment With IRX4204 in Early Parkinson's Disease SubjectsParkinson's DiseaseDrug: IRX4204Io TherapeuticsNot recruiting18 YearsN/ABoth15Phase 1United States
482NCT02153632July 30, 201415 April 2019Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LIDA Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced DyskinesiasParkinson's Disease;Levodopa Induced Dyskinesia (LID)Drug: amantadine HCl ER;Drug: PlaceboOsmotica Pharmaceutical US LLCNot recruiting30 Years85 YearsAll135Phase 3United States;Canada;France;Germany;Spain
483JPRN-UMIN0000147092014/07/012 April 2019Study on Parkinson's disease and related disorders with dopamine transporter ligand [C-11]PE2IPatients of Parkinson's disease and related disordersThe dosage in the vein of [C-11]PE2I, [C-11]raclopride, and [F-18]FDG for PET/CT imaging.Tokyo Metropolitan Institute of GerontologyRecruiting18years-oldNot applicableMale and Female200Not selectedJapan
484NCT02138682July 201419 February 2015Validation of DaTscan for Detection of Parkinson Disease Related DisordersValidation of DaTscan for Detection of Parkinsonian Disease and Related Disorders Using Neuropathologically-confirmed Parkinson Disease From Human Brain TissueParkinson Disease;Movement DisordersDrug: l-123 IoflupaneWisconsin Institute for Neurologic and Sleep Disorders S.C.Wisconsin Parkinson Association;Medical College of Wisconsin;GE HealthcareRecruiting75 YearsN/ABoth20Phase 4United States
485NCT02202551July 201416 December 2017Open-Label Safety Study of ADS-5102 in PD Patients With LIDOpen-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)Dyskinesia;Levodopa Induced Dyskinesia (LID);Parkinson's Disease (PD)Drug: ADS-5102Adamas Pharmaceuticals, Inc.Not recruiting30 Years85 YearsAll250Phase 3United States;Austria;Canada;France;Germany;Spain
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
486NCT02206620July 201419 February 2015Effects of Cholinergic Augmentation on Measures of Balance and GaitEffects of Cholinergic Augmentation on Measures of Balance and GaitParkinson's DiseaseDrug: DonepezilOregon Health and Science UniversityMichael J. Fox Foundation for Parkinson's ResearchRecruiting30 YearsN/ABoth100Phase 2United States
487NCT02472210July 20143 August 2015The Use of Botox in Advanced Parkinson's Patients Experiencing PainA Study of the Utility of Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease Double Blind Placebo Control Crossover Pilot StudyParkinson's DiseaseDrug: Botulinum ToxinUniversity Health Network, TorontoNot recruiting18 YearsN/ABoth14Phase 4
488EUCTR2014-000868-17-ES26/06/201418 January 2016Effect of dexmedetomidine vs propofol on basal ganglia activity (local field potentials) recorded through implanted stimulatorsEffect of dexmedetomidine vs propofol on basal ganglia activity (local field potentials) recorded through implanted stimulatorsParkinson's disease
MedDRA version: 16.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]		Trade Name: Dexdor
Product Name: Dexdor
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: DEXMEDETOMIDINE
CAS Number: 113775-47-6
Other descriptive name: DEXMEDETOMIDINA
Concentration unit: mg/kg/h milligram(s)/kilogram/hour
Concentration type: range
Concentration number: 0.0002-0.0014
Trade Name: Propofol-Lipuro
Product Name: Propofol-Lipuro
Pharmaceutical Form: Emulsion for infusion
INN or Proposed INN: PROPOFOL
Other descriptive name: PROPOFOL
Concentration unit: mg/kg/h milligram(s)/kilogram/hour
Concentration type: range
Concentration number: 0.5-4		Clínica Universidad de Navarra/Universidad de NavarraNot RecruitingFemale: yes
Male: yes		Spain
489ChiCTR-TRC-140047072014-06-0918 April 2017The effect of different patterns of rehabilitation training in idiopathic Parkinson's diseaseThe effect of different patterns of rehabilitation training in idiopathic Parkinson's diseaseParkinson's diseaseTai Chi group:Tai Chi;Balance function training group:Balance function training;Shanghai Tongji HospitalNot Recruiting2090BothTai Chi group:30;Balance function training group:30;OtherChina
490NCT01971242June 201428 November 2016Trial of Exenatide for Parkinson's DiseaseA Randomised, Double Blind, Placebo Controlled, Single Centre, 60 Week Trial of Exenatide Once Weekly for the Treatment of Moderate Severity Parkinson's DiseaseParkinson's DiseaseDrug: Exenatide;Other: PlaceboUniversity College, LondonNot recruiting25 Years75 YearsBoth60Phase 2United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
491NCT02157714June 201431 October 2016Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's DiseaseA Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PRX002 Administered By Intravenous Infusion in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: PRX002;Other: PlaceboProthena Biosciences LimitedHoffmann-La RocheNot recruiting40 Years80 YearsBoth64Phase 1United States
492NCT02174250June 201414 September 2015The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.Effect of a Strong Enzyme Inducer, Rifampin, on the Single-Dose Pharmacokinetics of Istradefylline in Healthy SubjectsParkinson's DiseaseDrug: Istradefylline 40 mg;Drug: Rifampin 300mg BID + istradefylline 40mg Day 8 onlyKyowa Hakko Kirin Pharma, Inc.Not recruiting18 Years65 YearsBoth20Phase 1United States
493NCT02046447May 20148 January 2018Neuroimaging of DystoniaNeuroimaging of Dystonia: The Bachmann-Strauss Dystonia and Parkinson Disease Center of Excellence at the University of FloridaPrimary Cervical Dystonia;DYT 1 DystoniaDrug: Primary Cervical Dystonia (Trihexyphenidyl);Other: Controls Primary Cervical Dystonia (Trihexyphenidyl);Other: DYT 1 Dystonia (Healthy Control);Other: DYT 1 DystoniaUniversity of FloridaBachmann Strauss Dystonia & Parkinson Foundation, Inc.Not recruiting7 Years70 YearsAll20N/AUnited States
494NCT02096601May 201419 February 2015A Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease PatientsA Phase I/II Pharmacokinetic (PK) Study of ND0612, a Liquid Formulation of Levodopa/Carbidopa (LD/CD), Delivered as a Continuous Subcutaneous in Parkinson's Disease (PD) Patients Treated With LDParkinson's DiseaseDrug: Levodopa and carbidopa SC solution;Drug: Oral levodopa and carbidopaNeuroDerm Ltd.Michael J. Fox Foundation for Parkinson's ResearchNot recruiting30 Years80 YearsBothPhase 1/Phase 2United States;Israel
495NCT02136914May 201416 December 2017ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)Efficacy and Safety of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease Patients (EASE LID Study)Dyskinesia;Levodopa Induced Dyskinesia (LID);Parkinson's DiseaseDrug: ADS-5102;Other: PlaceboAdamas Pharmaceuticals, Inc.Not recruiting30 Years85 YearsAll126Phase 3United States;Canada
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
496NCT02780895May 201420 June 2016Parkinsonian Brain Repair Using Human Stem CellsHuman OK99 Allogeneic Stem Cell Transplantation for Patients With Severe Parkinson's DiseaseIdiopathic Parkinson DiseaseDrug: Human Stem CellsCelavie Bioscences, LLCHospital Angeles del PedregalNot recruiting18 Years75 YearsBoth8Phase 1Mexico
497EUCTR2012-005539-10-DE29/04/20142 October 2017Clinical study to investigate the efficacy and safety of two dose levels of NT 201 versus placebo in treating chronic troublesome sialorrhea in various neurological conditions.Prospective, randomized, double-blind, placebo-controlled, parallel-group multicenter study, with an extension period of dose-blinded active treatment, to investigate the efficacy and safety of two dose levels of NT 201 in treating chronic troublesome sialorrhea in various neurological conditions - SIAXI – Sialorrhea in Adults Xeomin InvestigationChronic troublesome sialorrhea resulting from neurological conditions in adults with Parkinson's disease or atypical parkinsonism (multiple system atrophy, corticobasal degeneration or progressive supranuclear palsy), or after stroke or traumatic brain injury.
MedDRA version: 18.1 Level: PT Classification code 10039424 Term: Salivary hypersecretion System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Xeomin
Pharmaceutical Form: Powder for solution for injection
INN or Proposed INN: NT 101
CAS Number: 93384-43-1
Current Sponsor code: NT 101
Other descriptive name: BOTULINUM TOXIN TYPE A
Concentration unit: U unit(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Powder for solution for injection
Route of administration of the placebo: Intraglandular use
Trade Name: Xeomin
Pharmaceutical Form: Powder for solution for injection
INN or Proposed INN: NT 101
CAS Number: 93384-43-1
Current Sponsor code: NT 101
Other descriptive name: BOTULINUM TOXIN TYPE A
Concentration unit: U unit(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Powder for solution for injection
Route of administration of the placebo: Intraglandular use		Merz Pharmaceuticals GmbHNot RecruitingFemale: yes
Male: yes		180Phase 3United States;Poland;Germany
498JPRN-UMIN0000155592014/04/142 April 2019Comparative study between SSRI and SNRI treatment on depressive patients with Parkinson diseasesParkinson's disease Depression, Depressive stateparoxetine 20mg
Escitalopram 10mg
Duloxetine 40mg		Osaka Redcross HospitalNot Recruiting40years-oldNot applicableMale and Female40Not selectedJapan
499NCT03314597April 2, 201416 December 2017Instrumental or Physical-Exercise Rehabilitation of Balance in Parkinson's Disease? (IPER-PD)Instrumental or Physical-exercise Rehabilitation of Balance Improve Both Balance and Gait in Parkinson's Disease.Parkinson's Disease;RehabilitationOther: Balance exercise;Other: Mobile platform exerciseUniversity of PaviaFondazione Salvatore MaugeriNot recruiting50 Years85 YearsAll38N/A
500NCT01738178April 201416 December 2017Caffeine as a Therapy for Parkinson's DiseaseCaffeine as a Therapeutic Agent in Parkinson's DiseaseParkinson's DiseaseDrug: Caffeine;Drug: PlaceboMcGill University Health CenterPontifícia Universidade Católica do Paraná;University of Calgary;University of Newfoundland and Eastern Health;University Health Network, Toronto;UBC Hospital;Movement Disorder Clinic - Deer Lodge Centre;The Ottawa HospitalNot recruiting45 Years75 YearsAll119Phase 3Brazil;Canada
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
501NCT02111122April 201419 February 2015Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's DiseaseA Phase II, Prospective, Randomized, Double-blind, Crossover Placebo-controlled Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's DiseaseSleep-wake Disturbances in Motor-phase Parkinson`s DiseaseDrug: Sodium OxybateUniversity of ZurichRecruiting18 Years90 YearsBoth16Phase 2Switzerland
502NCT02365012April 20147 September 2015Treatment of Orthostatic Intolerance in Patients With Parkinson's Disease Using MidodrineTreatment of Orthostatic Intolerance in Patients With Parkinson's Disease Using MidodrineOrthostatic Intolerance;Parkinson's DiseaseDrug: MidodrinePhiladelphia Veterans Affairs Medical CenterRecruiting22 Years89 YearsBoth50N/AUnited States
503NCT02741947April 201425 April 2016Levodopa Benserazide Generic Formulation Versus the OriginatorClinical and Pharmacokinetics Study to Evaluate the Therapeutic Equivalence and Bioequivalence of Levodopa Benserazide Generic Formulation (Teva Italia) Versus the Originator (Madopar®)Parkinson DiseaseDrug: Levodopa Benserazide Madopar;Drug: Levodopa Benserazide Teva ItaliaIRCCS San RaffaeleAgenzia Italiana del FarmacoNot recruiting30 Years75 YearsBoth44Phase 4Italy
504NCT02082249March 10, 201410 December 2018An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian MedicationsAn Open-Label Three-Part Extension Study Assessing Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian MedicationsAdvanced Parkinson's DiseaseDrug: ABT-SLV187AbbVieNot recruiting30 Years99 YearsAll1Phase 3Japan;Korea, Republic of;Taiwan
505NCT02006290March 201412 October 2015Efficacy, Safety And Tolerability Study In Subjects With Parkinson's DiseaseA Phase 1b, Randomized, Subject And Investigator-Blinded, Sponsor-Open, Placebo Controlled, Cross-Over Efficacy, Safety And Tolerability Study Of Single Oral Split Dose Administration Of PF-06412562 In Subjects With Parkinson's DiseaseParkinson's DiseaseDrug: PF-06412562;Drug: PlaceboPfizerNot recruiting30 Years75 YearsBoth19Phase 1United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
506NCT02092181March 201423 July 2018A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease. (MAESTRO)Parkinsons DiseaseDrug: Mirabegron;Drug: PlaceboDaniel Burdick, MDAstellas Pharma US, Inc.Not recruiting30 Years85 YearsAll30Phase 4United States
507NCT02095171March 201419 February 2015Single Ascending Dose Study of PRX002 in Healthy SubjectsA Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of PRX002 Administered by Intravenous Infusion in Healthy SubjectsParkinson's DiseaseDrug: PRX002;Other: PlaceboProthena Biosciences LimitedHoffmann-La RocheNot recruiting21 Years65 YearsBoth40Phase 1United States
508NCT02111330March 201411 April 2016Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) After Multiple Oral Doses in Healthy VolunteersRandomized, Double Blind, Placebo Controlled, Parallel Groups Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) After Multiple Oral Doses in Healthy VolunteersParkinson DiseaseDrug: PBF-509;Drug: PlaceboFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauPalo Biofarma, S.LNot recruiting18 Years45 YearsBoth16Phase 1Spain
509NCT02305017March 201419 October 2017Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy VolunteersEffect of Paracetamol on Opicapone Pharmacokinetics in Healthy VolunteersParkinson's DiseaseDrug: BIA 9-1067;Drug: ParacetamolBial - Portela C S.A.Not recruiting18 Years45 YearsAll28Phase 1
510NCT02305030March 201419 February 2015Effect of Opicapone at Steady State on Warfarin PharmacokineticsEffect of Opicapone at Steady State on Warfarin Pharmacokinetics in Healthy VolunteersParkinson's DiseaseDrug: BIA 9-1067;Drug: WarfarinBial - Portela C S.A.Not recruiting18 Years45 YearsBoth20Phase 1
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
511NCT02445651March 201423 April 2019Physiological Effects of Nutritional Support in Patients With Parkinson's DiseasePhysiological Effects of Nutritional Support in Patients With Parkinson's DiseaseParkinson Disease;Idiopathic Parkinson DiseaseDietary Supplement: Intravenous and Oral n—acetyl cysteineThomas Jefferson UniversityNot recruiting30 Years80 YearsAll65N/AUnited States
512NCT02064166February 20143 December 2018Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin.A Double-blinded Placebo-controlled Single-center Study to Evaluate the Efficacy of Intranasal Insulin 40 International Units Day as Treatment for Subjects With Parkinson Disease and Multiple System AtrophyParkinson Disease;Multiple System AtrophyDrug: Intranasal InsulinPeter NovakNot recruiting18 YearsN/AAll15Phase 2United States
513NCT02103894February 20149 January 2017Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy SubjectsEvaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Clinically Diagnosed Tauopathies in Comparison to Healthy SubjectsAlzheimer's Disease (AD);Parkinson's Disease (PD);Chronic Traumatic Encephalopathy (CTE);Progressive Supranuclear Palsy (PSP);Frontal Temporal Dementia (FTD);Pick's Disease;TauopathiesDrug: [18F]T807 ([18F]MNI-777)Molecular NeuroImagingInstitute for Neurodegenerative DisordersNot recruiting18 Years85 YearsBoth16Phase 1United States
514NCT02305316February 201419 October 2017Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of OpicaponeSingle-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone in Healthy VolunteersParkinson DiseaseDrug: BIA 9-1067 non-micronized;Drug: BIA 9-1067 micronizedBial - Portela C S.A.Not recruiting18 Years45 YearsAll28Phase 1
515EUCTR2013-002545-10-SE08/01/201427 June 2016An open safety study with the monoaminergic stabilizer (-)-OSU6162 in patients with mental fatigue and related vitality and wakefulness disturbances associated with neurologiacal disorders, e g Parkinson’s disease, Huntington’s disease, brain trauma, stroke, myalgic encephalomyelitis and narcolepsy.An open safety study with the monoaminergic stabilizer (-)-OSU6162 in patients with mental fatigue and related vitality and wakefulness disturbances associated with neurologiacal disorders, e g Parkinson’s disease, Huntington’s disease, brain trauma, stroke, myalgic encephalomyelitis and narcolepsy. - OSU6162Open1309Parkinsons disease Huntingtons disease Multiple scleros Brain trauma Stroke Myalgic encephalomyelitis Narcolepsy;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Code: OSU6162 similar to (-)-OSU 6162
Pharmaceutical Form: Coated tablet		A. Carlsson Research ABAuthorisedFemale: yes
Male: yes		240Phase 2Sweden
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
516NCT02046434January 201414 January 2019Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the BrainPhenylbutyrate Response As a Biomarker for Alpha-Synuclein Clearance From BrainParkinson's DiseaseDrug: Glycerol PhenylbutyrateUniversity of Colorado, DenverNot recruiting21 Years80 YearsAll40Phase 1United States
517NCT02384512January 201420 April 2015Azilect® In Wearing-Off (AIWO)Azilect® In Wearing-Off (AIWO) Non-interventional Study on Efficacy and Tolerability of Rasagiline (1mg/d) add-on in Ambulatory Parkinson's Disease Patients With Wearing-off Symptoms Diagnosed by Wearing-off Questionnaire (WOQ-32)Parkinson's DiseaseDrug: Azilect®Teva Pharma GmbHAnfomed GmbHNot recruiting18 YearsN/ABoth261N/AGermany
518NCT01883505December 201311 April 2016A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients Receiving ND0612A Phase 2a Multicentre Randomized Double Blind Placebo Controlled Study Followed by an Open Label Period, to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations, Administered With Repeated Continuous Subcutaneous ND0612Parkinson's DiseaseDrug: Levodopa and carbidopa;Drug: PlaceboNeuroDerm Ltd.Not recruiting30 YearsN/ABoth30Phase 2Israel
519NCT01968460December 201316 December 2017Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's DiseaseA Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's DiseaseParkinson's DiseaseDrug: P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),;Drug: Placebo;Drug: P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),Pharma Two B Ltd.Not recruiting35 Years75 YearsAll149Phase 2/Phase 3United States;Israel
520NCT02018406December 20138 April 2019Establishment of Clinical Basis for Hematopoietic Growth Factors Therapy in Brain InjuryNeurological Diseases;Ischemic Stroke;Hemorrhagic Stroke;Cerebral Palsy;Atypical Parkinson DiseaseDrug: Combination injection of EPO and G-CSF;Drug: Injection of normal salineYonsei UniversityNot recruiting20 YearsN/AAll16Phase 1/Phase 2Korea, Republic of
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
521NCT02108704December 20134 November 2019Helicobacter Pylori Eradication Study in Parkinson's DiseaseHelicobacter Pylori Eradication in Parkinson's Disease: A Double-blind Randomised Placebo Controlled TrialParkinson's Disease;Helicobacter Pylori InfectionDrug: Helicobacter pylori eradication therapy;Drug: PlaceboUniversity of MalayaNot recruiting18 YearsN/AAll75N/AMalaysia
522NCT01856738November 201315 October 2018Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s DiseaseCholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson's Disease:a Multi-center Placebo-controlled Trial.Parkinson's DiseaseDrug: Rivastigmine;Drug: Placebo (for rivastigmine)VU University Medical CenterAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);Atrium Medical Center;University Medical Center Groningen;Leiden University Medical Center;University Medical Center Nijmegen;International Parkinson Fonds Germany GmbH;ZonMw: The Netherlands Organisation for Health Research and DevelopmentNot recruiting40 YearsN/AAll91Phase 4Netherlands
523NCT01927055November 201319 October 2017A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa TherapyA Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa TherapySymptomatic Neurogenic Orthostatic Hypotension;Parkinson's Disease;Multiple Systems Atrophy;Pure Autonomic Failure;Dopamine Beta Hydroxylase DeficiencyDrug: Droxidopa;Drug: PlaceboChelsea TherapeuticsNot recruiting18 YearsN/AAll61Phase 3United States
524EUCTR2013-000980-10-AT18/10/20132 October 2017Clinical trial of apomorphine subcutaneous infusion in patients with advanced Parkinson’s diseaseTOLEDO Multicenter, parallel-group, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of apomorphine subcutaneous infusion in Parkinson’s disease patients with motor complications not well controlled on medical treatment - TOLEDOParkinson Disease (PD) in patients with motor fluctuations not well controlled on medical treatment
MedDRA version: 18.0 Level: LLT Classification code 10034006 Term: Parkinson's disease aggravated System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Apo-go®
Product Name: Apomorphine hydrochloride
Product Code: Apo-go®
Pharmaceutical Form: Solution for infusion in pre-filled syringe
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 314-19-2
Other descriptive name: Apomorphine hydrochloride
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Solution for infusion in pre-filled syringe
Route of administration of the placebo: Subcutaneous use		Britannia Pharmaceuticals LimitedNot RecruitingFemale: yes
Male: yes		102Phase 3France;Spain;Denmark;Austria;Netherlands;Germany
525NCT01960842October 201311 June 2018A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian MedicationsAn Open-Label, Single-Arm, Baseline-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian MedicationAdvanced Parkinson's DiseaseDrug: Levodopa-carbidopa intestinal gel;Device: CADD-Legacy® 1400 ambulatory infusion pump;Device: PEG tube;Device: J-tubeAbbVieNot recruiting30 YearsN/AAll31Phase 3Japan;Korea, Republic of;Taiwan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
526NCT01968031October 20139 January 2017A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's DiseaseA Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's DiseaseIdiopathic Parkinson's DiseaseDrug: Istradefylline 40 mg;Drug: Istradefylline 20 mg;Drug: PlaceboKyowa Hakko Kirin Pharma, Inc.Kyowa Hakko Kirin Co., LtdNot recruiting30 YearsN/ABoth613Phase 3United States;Canada;Czech Republic;Germany;Israel;Italy;Poland;Serbia
527NCT01973543October 20138 April 2019Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's DiseaseAn Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Into the Putamen of Subjects With Parkinson's Disease With Fluctuating Responses to LevodopaParkinson's DiseaseBiological: VY-AADC01Neurocrine BiosciencesUniversity of California, San Francisco;Veristat, Inc.;Feinstein Institute for Medical Research;Oregon Health and Science University;Voyager TherapeuticsNot recruiting40 Years70 YearsAll15Phase 1United States
528NCT02012595October 20138 June 2015[11C]Donepezil PET For Imaging The Autonomous Nervous System In Parkinsons Disease[11C]Donepezil PET For Imaging The Autonomous Nervous System In Parkinsons DiseaseParkinson's DiseaseOther: [11C]donepezil PETPer BorghammerLundbeck Foundation;Jascha Fonden;Fonden af 2. Juli 1984 til bekæmpelse af Parkinsons SygdomNot recruiting40 Years80 YearsBoth24N/ADenmark
529NCT02055274October 20132 November 2015Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's DiseaseA Randomized, Double-blinded, Multiple Ascending Dose Study in Patients With Early-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular InjectionsParkinson's DiseaseDrug: LY03003;Drug: NeuproLuye Pharma Group Ltd.Not recruiting18 YearsN/ABoth39Phase 1United States
530NCT02207387October 201313 April 2015Ambulosono Rasagiline Musical Walking StudyA Sensorimotor Contingency-based Musical Walking Program for People Living With Parkinson's DiseaseParkinson's DiseaseDrug: Azilect;Behavioral: Exercise;Other: MusicUniversity of British ColumbiaTeva Pharmaceutical IndustriesRecruiting19 YearsN/ABoth60N/ACanada
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
531EUCTR2013-001881-40-GB16/09/201330 April 2019Extension study to Assess the Benefit and Safety of Administering Intermittent GDNF Infusions in Parkinson's Disease (PD)An Extension Study to Assess the Safety and Efficacy of Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administered via onvection Enhanced Delivery (CED) in Subjects with Parkinson’s Disease - Intermittent Bilateral GDNF for Parkinson’s DiseaseParkinson's disease
MedDRA version: 18.1 Level: LLT Classification code 10034008 Term: Parkinson's syndrome System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Glial Cell Line-Derived Neurotrophic Factor (GDNF)
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: Liatermin
Other descriptive name: r-metHuGDNF
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: range
Concentration number: 9.0-11.0		North Bristol NHS Trust (NBT)Not Recruiting Female: yes
Male: yes		42Phase 2United Kingdom
532NCT01882010September 201330 May 2016Leukine (Sargramostim) for Parkinson's DiseaseLeukine (Sargramostim) for Parkinson's DiseaseParkinson's DiseaseProcedure: blood draw;Procedure: physical exam and UPDRS part III assessment;Procedure: MEG;Drug: sargramostim;Drug: placebo;Behavioral: physical exam and UPDRS part III assessment;Procedure: Motion AnalysisHoward Gendelman, MDSanofi;National Institute of Neurological Disorders and Stroke (NINDS);UNeMed;Nebraska Neuroscience AllianceNot recruiting35 Years85 YearsBoth37Phase 1United States
533NCT01923584September 201326 September 2016A Phase 2A Trial of EPI-743 for Patients With Parkinson's DiseaseA Phase 2A Trial of EPI-743 for Patients With Parkinson's DiseaseParkinson's DiseaseDrug: EPI-743 400mg;Drug: EPI-743 200mgUniversity of South FloridaEdison Pharmaceuticals IncNot recruiting40 Years75 YearsBoth15Phase 2United States
534NCT01955616September 20133 October 2016A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease & Chronic ConstipationA Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Parallel Group Study to Evaluate the Pharmacodynamics, Efficacy and Safety of RM-131 Administered to Patients With Parkinson's Disease and Chronic Constipation Dissatisfied With Current TherapyParkinson's DiseaseDrug: RM-131;Drug: PlaceboMotus Therapeutics, Inc.Michael J. Fox Foundation for Parkinson's ResearchNot recruiting18 Years80 YearsBoth18Phase 2United States
535NCT01929317August 28, 20132 July 2018A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.A Study ROP116991, Clinical Evaluation of 18 to 24mg/Day Ropinirole CR for Parkinson's Disease.Parkinson DiseaseDrug: Ropinirole CR 2mg tablet;Drug: Ropinirole CR 8mg tablet;Drug: Ropinirole CR matching Placebo tabletGlaxoSmithKlineNot recruiting20 YearsN/AAll81Phase 3Japan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
536JPRN-UMIN0000111112013/07/162 April 2019Spinal blood flow and metabolism in neurological diseasesmotor neuron disease including ALS, multiple sclerosis, stroke, Parkinson disease, spinocerebellar degeneration, multiple system atrophyPET scan study with 11C-flumazenil
PET scan study with 18F- FDG
PET scan study with 15O-H2O		Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesRecruiting20years-oldNot applicableMale and Female70Not applicableJapan
537NCT01767129July 201322 January 2018Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease PatientsA Phase 2a, Double-blind, Randomized, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients.Dyskinesia;Parkinson's DiseaseDrug: AVP-923-45;Drug: PlaceboAvanir PharmaceuticalsMichael J. Fox Foundation for Parkinson's ResearchNot recruiting30 Years80 YearsAll14Phase 2United States;Canada
538EUCTR2012-001245-40-IT05/06/201311 April 2016CLINICAL AND PHARMACOLOGICAL STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE AND BIOEQUIVALENCE OF LEVODOPA BENSERAZIDE GENERIC FORMULATION (TEVA ITALIA) VERSUS THE ORIGINATOR (MADOPAR®)CLINICAL AND PHARMACOKINETICS STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE AND BIOEQUIVALENCE OF LEVODOPA BENSERAZIDE GENERIC FORMULATION (TEVA ITALIA) VERSUS THE ORIGINATOR (MADOPAR®)PARKINSON'S DISEASE
MedDRA version: 16.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Madopar 200+50 mg
Pharmaceutical Form: Tablet
Trade Name: LEVODOPA / BENSERAZIDE 200 + 50 MG
Pharmaceutical Form: Tablet		Not RecruitingFemale: yes
Male: yes		Italy
539JPRN-JapicCTI-13218901/6/201323 April 2019A Phase 1 Study of ONO-2160/CDA Phase 1 study on single oral dose administration of ONO-2160/CD in healthy adult male subjects and Parkinson's disease patientsParkinson's diseaseIntervention name : ONO-2160/CD
Dosage And administration of the intervention : Oral administration
Control intervention name : Levodopa/carbidopa hydrate
INN of the control intervention : Levodopa/Carbidopa Hydrate
Dosage And administration of the control intervention : Oral administration		ONO PHARMACEUTICAL CO.,LTD.BOTH42Phase 1
540NCT01850381June 201326 August 2019Phase 2A Study of GM 608 in Mild to Moderate Parkinson DiseaseGM 608 in A Phase IIA Pilot Double-blinded, Randomized, Placebo Controlled Trial in Mild to Moderate Parkinson DiseaseParkinson's DiseaseDrug: GM608;Drug: Placebo ComparatorGenervon Biopharmaceuticals, LLCColumbia UniversityNot recruiting30 YearsN/AAll6Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
541NCT01879748June 201319 February 2015A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of RasagilineA Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses (0.5, 1.0, and 2.0 mg) of Rasagiline Administered to Healthy Japanese and Caucasian SubjectsParkinson's DiseaseDrug: Rasagiline;Drug: PlaceboTeva Pharmaceutical IndustriesNot recruiting20 Years50 YearsBoth64Phase 1United States
542NCT02263235June 201317 May 2016In Vivo Alzheimer ProteomicsUse of Targeted Quantitative Proteomics and Metabolic Labelling With Stable Isotopes for the Diagnosis and the Investigation of Neurological Disorders and in Particular Alzheimer DiseaseProbable Alzheimer Disease;Parkinson Disease;Neurological Disease Without Cognitive Degradation;Brain Trauma;Acute HydrocephalyBiological: administration of stable isotope-labelled leucine-;Other: collection of CSF, blood, urine, salivaUniversity Hospital, MontpellierAssistance Publique - Hôpitaux de Paris;University Hospital, Clermont-Ferrand;International Atomic Energy AgencyRecruiting55 Years85 YearsBoth110N/AFrance
543NCT02275884June 201319 February 2015Pharmacologically Active Constituents of Chocolate and Their Symptomatic Effects in Patients With Idiopathic Parkinson's DiseaseEvaluation of Plasma Concentrations of Pharmacologically Active Constituents of Chocolate and Their Symptomatic Effects in Patients With Idiopathic Parkinson's DiseaseParkinson DiseaseDietary Supplement: Dark chocolate (85% cocoa);Dietary Supplement: White chocolate (0% cocoa)Technische Universität DresdenUniversity of WuerzburgRecruiting40 YearsN/ABoth30N/AGermany
544JPRN-UMIN0000107522013/05/172 April 2019A study on usefulness and safety of donepezil for cognitive function and phychological symptoms of patients with Parkinson's disease and Alzheimer type dementia.Parkinson's diseasedonepezilKansai Medical UniversityNot RecruitingNot applicableNot applicableMale and Female50Not selectedJapan
545EUCTR2013-000827-15-IT11/05/201318 January 2016LATE ONSET PARKINSON’S DISEASE IN SUBJECTS 70 YEARS AND OLDER: POSSIBLE USE OF ROTIGOTINELATE ONSET PARKINSON’S DISEASE IN SUBJECTS 70 YEARS AND OLDER: POSSIBLE USE OF ROTIGOTINE - PARROTParkinson disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Rotigotine
Product Name: neurpro
Product Code: SPM962
Pharmaceutical Form: Transdermal patch
Pharmaceutical form of the placebo: Transdermal patch
Route of administration of the placebo: Transdermal use		Unità Malattie Neurodegenerative, Ospedale Cardinale Giovanni Panico, TricaseNot RecruitingFemale: yes
Male: yes		Italy
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
546JPRN-UMIN0000105962013/05/012 April 2019Randomized crossover trial comparing memantine or amantadine for Parkinson's disease with motor fluctuations in JuntendoParkinson's diseaseMemantine preceding arm
Titrate the memantine, administered for 3 months. And tapering memantine and amantadine titrate the dose for 3 months.

Amantadine preceding arm
Titrate the amantadine, administered for 3 months. And tapering amantadine and memantine titrate the dose for 3 months.		Department of Neurology, Juntendo University School of MedicineNot Recruiting20years-oldNot applicableMale40Not selectedJapan
547NCT01851850May 201319 February 2015Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical TrialContinue Providing Care for Patient Who Participated in the BIA 9-1067-302 Clinical TrialParkinson DiseaseDrug: OpicaponeRabin Medical CenterNot recruiting30 Years80 YearsBoth1Phase 3Israel
548NCT01860794May 201316 December 2017Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's DiseaseInvestigator Clinical Trial for Evaluation of Safety and Tolerability After Transplantation of Fetal Mesencephalic Dopamine Neuronal Precursor Cells in Patients With Parkinson's DiseaseIdiopathic Parkinson Disease;Primary ParkinsonismDrug: Mesencephalic Neuronal Precursor CellsBundang CHA HospitalRecruiting18 Years70 YearsFemale15Phase 1/Phase 2Korea, Republic of
549NCT01877538May 201319 October 2017Study to Investigate the Ability of [11C]Donepezil PET to Image the Parasympathetic Nervous System[11C]Donepezil PET for Imaging the Parasympathetic Nervous System in Healthy AdultsParkinson's DiseaseOther: [11C]donepezil PETPer BorghammerLundbeck FoundationNot recruiting45 Years75 YearsMale7Phase 1Denmark
550NCT02473562May 201315 October 2018Varenicline Treatment for Excessive Daytime Sleepiness in Parkinson's DiseaseVarenicline, a Partial Nicotinic Receptor Agonist for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease: a Placebo-controlled Cross-over Pilot StudyParkinson's DiseaseDrug: Varenicline;Drug: Placebo (for varenicline)VU University Medical CenterCentre for Human Drug Research, NetherlandsNot recruitingN/AN/AAll22Phase 4Netherlands
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
551NCT02500108May 201325 April 2016Domperidone and Risk of Sudden Cardiac DeathDomperidone Use in Parkinson's Disease and Risk of Sudden Cardiac DeathParkinson's DiseaseDrug: DomperidoneCanadian Network for Observational Drug Effect Studies, CNODESDrug Safety and Effectiveness Network, Canada;Canadian Institutes of Health Research (CIHR)Not recruiting50 YearsN/ABoth214962N/ACanada
552NCT03022201May 20131 April 2019Comparing the Therapeutic Efficacy and Safety of DA-9701 With Domperidone in Patients With Parkinson's DiseaseTherapeutic Efficacy of DA-9701 on Gastric Motility in Patients With Parkinson's Disease Evaluated by Magnetic Resonance Imaging: A Randomized Controlled, Double-Blind, Non-Inferiority TrialParkinson's Disease,IdiopathicDrug: DA-9701;Drug: Domperidone;Drug: Placebo domperidone;Drug: Placebo DA-9701Seoul National University HospitalNot recruiting20 Years80 YearsAll40Phase 4Korea, Republic of
553EUCTR2011-002827-17-EE23/04/20136 January 2015A fixed dose, dose response study for ropinirole prolonged release (PR) in patients with early stage Parkinson’s Disease.A fixed dose, dose response study for ropinirole prolonged release (PR) in patients with early stage Parkinson’s Disease.Early stage Parkinson's Disease.
MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: REQUIP-MODUTAB , 2mg
Product Name: ropinirole PR, 2mg
Product Code: SK&F101468
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: ROPINIROLE
CAS Number: 91374-21-9
Current Sponsor code: SK&F101468
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Trade Name: REQUIP-MODUTAB , 4mg
Product Name: ropinirole PR, 2mg
Product Code: SK&F101468
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: ROPINIROLE
CAS Number: 91374-21-9
Current Sponsor code: SK&F101468
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Trade Name: REQUIP-MODUTAB , 8mg
Product Name: ropinirole PR
Product Code: SK&F101468
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: ROPINIROLE
CAS Number: 91374-21-9
Current Sponsor code: SK&F101468
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 8-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use		GlaxoSmithKline Research & Development LimitedNot RecruitingFemale: yes
Male: yes		210United States;Estonia;Slovakia;Russian Federation;Korea, Republic of
554EUCTR2011-002828-41-EE23/04/201310 July 2015A study to test the effectiveness of varying doses of ropinirole PR while taking L-dopa in patients with late stage Parkinson's disease.A fixed dose, dose-response study of ropinirole prolonged release (PR) as adjunctive treatment to L-dopa in patients with advanced Parkinson's disease.Advanced Parkinson's disease.
MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: REQUIP-MODUTAB, 2mg
Product Name: ropinirole PR, 2mg
Product Code: SK&F101468
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: ROPINIROLE
CAS Number: 91374-21-9
Current Sponsor code: SK&F101468
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Trade Name: REQUIP-MODUTAB, 4mg
Product Name: ropinirole PR, 2mg
Product Code: SK&F101468
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: ROPINIROLE
CAS Number: 91374-21-9
Current Sponsor code: SK&F101468
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use
Trade Name: REQUIP-MODUTAB, 8mg
Product Name: ropinirole PR
Product Code: SK&F101468
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: ROPINIROLE
CAS Number: 91374-21-9
Current Sponsor code: SK&F101468
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 8-
Pharmaceutical form of the placebo: Prolonged-release tablet
Route of administration of the placebo: Oral use		GlaxoSmithKline Research & Development LimitedNot RecruitingFemale: yes
Male: yes		406United States;Taiwan;Estonia;Slovakia;Argentina;Chile;Russian Federation;Korea, Republic of
555JPRN-UMIN0000107782013/04/102 April 2019Delayed start study of donepezil hydrocloride for cognitive decline in Parkinson disease following EDAP-1Parkinson disease5mg donepezil hydroclorideNational Hospital of UtanoNot Recruiting20years-oldNot applicableMale and Female50Not selectedJapan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
556JPRN-UMIN0000103712013/04/082 April 2019Study of zonisamide ( TRERIEF&reg; tablet 25mg ) to tremor in patients with early Parkinson's disease.Parkinson's diseaseStart 25mg of Zonisamide and carry out observation 24weeks.
Evaluate start point, after 4weeks, after 8weeks, after 16weeks, and after 24weeks.		Department of Neurology, University of YamanashiNot RecruitingNot applicableNot applicableMale and Female10Not selectedJapan
557NCT01777555April 201320 August 2018Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF EpisodesA Phase 2b, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Inhaled CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)Idiopathic Parkinson's DiseaseDrug: CVT-301;Drug: PlaceboAcorda TherapeuticsNot recruiting30 Years80 YearsAll89Phase 2United States;Italy;Serbia;United Kingdom
558NCT01829867April 20138 February 2016A Study With an Increased Dose Step in Patients That Have Previously Received Placebo or sNN0031.A Phase I, Open-label Study in Patients With Parkinson's Disease to Further Assess Safety and Tolerability of sNN0031 Administered at the Total Dose of 95 µg by Intracerebroventricular InfusionParkinson's DiseaseDrug: sNN0031Newron Sweden ABNot recruiting55 Years75 YearsBoth5Phase 1Sweden
559NCT02005029April 201319 October 2017Erythromycin in Parkinson's DiseaseErythromycin in Parkinson's Disease: A Pilot Study of Its Effects on Levodopa Pharmacokinetics and PharmacodynamicsParkinson's Disease;LevodopaDrug: Erythromycin;Drug: placeboVirginia Commonwealth UniversityNot recruiting18 Years80 YearsAll18N/AUnited States
560JPRN-UMIN0000099582013/03/082 April 2019Effects of donepezil on the prognosis of Parkinson's disease with severe olfactory dysfunctionParkinson's diseaseDonepezil hydrochloride added to standard therapy
Placebo added to standard therapy		National Hospital Organization, Sendai-Nishitaga HospitalNot Recruiting55years-old75years-oldMale and Female200Not applicableJapan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
561EUCTR2012-002840-26-AT05/03/201331 March 2014Study to test the efficacy of two doses of Rotigotine on depressive mood (apathy) associated with Parkinson's DiseaseA Multicenter, Multinational, Double-blind, Placebo-controlled, 3-arm Phase 4 Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease- Associated Apathy, Motor Symptoms, and MoodParkinson's disease
MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Neupro
Product Name: Rotigotine
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: ROTIGOTINE
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4.5-
Pharmaceutical form of the placebo: Transdermal patch
Route of administration of the placebo: Transdermal use
Trade Name: Neupro
Product Name: Rotigotine
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: ROTIGOTINE
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 9-
Trade Name: Neupro
Product Name: Rotigotine
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: ROTIGOTINE
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 13.5-
Trade Name: Neupro
Product Name: Rotigotine
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: ROTIGOTINE
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 18-		UCB Biosciences GmbHNot RecruitingFemale: yes
Male: yes		504Phase 4United States;Serbia;Slovakia;Slovenia;Spain;Ukraine;Turkey;Austria;Italy;Hungary;Poland;Croatia;Romania;Bulgaria
562NCT01736176March 201319 October 2017A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's DiseaseAn Open-Label, Two Part, Multicenter Study to Assess the Safety and Efficacy of Levodopa-Carbidopa Intestinal Gel (LCIG) for the Treatment of Non-Motor Symptoms in Subjects With Advanced Parkinson's DiseaseAdvanced Parkinson's DiseaseDrug: Levodopa-Carbidopa Intestinal Gel;Procedure: Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J);Drug: Levodopa-carbidopa Immediate Release (LC-IR) TabletsAbbVie (prior sponsor, Abbott)Not recruiting30 YearsN/AAll39Phase 3United States
563NCT01789047March 201314 November 2016Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's DiseaseTopiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's DiseaseIdiopathic Parkinson's Disease;Drug Induced DyskinesiaDrug: Topiramate;Drug: PlaceboRush University Medical CenterMichael J. Fox Foundation for Parkinson's ResearchNot recruiting30 Years90 YearsBoth44Phase 2United States
564JPRN-UMIN0000100142013/02/282 April 2019Randomized Double-blind, Placebo-controlled multi-center trial on molecular hydrogen water in Parkinson DiseaseParkinson's disesasehydrogen water made by "Suisosui5.0"
placebo-water (nitrogen filling water)		Juntendo University School of Medicine, NeurologyNot Recruiting20years-oldNot applicableMale and Female200Not selectedJapan
565EUCTR2012-000801-64-GB09/02/201319 November 2018A study of the effects of medication on memory in Parkinson's DiseaseA Phase IV Acceptability and Feasibility Trial of the Effects of Medication on Memory in Idiopathic Nondementing Parkinson’s Disease. - Medication and Memory in Parkinson’s Disease (MeMory PaD)Idiopathic Parkinson's Disease
MedDRA version: 17.0 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Mirapexin extended release various strengths
Product Name: Pramipexole dihydrochloride monohydrate extended release
Product Code: N/A
Pharmaceutical Form: Modified-release tablet
INN or Proposed INN: pramipexole dihydrochloride monohydrate
CAS Number: 104632-26-0
Current Sponsor code: not available
Other descriptive name: Mirapexin
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: 3.15-
Trade Name: Requip prolonged release
Product Name: Ropinirole hydrochloride prolonged release
Pharmaceutical Form: Modified-release tablet
INN or Proposed INN: Ropinirole (as hydrochloride)
CAS Number: 91374-21-9
Current Sponsor code: not available
Other descriptive name: Requip XL prolonged-release
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: 24-		University Hospital of North StaffordshireKeele UniversityNot RecruitingFemale: yes
Male: yes		55Phase 4United Kingdom
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
566NCT01766128February 201319 February 2015Study of Zonisamide in Early Parkinson DiseaseRandomized Double Blind Placebo-controlled Study of Zonisamide Effectiveness in Early Parkinson DiseaseParkinson DiseaseDrug: ZonisamideMazandaran University of Medical SciencesNot recruiting45 Years85 YearsBoth60Phase 2/Phase 3
567NCT01789385February 201319 February 2015Anesthesia for Deep Brain StimulationAnesthesia for Deep Brain Stimulation for the Treatment of Parkinsons DiseaseParkinsons DiseaseDrug: DexmedetomidineDiskapi Teaching and Research HospitalNot recruiting19 Years85 YearsBoth26Phase 4Turkey
568NCT02059733February 20139 October 2018Developing a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and ParkinsonismDeveloping a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and Parkinsonism by 18F-DTBZ PETParkinson's DiseaseDrug: 18F-DTBZChang Gung Memorial HospitalNot recruiting20 Years80 YearsAll72Phase 2Taiwan
569EUCTR2012-002608-42-DE10/01/201326 August 2013A study to evaluate the efficacy of Rotigotine (the treatment) versus placebo in patients with pain associated with Parkinson's DiseaseA Multicenter, Multinational, Double-blind, Placebo-controlled, 2-arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated PainParkinson’s disease
MedDRA version: 16.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Neupro
Product Name: Rotigotine
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: ROTIGOTINE
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 9-
Pharmaceutical form of the placebo: Transdermal patch
Route of administration of the placebo: Transdermal use
Trade Name: Neupro
Product Name: Rotigotine
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: ROTIGOTINE
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 13.5-
Trade Name: Neupro
Product Name: Rotigotine
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: ROTIGOTINE
CAS Number: 99755-59-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 18-		UCB Biosciences GmbHNot RecruitingFemale: yes
Male: yes		64United States;Hungary;Slovakia;Poland;Germany;United Kingdom
570JPRN-UMIN0000176952013/01/012 April 2019Oxybuprocaine for apraxia of lid opening in Parkinson's diseaseapraxia of lid opening in Parkinson's diseaseArm 1 intervention consisted of 4%oxybuprocaine eye drop treatment, washout for 24 hours or more, and a saline eye drop treatment
Arm 2 intervention consisted of saline eye drop treatment, a washout period, and an oxybuprocaine treatment		Utano National Hospital, National Hospital OrganizationNot RecruitingNot applicableNot applicableMale and Female10Not selectedJapan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
571NCT01500707January 201319 February 2015Single Dose Study to Assess the Pharmacokinetics of SCH 900800 in Subjects With Parkinson's Disease Being Treated With Levodopa (L-DOPA) (P08235)A Single Dose Study to Assess the Pharmacokinetics of SCH 900800 Administered as Oral Tablets in L-DOPA-treated Subjects With Parkinson's DiseaseParkinson's DiseaseDrug: SCH 900800Merck Sharp & Dohme Corp.Not recruiting30 Years85 YearsBoth0Phase 1
572NCT01803945January 201312 October 2015A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's DiseaseA Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: AVE8112;Drug: PlaceboMichael J. Fox Foundation for Parkinson's ResearchSanofiNot recruiting35 Years70 YearsBoth32Phase 1United States
573NCT02100176January 201319 February 2015MIRT and Rotigotine in the Early Stage of PDMultidisciplinary Intensive Rehabilitation Treatment and Rotigotine in the Early Stages of Parkinson's Disease: a Randomized Controlled Study.Parkinson's DiseaseOther: Multidisciplinary intensive rehabilitation treatment;Drug: RotigotineOspedale Generale Di Zona Moriggia-PelasciniRecruiting50 Years75 YearsBoth40N/AItaly
574NCT03651856January 201310 September 2018Atomoxetine for Freezing of Gait in Parkinson's DiseaseA Pilot Study of Atomoxetine for Freezing of Gait in Parkinson's DiseaseParkinson's Disease;Freezing of GaitDrug: ATM FOG in PDMedical University of South CarolinaNot recruiting18 Years80 YearsAll10Phase 3United States
575NCT01725802December 201211 April 2016A Phase I/IIa Study of Safety, Tolerability and Plasma Concentration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in PD PatientsA Phase I/IIa, Single Dose, Single-centre, Randomized, Crossover, Double-blind, Placebo-controlled Study Evaluating Safety, Tolerability and Levodopa Plasma Concentration Following Administration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in PD PatientsParkinson's DiseaseDrug: levodopa and carbidopa solution for SC administration;Drug: PlaceboNeuroDerm Ltd.Not recruiting30 YearsN/ABoth8Phase 1/Phase 2Israel
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
576NCT01741701December 201219 October 2017A Pilot Study of Oxaloacetate in Subjects With Treated PDA Pilot Double-Blind, Parallel Group, Placebo Controlled Study of Oxaloacetate in Subjects With Treated Parkinson's Disease (PD)Parkinson's DiseaseDrug: Oxaloacetate (OAA);Drug: PlaceboUniversity of Kansas Medical CenterTerra Biological LLCNot recruiting30 YearsN/AAll33Phase 2/Phase 3United States
577NCT01770145December 201216 December 2017Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa ActionParkinson's Disease;Motor Symptoms;Akinesia;Hypomobility;Delayed Levodopa OnsetDrug: APOKYN;Drug: L-dopa;Drug: TrimethobenzamideUS WorldMeds LLCNot recruiting18 YearsN/AAll127Phase 4United States
578NCT02112812December 201219 February 2015Effects of Helicobacter Pylori Infection Eradication in Patients With Parkinson's DiseaseA Study on Clinical Response Following Eradication Therapy of Helicobacter Pylori Infection in Parkinson's DiseaseResponse to Levodopa;Motor Outcomes;Quality of Life OutcomesDrug: Eradication therapy for H.pylori infection;Drug: Eradication of Helcobacter Pylori;Drug: Eradication therapy for Helicobacter pyloriNational University of MalaysiaNot recruiting17 YearsN/ABoth82N/AMalaysia
579NCT01683253November 201211 June 2018Remission of ICD by Switching Dopamine Agonist to Levodopa/CarbidopaThe REmission of the Impulse Control Disorder and the Changes of the Neuropsychiatric Characteristics After Switching Into Levodopa/Carbidopa in Patients With Parkinson's Disease Who Have Developed Impulse Control Disorders Due to the Dopamine Replacement TherapyImpulse Control DisorderDrug: Levodopa/Carbidopa(200mg/50mg);Drug: Dopaminergic AgonistsSandozNot recruiting30 Years80 YearsAll150Phase 4
580NCT01721460November 201216 December 2017Effects of Dexmedetomidine on Activity in the Subthalamic NucleusEffects of Dexmedetomidine on Neuronal Activity in the Subthalamic Nucleus During Deep Brain Stimulation (DBS) Electrode Implantation SurgeryParkinson's Disease;Deep Brain Stimulation SurgeryDrug: DexmedetomidineUniversity of Wisconsin, MadisonNot recruiting18 Years85 YearsAll6Phase 4United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
581NCT01723228November 201219 October 2017Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's DiseaseA 24-Week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Add-on, Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: Rasagiline;Drug: PlaceboTeva Branded Pharmaceutical Products, R&D Inc.Not recruiting45 Years80 YearsAll170Phase 4United States
582NCT01738191November 201211 April 2016Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)Parkinson's Disease;Cognitive ImpairmentDrug: Atomoxetine;Drug: PlaceboMedical University of South CarolinaMichael J. Fox Foundation for Parkinson's ResearchNot recruiting35 Years75 YearsBoth30Phase 2United States
583NCT03652363October 25, 20123 September 2018GDNF in ideopathicParkinsons DiseaseA Placebo-Controlled, Randomised, Double-Blind Trial to Assess the Safety and Efficacy of Intermittent Bilateral Intraputamenal (GDNF) Infusions Administered Via Convection Enhanced Delivery (CED) in Subjects With Parkinson&Apos;s DiseaseIdiopathic Parkinson DiseaseDrug: glial cell line-derived neurotrophic factorNorth Bristol NHS TrustNot recruiting35 Years75 YearsAll42Phase 2
584JPRN-UMIN0000090992012/10/012 April 2019The effect of lidocaine injection into the external oblique in Parkinson's disease patients with upper camptorcormiaParkinson's diseaselidocaine injection into the external oblique
normal saline injection into the external oblique		Parkinson's disease and Movement Disorder CenterRecruiting20years-oldNot applicableMale and Female10Not applicableJapan
585NCT01560754October 201212 October 2015Disease-modifying Potential of Transdermal NICotine in Early Parkinson's DiseaseA Randomized, Placebo-controlled, Double-blind, Multi-center Trial to Assess the Disease-modifying Potential of Transdermal Nicotine in Early Parkinson's Disease in Germany and the USAParkinson's DiseaseDrug: nicotine transdermal patchJames BOYD MDMichael J. Fox Foundation for Parkinson's Research;Parkinson Study Group (PSG);International Parkinson Fonds (IPF);German Parkinson Study Group (GPS);German Parkinson Society (DPG);Philipps-University Marburg, GermanyNot recruiting30 YearsN/ABoth160Phase 2United States;Germany
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
586NCT01563913October 201211 July 2016Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty AcidsReducing Dyskinesia in Parkinson Disease With Omega-3 Fatty AcidsParkinson's DiseaseDrug: Docosahexaenoic Acid (DHA);Drug: PlaceboVA Office of Research and DevelopmentOregon Health and Science University;Oregon Health and Science UniversityNot recruiting21 Years99 YearsBoth40Phase 1United States
587NCT01603069October 201219 February 2015A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's DiseaseA Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: AZD3241 300 mg BID;Drug: AZD3241 600 mg BID;Drug: PlaceboAstraZenecaNot recruiting30 Years80 YearsBoth51Phase 2United States
588NCT01691924October 201211 April 2016Study To Assess the Safety and Tolerability of PBF-509 in Male Healthy VolunteersRandomized, Double Blind, Placebo Controlled First In-human Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-509 in Male Healthy VolunteersParkinson DiseaseDrug: PBF-509;Drug: PlaceboFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauPalo Biofarma, S.LNot recruiting18 Years45 YearsMale56Phase 1Spain
589NCT01723904October 201219 October 2017A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's DiseaseAn Open-Label Study to Investigate the Safety and Efficacy of Rotigotine Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease Phase 3BAdvanced Parkinson's DiseaseDrug: RotigotineUCB BIOSCIENCES GmbHOtsuka Pharmaceutical Co., Ltd.Not recruiting30 Years80 YearsAll90Phase 3Australia;Korea, Republic of;Malaysia;Singapore;Taiwan
590NCT01796483October 20123 June 2019EEG and Pharmacological Exploration of Executive Dysfunctions Induced by STN-DBS in PDExploration électroencéphalographie et Pharmacologique Des Dysfonctionnements exécutifs Induits Par la Stimulation cérébrale Profonde du Noyau Sous-thalamique Dans la Maladie de ParkinsonParkinson DiseaseDevice: Clonidine (Catapressan);Device: Placebo 90 minutes before EEGHospices Civils de LyonNot recruiting40 Years70 YearsAll37N/AFrance
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
591EUCTR2011-003866-34-GB24/09/201216 November 2015Assessing the Benefit and Safety of Administering Intermittent GDNF Infusions in Parkinson's Disease (PD)A Placebo-Controlled, Randomised, Double-Blind Trial to Assess the Safety and Efficacy of Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administered via Convection Enhanced Delivery (CED) in Subjects with Parkinson’s Disease - Intermittent Bilateral GDNF for Parkinson’s DiseaseParkinson's disease
MedDRA version: 18.1 Level: LLT Classification code 10034008 Term: Parkinson's syndrome System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Glial Cell Line-Derived Neurotrophic Factor (GDNF)
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: Liatermin
Other descriptive name: r-metHuGDNF
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: range
Concentration number: 9.0-11.0
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intracerebral use		North Bristol NHS Trust (NBT)AuthorisedFemale: yes
Male: yes		United Kingdom
592ChiCTR-OCS-120027202012-09-0118 April 2017Pharmacogenetics study of anti-parkinson's disease drug levodopaThe association between polymorphisms of DRD2, DRD2, SLC6A3 and the levodopa responseParkinson's DiseaseA:levodopa;Institute of Clinical Pharmacology, Central South UniversityNot Recruiting3872BothA:200;Post-market
593NCT01662791September 201219 October 2017Weight Loss in Parkinson's Disease and Role of Small Bowel Bacterial OvergrowthWeight Loss in Parkinson's Disease and the Potential Role of Small Bowel Bacterial OvergrowthParkinson's DiseaseDrug: RifaximinMayo ClinicNot recruiting18 YearsN/AAll49Phase 3United States
594NCT01676103September 201219 February 2015The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's DiseaseThe Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's DiseaseParkinson's DiseaseDietary Supplement: Tyrosine;Other: Placebo Comparator:Sugar PillNew York Institute of TechnologyMichael J. Fox Foundation for Parkinson's ResearchNot recruiting50 Years80 YearsBoth40Phase 1/Phase 2United States
595NCT01684475September 201219 February 2015A STUDY TO EVALUATE THE EFFICACY OF CJH1 (CLR4001) IN PARKINSON'S DISEASEA STUDY TO EVALUATE THE EFFICACY OF CJH1 [CLR4001] IN THE TREATMENT OF PARKINSON'S DISEASEParkinson's DiseaseDrug: CJH1 (CLR4001)Alexandra Marine and General HospitalRecruiting40 Years85 YearsBoth21Phase 1/Phase 2Canada
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
596NCT01711866September 201219 October 2017A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's DiseaseAn Open-Label, Multicenter, Multinational Study to Assess the Feasibility of Switching Therapy From Pramipexole or Ropinirole to the Rotigotine Transdermal System and Its Effect on Motor and Non-Motor Symptoms in Subjects With Advanced Idiopathic Parkinson's Disease Phase 4Advanced Idiopathic Parkinson's DiseaseDrug: RotigotineUCB BIOSCIENCES GmbHOtsuka Pharmaceutical Co., Ltd.Not recruiting30 Years80 YearsAll87Phase 4United States;Korea, Republic of;Malaysia;Singapore;Taiwan
597EUCTR2012-000122-21-DK10/08/201219 March 2018Improving the blood pressure regulating system in patients with parkinsons diseaseAcethylcholineesterase inhibition and orthostatic hypotension in patients with parkinsons diseaseOrtostatic hypotension in patients with Parkinsons disease
MedDRA version: 14.1 Level: PT Classification code 10031127 Term: Orthostatic hypotension System Organ Class: 10047065 - Vascular disorders ;Therapeutic area: Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09]		Trade Name: Mestinon
Product Name: Mestinon
Pharmaceutical Form: Capsule
INN or Proposed INN: PYRIDOSTIGMINE BROMIDE
CAS Number: 101-26-8
Current Sponsor code: SJ-193
Other descriptive name: Mestinon
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: 60-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use		Department of Neurology, Roskilde HospitalNot RecruitingFemale: yes
Male: yes		20Phase 2Denmark
598EUCTR2012-001530-34-NL09/08/201226 March 2018Vareniciline treatment for Excessive Daytime Sleepiness in Parkinson’s DiseaseVarenicline, a partial nicotinic receptor agonist for the treatment of Excessive Daytime Sleepiness in Parkinson’s Disease: a placebo-controlled cross-over study - Vareniciline for Excessive daytime Sleepiness in PArkinson’s disease (VESPA)Idiopathic Parkinson's disease
MedDRA version: 18.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Champix
Pharmaceutical Form: Coated tablet
INN or Proposed INN: VARENICLINE
CAS Number: 375815-87-5
Other descriptive name: VARENICLINE TARTRATE
Concentration unit: mg milligram(s)
Concentration type: range
Concentration number: 0.5-3
Pharmaceutical form of the placebo: Coated tablet
Route of administration of the placebo: Oral use		VU University Medical CenterCenter Human Drug ResearchNot RecruitingFemale: yes
Male: yes		32Phase 3Netherlands
599NCT00947037August 20127 December 2015Gastric Retentive Carbidopa/ Levodopa in Parkinson's Patients; a One Year, Open Label, Safety Extension StudyAn Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease SubjectsParkinson's DiseaseDrug: AP-CD/LDIntec Pharma Ltd.Not recruiting30 Years95 YearsBoth0Phase 2Israel
600NCT02419313August 201219 October 2017Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized ApproachInvestigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Disease Tremor: A Customized ApproachParkinson;TremorDrug: incobotulinumtoxinA;Drug: SalineYale UniversityNot recruiting18 YearsN/AAll33Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
601NCT02764892August 201217 May 2016A Study in Healthy Male Volunteers to Investigate a New Drug for the Treatment of Parkinson's DiseaseAn Open Label Study of V81444 Using Positron Emission Tomography to Assess Occupancy of Brain Adenosine A2A Receptors & Functional & Perfusion MRI to Explore Effects on Regional Brain Activity & Perfusion in Healthy Male VolunteersParkinson's DiseaseDrug: V81444Vernalis (R&D) LtdNot recruiting25 Years55 YearsMale6Phase 1
602JPRN-UMIN0000084772012/07/192 April 2019Clinical study of selegiline hydrochloride ( FP OD tablet 2.5) to flexion of spine in Parkinson's disease.Parkinson diseaseSelegiline hydrochloride 5mg 8weeks, 7.5mg 8weeks and stop it, followed after 8weeks, and evaluate each points.Department of Neurology, Juntendo Koshigaya HospitalNot Recruiting20years-oldNot applicableMale and Female20Not selectedJapan
603JPRN-UMIN0000081382012/07/012 April 2019Efficacy and safety of silodosin on lower urinary tract symptoms (LUTS) in patients with Parkinson's diseaseParkinson's diseaseSilodosin 8mg BIDJuntendo University School of MedicineNot RecruitingNot applicableNot applicableMale100Not selectedJapan
604NCT01398748July 201216 December 2017Intranasal Glutathione in Parkinson's DiseaseA Phase 1 Study of Intranasal Reduced Glutathione in Parkinson's DiseaseParkinson's Disease (PD)Drug: Intranasal glutathione - (in)GSH;Drug: Saline Intranasal DeliveryBastyr UniversityNational Center for Complementary and Integrative Health (NCCIH)Not recruiting21 Years100 YearsAll34Phase 1United States
605NCT01491022July 201216 December 2017A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's DiseaseA Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's DiseaseParkinson's DiseaseDrug: Ampyra first, then Placebo;Drug: placebo first, then AmpyraUniversity of MiamiAcorda TherapeuticsNot recruiting45 Years80 YearsAll22Phase 1/Phase 2United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
606NCT01602549July 201219 October 2017A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric EmptyingA Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric EmptyingGastroparesisDrug: GSK962040 (25 mg tablet);Drug: PlaceboGlaxoSmithKlineNot recruiting40 Years80 YearsAll58Phase 2Australia;Germany;Sweden;United Kingdom
607NCT01646255July 201211 June 2018Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease PatientsA Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of The Efficacy And Safety of Rotigotine Transdermal Patch In Chinese Subjects With Advanced-stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled On LevodopaIdiopathic Parkinson's DiseaseDrug: Rotigotine;Drug: Placebo Patch;Drug: L-dopaUCB PharmaUCB Trading (Shanghai) Co. Ltd.Not recruiting30 YearsN/AAll346Phase 3China
608NCT01646268July 201219 October 2017Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease PatientsA Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Of The Efficacy And Safety Of The Rotigotine Transdermal Patch In Chinese Subjects With Early-stage Idiopathic Parkinson's DiseaseIDIOPATHIC PARKINSON'S DISEASEDrug: Rotigotine;Drug: Placebo PatchUCB PharmaNot recruiting30 YearsN/AAll249Phase 3China
609JPRN-JapicCTI-12188011/6/20122 April 2019Phase II clinical study in patients with Parkinson's disease not taking L-DOPAA randomized, double-blind, placebo-controlled, comparative study of HP-3000 in patients with Parkinson's disease not taking L-DOPAParkinson's diseaseIntervention name : HP-3000(ropinirole hydrochloride patch)
Dosage And administration of the intervention : Transdermal, once daily
Control intervention name : HP-3000 placebo
Dosage And administration of the control intervention : Transdermal, once daily		Hisamitsu Pharmaceutical Co.,Inc.2079BOTHPhase 2
610JPRN-JapicCTI-12187907/6/20122 April 2019Phase II clinical study in patients with Parkinson's disease taking L-DOPAA randomized, double-blind, placebo-controlled, comparative study of HP-3000 in patients with Parkinson's disease taking L-DOPAParkinson's diseaseIntervention name : HP-3000(ropinirole hydrochloride patch)
Dosage And administration of the intervention : Transdermal, once daily
Control intervention name : HP-3000 placebo
Dosage And administration of the control intervention : Transdermal, once daily		Hisamitsu Pharmaceutical Co.,Inc.2079BOTHPhase 2
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
611NCT01892176June 201219 February 2015Effects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson DiseaseEffects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson DiseaseParkinson DiseaseDietary Supplement: coenzyme q10National University Hospital, SingaporeNot recruiting21 MonthsN/ABoth20Phase 2/Phase 3Singapore
612NCT01993680June 201212 October 2015Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -TreatmentA Monocentric Randomized, Controlled, Double Blind, Crossover Phase II Trial to Show Non-inferiority of the Effect of Pyridostigmine Bromide vs. Fludrocortisone on Symptoms of Autonomic Dysregulation in Parkinson`s DiseaseAutonomic Disturbances in Parkinson`s DiseaseDrug: Pyridostigmine bromide;Drug: fludrocortisoneUniversity of ZurichNot recruiting50 Years80 YearsBoth18Phase 2Switzerland
613NCT02786667June 201216 December 2017Non Motors Aspects in De Novo Parkinson's DiseaseNon Motors Aspects in De Novo Parkinson's Disease: Clinical and Physiopathological Description; Dopamine Agonist Treatment Effects.Parkinson Disease;ApathyDrug: Rotigotine;Drug: PlaceboUniversity Hospital, GrenobleNot recruiting30 Years72 YearsAll199Phase 3France
614EUCTR2012-001218-40-IT21/05/201231 July 2012EFFICACY OF ROTIGOTINE ON GAIT PERFORMANCE OF PARKINSONIAN PATIENTSEFFICACY OF ROTIGOTINE ON GAIT PERFORMANCE OF PARKINSONIAN PATIENTSPatients suffering for Idiopathic Parkinson’s Disease. H&Y stage > or = 2 with un-satisfactory control by on-going pharmacological therapy (Levodopa, COMT & MAO-inhibitors), characterised by an incomplete control of motor signs, in particular presence of early morning akinesia, as well as gait deficits in the morning.
MedDRA version: 14.1 Level: PT Classification code 10056242 Term: Parkinsonian gait System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: NEUPRO*7CER 4MG/24H
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: rotigotina
CAS Number: 92206-54-7
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: 9-
Trade Name: NEUPRO*7CER 6MG/24H
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: rotigotina
CAS Number: 92206-54-7
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: 13.5-
Trade Name: NEUPRO*7CER 8MG/24H
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: rotigotina
CAS Number: 92206-54-7
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: 18-
Trade Name: NEUPRO*28CER 2MG/24H
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: rotigotina
CAS Number: 92206-54-7
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: 4.5-
Trade Name: NEUPRO*28CER 4MG/24H
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: rotigotina
CAS Number: 92206-54-7
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: 9-
Trade Name: NEUPRO*28CER 6MG/24H
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: rotigotina
CAS Number: 92206-54-7
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: 13.5-
Trade Name: NEUPRO*28CER 8MG/24H
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: rotigotina
CAS Number: 92206-54-7
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: 18-		FONDAZIONE SANTA LUCIAAuthorisedFemale: yes
Male: yes		Italy
615JPRN-UMIN0000078962012/05/012 April 2019Levodopa challenge test for Parkinson's disease and other parkinsonian syndromesParkinson's disease and other parkinsonian syndromesThe patients are given domperidone 30 mg/day for 3 days. When a patient is already on any anti-parkinson drugs, these drugs were withdrawn from the night before of the evaluation day. On the fourth day lactose powder is given to the patients and levodopa (250 mg)/carbidopa (25 mg) is given on the fifth day in a double-blind manner. On fourth and fifth day, motor symptoms of the patients are examined using the Unified Parkinson's Disease Rating Scale motor scores by a clinician who is blind to the test drug.
The patients are given domperidone 30 mg/day (standard dose in Japan) for 3 days. When a patient is already on any anti-parkinson drugs, these drugs were withdrawn from the night before of the evaluation day. On the fourth day levodopa (250 mg)/carbidopa (25 mg) is given to the patients and lactose powder is given on the fifth day in a double-blind manner. Motor symptoms of the patients are examined using the Unified Parkinson's Disease Rating Scale motor scores by a clinician who is blind to the test drug.		Kansai Medical UniversityRecruitingNot applicableNot applicableMale and Female100Not selectedJapan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
616NCT01652313May 201219 February 2015Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and WomenA Single Centre, Open-label, Multiple-dose Interventional Study Investigating the Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and WomenParkinson's DiseaseDrug: RasagilineH. Lundbeck A/SNot recruiting18 Years45 YearsBoth12Phase 1China
617EUCTR2011-004438-32-GB25/04/201228 February 2019The effect of repeat doses of GSK962040 on the pharmacokinetics of L-DOPA in subjects with Parkinson’s disease with slow gastric emptyingA randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the effect of repeat doses of GSK962040 on the pharmacokinetics of levodopa in subjects with Parkinson’s disease exhibiting delayed gastric emptying - GSK962040 Parkinson's disease PoCInvestigate the ability of the motilin receptor agonist GSK962040 to improve levodopa pharmacokinetics (PK) by enhancing GE via motilin receptor agonism.
MedDRA version: 20.1 Level: PT Classification code 10051153 Term: Diabetic gastroparesis System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: GSK962040
Product Code: GSK962040
Pharmaceutical Form: Tablet
INN or Proposed INN: GSK962040
CAS Number: 923565-21-3
Current Sponsor code: GSK962040
Other descriptive name: GSK962040
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: GSK962040
Product Code: GSK962040
Pharmaceutical Form: Tablet
INN or Proposed INN: GSK962040
CAS Number: 923565-21-3
Current Sponsor code: GSK962040
Other descriptive name: GSK962040
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: GSK962040
Product Code: GSK962040
Pharmaceutical Form: Tablet
INN or Proposed INN: GSK962040
CAS Number: 923565-21-3
Current Sponsor code: GSK962040
Other descriptive name: GSK962040
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 125-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use		GlaxoSmithKline Research and Development LimitedNot Recruiting Female: yes
Male: yes		70Phase 2Germany;United Kingdom;Sweden
618EUCTR2012-000181-37-GB25/04/201221 January 2013A study investigating the safety of CVT-301 in patients with Parkinson's DiseaseA Randomized, Placebo-Controlled Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CVT-301 (Levodopa Inhalation Powder) in Patients with Parkinson’s Disease and Motor Response Fluctuations (“Off” Episodes)Parkinson's Disease
MedDRA version: 14.1 Level: LLT Classification code 10034007 Term: Parkinson's disease NOS System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: CVT-301
Product Code: CVT-301
Pharmaceutical Form: Inhalation powder, hard capsule
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Current Sponsor code: CVT-301
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 12.5-
Pharmaceutical form of the placebo: Inhalation powder, hard capsule
Route of administration of the placebo: Inhalation use
Trade Name: Sinemet®
Product Name: SINEMET® Plus 25 mg/100 mg Tablets
Pharmaceutical Form: Tablet
INN or Proposed INN: LEVODOPA
CAS Number: 59-92-7
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
CAS Number: 38821-49-7
Other descriptive name: CARBIDOPA MONOHYDRATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-		Civitas Therapeutics, Inc.Not RecruitingFemale: yes
Male: yes		24Phase 2Serbia;Israel;United Kingdom
619EUCTR2011-005839-91-ES02/04/201229 January 2018Gabapentin in the disorder of the impulse control in the Parkinson´s Disease: multicentric study, double-blind, randomized, controlled with placebo.Gabapentin int he disorder of the impulse control in the Parkinson´s Disease: multicentric study, double-blind, randomized, controlled with placebo. - IMULPARKPARKINSON´S DISEASE
MedDRA version: 14.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: GABAPENTINA KERN PHARMA
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: GABAPENTINA
CAS Number: 60142-96-3
Other descriptive name: GABAPENTIN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 400-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use		ASOCIACIÓN INSTITUTO BIODONOSTIANot RecruitingFemale: yes
Male: yes		100Phase 2Spain
620NCT01494532April 2, 20122 July 2018A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's DiseaseA Fixed Dose, Dose-response Study of Ropinirole Prolonged Release (PR) as Adjunctive Treatment to L-dopa in Patients With Advanced Parkinson's DiseaseParkinson DiseaseDrug: ropinirole/L-dopa;Drug: placebo/L-dopaGlaxoSmithKlineNot recruiting30 YearsN/AAll352Phase 4United States;Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Poland
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
621ChiCTR-TTRCC-120027512012-04-0118 April 2017Clinical pharmacology study of anti-parkinson's drug pramipexoleA rondomised clinical trial of the potential drug-drug interaction between pramipexole and metforminParkinson's diseaseA:Given pramipexole only;B:Given pramipexole and metformin simultaneously ;Institute of Clinical Pharmacology, Central South UniversityNot Recruiting1926MaleA:18;B:18;Phase 1 studyChina
622JPRN-JapicCTI-12200001/4/20122 April 2019Long-term study of FPF1100NW monotherapyLong-term study on FPF1100NW monotherapy with early Parkinson's disease patientsEarly Parkinson's diseaseIntervention name : FPF1100NW
INN of the intervention : Selegiline
Dosage And administration of the intervention : oral
Control intervention name : null		FP Pharmaceutical Corp.BOTH130Phase 2
623JPRN-UMIN0000076172012/04/012 April 2019Effect of lidocaine injection for postural deformities in Parkinson's diseaseParkinson's diseaseintramuscular injection of lidocaineDept. of Clinical pharmacology and Neurology, Ehime UniversityRecruiting20years-old80years-oldMale and Female30Not selectedJapan
624NCT01331122April 201219 February 2015Study to Assess Droxidopa in the Treatment of Freezing Of Gait Symptoms in Patients With Parkinson's DiseaseA Phase II, Double-Blind, Placebo-Controlled Randomized Crossover Study to Assess the Clinical Benefit and Safety of Droxidopa in the Treatment of Freezing of Gait Symptoms in Patients With Parkinson's DiseaseGait Disorders, NeurologicDrug: droxidopaChelsea TherapeuticsNot recruiting30 YearsN/ABoth0Phase 1/Phase 2United States;Canada
625NCT01486628April 201211 April 2016Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy VolunteersA Phase I, Single Dose, Single-centre, Randomized, Double-blind, Placebo-controlled Dose Escalation Study Evaluating Safety, Tolerability and Levodopa Plasma Concentration Following Administration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in Healthy VolunteersParkinson's DiseaseDrug: ND0612;Drug: PlaceboNeuroDerm Ltd.Not recruiting18 Years40 YearsMale36Phase 1Israel
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
626NCT01491529April 201219 February 2015Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's DiseaseDyskinesias;Parkinson Disease;Movement Disorders;Parkinsonian Disorders;Anti-Dyskinesia AgentsDrug: AFQ056;Drug: PlaceboNovartis PharmaceuticalsNot recruiting30 Years80 YearsBoth154Phase 2United States;Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey
627NCT01523301April 201219 October 2017Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease PatientsDouble Blind, Placebo-controlled, Parallel, Multicenter, Randomized Interventional Phase IV Study to Evaluate the Efficacy of Rotigotine on Depressive Symptoms in Idiopathic Parkinson's Disease PatientsIdiopathic Parkinson's DiseaseDrug: Rotigotine;Drug: PlaceboUCB Korea Co., Ltd.Not recruiting20 YearsN/AAll380Phase 4Korea, Republic of
628NCT01527695April 201219 February 2015PET Study in Parkinson's Disease PatientsA Phase IIA, Multi Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Effect of 8 Weeks Treatment With Oral AZD3241 on Microglia Activation, as Measured by Positron Emission Tomography (PET), in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: ER tablet 25 mg AZD3241;Drug: ER tablet 100 mg AZD3241;Drug: Placebo for AZD3241 25 mg;Drug: Placebo for AZD3241 100 mgAstraZenecaNot recruiting45 Years75 YearsBoth24Phase 2Sweden
629NCT01550484April 201216 December 2017A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement DisordersAn Open Label, Multicenter Study, Evaluating the Safety and Efficacy of 18F-AV-133 PET Imaging to Identify Subjects With Dopaminergic Degeneration Among Subjects Presenting to a Movement Disorders Specialty Clinic With an Uncertain DiagnosisParkinson's Disease;Primary Parkinsonism;Lewy Body Parkinson's DiseaseDrug: 18F-AV-133Avid RadiopharmaceuticalsNot recruiting40 YearsN/AAll170Phase 2/Phase 3United States;Australia
630NCT01556165April 201219 October 2017Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in ChinaRandomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in ChinaParkinson's DiseaseDrug: rasagiline;Drug: placeboH. Lundbeck A/SNot recruiting35 YearsN/AAll130Phase 3China
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
631NCT01491932March 201216 December 2017Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced DyskinesiasAn Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced DyskinesiasDyskinesias;Parkinson Disease;Movement Disorders;Parkinsonian Disorders;Anti-Dyskinesia AgentsDrug: AFQ056Novartis PharmaceuticalsNot recruitingN/AN/AAll129Phase 2United States;Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey
632NCT01538329March 201217 May 2016Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's DiseaseImpact of Amantadine on L-DOPA-induced Dyskinesia in Early Parkinson's Disease: a Placebo-controlled Randomized Study (the PREMANDYSK Study)Parkinson DiseaseDrug: placebo;Drug: AmantadineUniversity Hospital, ToulouseRecruiting35 YearsN/ABoth202Phase 2France
633NCT01565395March 201216 December 2017Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)Parkinson Disease;Amyotrophic Lateral SclerosisDrug: Incobotulinum Toxin A;Drug: placeboBeth Israel Deaconess Medical CenterMerz PharmaceuticalsNot recruiting20 Years80 YearsAll0Phase 2United States
634NCT01653132March 201216 December 2017Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/ParkinsonismRandomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/ParkinsonismSialorrheaDrug: Incobotulinum Toxin A;Drug: PlaceboBeth Israel Deaconess Medical CenterNot recruiting18 Years90 YearsAll10Phase 2United States
635NCT02039024March 201225 January 2016Imaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PETImaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PETParkinson's DiseaseDrug: 18F- DTBZChang Gung Memorial HospitalNational Science Council, TaiwanNot recruiting20 Years80 YearsBoth18Phase 2Taiwan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
636NCT03061513February 28, 201216 December 2017Ubiquinol in Parkinson's Disease: Safety, Tolerability, and Effects Upon Oxidative Damage and Mitochondrial BiomarkersUbiquinol in Parkinson's Disease: Safety, Tolerability, and Effects Upon Oxidative Damage and Mitochondrial BiomarkersParkinson DiseaseDrug: Ubiquinol;Dietary Supplement: PlaceboWeill Medical College of Cornell UniversityNot recruiting40 Years75 YearsAll11Phase 2
637EUCTR2011-004803-19-SE22/02/201218 February 2013PET study in PD patientsA Phase IIA, Multi centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Effect of 8 Weeks Treatment with Oral AZD3241 on Microglia Activation, as Measured by Positron Emission Tomography (PET), in Patients with Parkinson’s DiseaseParkinson's Disease; Microglia activation as measured by [11C]PBR28 binding to TSPO
MedDRA version: 14.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: AZD3241 Extended release tablets 25 mg
Product Code: AZD3241
Pharmaceutical Form: Prolonged-release film-coated tablet
Current Sponsor code: AZD3241
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Product Name: AZD3241 Extended release tablets 100 mg
Product Code: AZD3241
Pharmaceutical Form: Prolonged-release film-coated tablet
Current Sponsor code: AZD3241
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Product Name: [11C]PBR28
Product Code: [11C]PBR28
Pharmaceutical Form: Solution for injection
Current Sponsor code: [11C]PBR28
Concentration unit: µg microgram(s)
Concentration type: up to
Concentration number: 5-
Product Name: [18F]FE-PE2I
Product Code: [18F]FE-PE2I
Pharmaceutical Form: Solution for injection
Current Sponsor code: [18F]FE-PE2I
Concentration unit: µg microgram(s)
Concentration type: up to
Concentration number: 5-		AstraZeneca ABNot RecruitingFemale: yes
Male: yes		24Phase 2AFinland;Sweden
638NCT01525641February 201219 October 2017Safety and Efficacy of Long-term Daily Use of Mirapex®-LA Tablets in Patients With Parkinson's DiseaseSpecial Survey on Long-term Drug Use of Mirapex®-LA Tablets in Patients With Parkinson's DiseaseParkinson DiseaseDrug: Mirapex LABoehringer IngelheimNot recruitingN/AN/AAll615N/AJapan
639NCT01568099February 201224 August 2015Tolerability and Safety of Subcutaneous Administration of Two Doses of AFFITOPE® PD01A in Early Parkinson's DiseaseA Randomized, Controlled, Parallel Group, Patient-blinded, Single-center, Phase I Pilot Study to Assess Tolerability and Safety of Repeated Subcutaneous Administration of Two Doses of AFFITOPE® PD01A Formulated With Adjuvant to Patients With Parkinson's DiseaseParkinson's DiseaseBiological: AFFITOPE® PD01A;Other: ControlAffiris AGNot recruiting40 Years65 YearsBoth32Phase 1Austria
640NCT01673724February 201216 December 2017Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's DiseaseEffect of Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease: Multicenter, Open-label, Parallel, Randomized StudyParkinson's DiseaseDrug: pramipexole;Drug: BromocriptineSandozNot recruiting30 YearsN/AAll121Phase 4Korea, Republic of
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
641NCT01485172January 31, 20122 July 2018A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's DiseaseA Fixed Dose, Dose Response Study for Ropinirole Prolonged Release (PR) in Patients With Early Stage Parkinson's DiseaseParkinson DiseaseDrug: ropinirole monotherapy;Drug: placebo monotherapyGlaxoSmithKlineNot recruiting30 YearsN/AAll186Phase 4United States;Estonia;Korea, Republic of;Russian Federation;Slovakia;Poland
642NCT01470027January 201211 June 2018N-Acetylcysteine for Neuroprotection in Parkinson's DiseaseN-Acetylcysteine for Neuroprotection in Parkinson's DiseaseParkinson DiseaseDrug: N-acetylcysteine;Drug: PlaceboWeill Medical College of Cornell UniversityNational Institute on Aging (NIA)Not recruiting50 Years75 YearsAll50Phase 1/Phase 2United States
643NCT01497652January 201228 December 2015A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic TherapyA Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic TherapyParkinson's DiseaseDrug: Rasagiline/Placebo;Drug: RasagilineGeorgetown UniversityTeva Neuroscience, Inc.Not recruiting40 YearsN/ABoth34Phase 4United States
644NCT01515410January 201219 October 2017Study in Advanced Parkinson's Disease Patients With Predictable Motor FluctuationsA Phase 2, Randomized, Open-Label, Crossover Study to Compare DM-1992, a Novel Gastric-Retentive Extended-Release Formulation of Levodopa/Carbidopa, to an Immediate-Release Carbidopa Tablet in Patients With Advanced Parkinson's Disease With Motor FluctuationsParkinson's Disease;Motor FluctuationsDrug: DM-1992;Drug: Sinemet IRDepomedNot recruiting30 YearsN/AAll34Phase 2United States
645NCT01536015January 201219 October 2017Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal DysfunctionA Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease With Motor Fluctuations and Symptoms of Gastrointestinal DysfunctionAdvanced Parkinson's DiseaseDrug: Rotigotine;Drug: PlaceboUCB PharmaNot recruiting30 YearsN/AAll25Phase 3United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
646EUCTR2009-017412-32-IT13/12/201115 July 2013RANDOMISED CONTROLLED TRIAL OF BOTULINUM TOXIN TYPE A AND B EFFICACY IN REDUCING DROOLING IN PARKINSON DISEASE - NDRANDOMISED CONTROLLED TRIAL OF BOTULINUM TOXIN TYPE A AND B EFFICACY IN REDUCING DROOLING IN PARKINSON DISEASE - NDParkinson disease
MedDRA version: 9.1 Level: LLT Classification code 10013363		Trade Name: BOTOX
Pharmaceutical Form: Powder for solution for injection
INN or Proposed INN: Botulinum toxin
Concentration unit: U unit(s)
Concentration type: equal
Concentration number: 100-
Trade Name: NEUROBLOC
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Botulinum toxin
Concentration unit: IU/ml international unit(s)/millilitre
Concentration type: equal
Concentration number: 5000-		AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESINot RecruitingFemale: yes
Male: yes		Italy
647NCT01351168December 201119 February 2015Use of Zolpidem in Parkinson's DiseaseA Randomized, Controlled, Double-Blind, Cross-over Study of Zolpidem for Patients With Parkinson's DiseaseParkinson's DiseaseDrug: Levodopa;Drug: Zolpidem first dose;Drug: Zolpidem second dose;Drug: sugar pillRush University Medical CenterNot recruiting30 Years75 YearsBoth0Phase 2United States
648NCT01470859December 201119 October 2017The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Diseasea Pilot Follow-up Study of Investigating the Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Chinese Patients With Early Parkinson's DiseaseIdiopathic Parkinson's DiseaseDrug: pramipexole;Drug: Sinemet CRHuashan HospitalBoehringer IngelheimNot recruiting30 Years75 YearsAll30N/AChina
649NCT01479530December 201119 October 2017Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in ChinaRandomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of [Azilect®] Rasagiline in Levodopa-treated Parkinson's Patients With Motor Fluctuations in ChinaParkinson's DiseaseDrug: Placebo;Drug: Azilect®H. Lundbeck A/SNot recruiting30 YearsN/AAll321Phase 3China
650NCT01519271December 201116 December 2017Mild Cognitive Impairment in Parkinson's DiseaseA Phase IV Randomized, Double-Blind, Placebo-Controlled, Crossover Single Site Study Of Exelon® Patch (Rivastigmine Transdermal System) For Mild Cognitive Impairment In Parkinson's DiseaseParkinson's Disease;Mild Cognitive ImpairmentDrug: Exelon Patch (rivastigmine transdermal system);Drug: Placebo PatchesUniversity of PennsylvaniaNot recruiting40 Years85 YearsAll28Phase 4United States
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
651NCT01521117December 201119 February 2015The Effect of Donepezil on Gait and Balance in Parkinson's DiseaseA Randomized, Double-blind, Placebo Controlled, Crossover Study to Evaluate the Effect of Donepezil on Gait and Balance in Parkinson's DiseaseParkinson's DiseaseDrug: DonepezilOregon Health and Science UniversityRecruitingN/AN/ABoth12Phase 4United States
652NCT02302144December 201116 December 2017A Multifactorial Exercise Program to Reduce Falls in People With Parkinson DiseaseA Multifactorial Exercise Program to Reduce Falls in People With Parkinson DiseaseParkinson DiseaseBehavioral: Balance & Strengthening ExercisesBoston University Charles River CampusNot recruiting18 YearsN/AAll32N/AUnited States
653NCT01385592November 201119 February 2015Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias12-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's DiseaseDyskinesias;Parkinson Disease;Movement Disorders;Parkinsonian DisordersDrug: AFQ056;Drug: PlaceboNovartis PharmaceuticalsNot recruiting30 Years80 YearsBoth78Phase 2United States;Canada;France;Germany;Hungary;Italy;Spain
654NCT01457807November 201119 February 2015To Assess the Effect of Administration of 2 Formulation of AZD3241 on Blood Concentration in Healthy VolunteersA Phase I, Single-centre, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Assess the Pharmacokinetics, Safety and Tolerability of Two Different Extended Release Formulations of Tablets of AZD3241 (300 mg) After Administration of Multiple Doses in Healthy Male and Female VolunteersParkinson's DiseaseDrug: AZD3241 ER formulation 1;Drug: Placebo;Drug: AZD3241 Alternative titration scheme with formulation 1 or 2AstraZenecaNot recruiting30 Years65 YearsBoth24Phase 1United Kingdom
655NCT01556100November 20118 January 2018Long-Term Vesicular Monoamine Transporter II Imaging and Clinical Assessment of Parkinson's Disease ProgressionLong-Term Vesicular Monoamine Transporter II Imaging and Clinical Assessment of Parkinson's Disease ProgressionParkinson DiseaseDrug: 18F-DTBZ AV-133Chang Gung Memorial HospitalNot recruiting20 YearsN/AAll40Phase 2
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
656NCT01736891November 201119 February 2015Clinical Trial of Rasagiline in Levodopa-Treated Parkinson's Disease Patients With Motor FluctuationsEvaluation for the Efficacy,Tolerability,and Safety of Rasagiline in Levodopa-treated PD Patients With Motor Fluctuations: A Multicenter, Double Blind, Randomized, Placebo-Controlled Group Study (China)Parkinson´s DiseaseDrug: Rasagiline;Drug: Placebo<